

DENIS EUNAN O'DONNELL

CURRICULUM VITAE

Work Address: Richardson House
102 Stuart Street
Kingston, Ontario, Canada
K7L 2V6

Telephone: Work: (613) 548-2339
Home: (613) 547-4583
Fax: (613) 549-1459

Nationality: Canadian

Marital Status: Married, 3 children

Place of Birth: Galway City, Ireland

QUALIFICATIONS

<u>Degree/Diploma</u>	<u>Institution</u>	<u>Date</u>
M.B., B.Ch., B.A.O.	National University of Ireland	June 1978
M.R.C.P. (I)	Royal College of Physicians, Ireland	June 1981
L.M.C.C.	Medical Council of Canada	June 1985
F.R.C.P. (C)	Royal College of Physicians and Surgeons of Canada	
	Specialty: 1. Internal Medicine	Nov 1986
	2. Respiriology (Certificate of Special Competency)	Nov 1987
M.D.	National University of Ireland	June 1989
F.R.C.P. (I)	Royal College of Physicians of Ireland	Sept 1993
Medical School:	University College	Sept 1972
	Galway, Ireland	June 1978

POSTGRADUATE APPOINTMENTS

<u>Position</u>	<u>Institution</u>	<u>Date</u>
Member	Department of Medicine Queen's University, Kingston, Ontario	
Professor	-of Medicine	July 98 - present
	-of Rehabilitation Medicine	Oct 98 - present
	-of Biomedical & Molecular Sciences	Aug 99 - present
	-of Kinesiology & Health Studies Queen's University, Kingston, Ontario	Jan 06 – present
Chair	Division of Respiriology	Jan 2001 – Nov 07

Associate Professor	Division of Respiriology & Critical Care Medicine Department of Medicine, Queen's University	Apr 94 - present
Director, Training Program in Respiriology	Division of Respiriology & Critical Care Medicine Department of Medicine, Queen's University	Sept 92 - Feb 00
Staff Respiriologist	Kingston General Hospital Hotel Dieu Hospital St. Mary's of the Lake Hospital	Nov 88 - present
Director, Pulmonary Rehabilitation Program	St. Mary's of the Lake Hospital	Nov 88 - present
Assistant Professor	Division of Respiriology & Critical Care Medicine Department of Medicine, Queen's University	Nov 88 - Apr 94
Fellow in Respiratory Medicine	Department of Medicine, University of Manitoba Winnipeg, Manitoba, Canada Supervisors: N.A. Anthonisen, M. Younes (a) Clinical Fellow (b) Research Fellow	July 84 - July 85 July 85 - Oct 88
Lecturer/Registrar	Department of Medicine, Respiriology Division St. James' Hospital, Dublin and the University of Dublin Trinity College	July 83 - June 84
Registrar, Cardiology/General Medicine	The Charitable Infirmary, Jervis Street, Dublin and the Royal College of Surgeons in Ireland	Jan 82 - June 83
Senior House Officer, Internal Medicine	Regional Hospital, Merlin Park Hospital and University College, Galway, Ireland	July 79 - Dec 81
Intern Medicine/Surgery	Regional Hospital, Galway, Ireland	June 78 - June 79

MEMBERSHIP LEARNED SOCIETIES

- Canadian Thoracic Society - **President, (2009-10)**
- American Thoracic Society
- American College of Chest Physicians - **Elected Fellow (FCCP), 1990**
- Canadian and Ontario Medical Association
- Ontario Thoracic Society - **President 1995-96**
- European Respiratory Society – **Elected Fellow (FERS) 2014**

COMMITTEE MEMBERSHIP

- Lung Association, Frontenac, Lennox and Addington Region - **Medical Advisor and Executive Board Member, 1990-95**
- Ontario Thoracic Society - **Executive Member, 1990-97**
- Research Space Allocation Committee, Kingston General Hospital - **1992-95**
- Respiratory Training Committee, Department of Medicine, Queen's University - **Chairman, 1992-2000**
- Subspecialty Training Committee, Department of Medicine, Queen's University - **1992-present**
- Department of Medicine Research Committee, Queen's University - **1994-2017**

- Department of Medicine Research Awards Committee, Queen's University - **Chairman, 1996-1999**
- Queen's OTS Block Term Grant Committee - **Chairman, 1998-present**
- Canadian Thoracic Society Subcommittee on COPD & Rehabilitation, **1995-1999**
- American Thoracic Society Subcommittee on Dyspnea Consensus Statement, **1995-97**
- American Thoracic Society Project on Standardized Scientific Basis of Measurement of Ventilatory Limitation, Ventilatory Reserve and Mechanical Impairment During Exercise (Contributor), **1996**
- Research and Graduate Studies Committee - **Queen's Faculty of Medicine, 1996**
- Task Force on OTS Research Funding - **Chairman, 1995-97**
- National Institute of Health. U.S.A. Symptom Control in Palliative Care Working Committee – **Member, 1997**
- Cardiology Chair Search Committee, Queen's University, **1997**
- Research Advisory Committee, Queen's Faculty of Health Sciences - **Member, 1997-98**
- Canadian Thoracic Society National Grant Review Panel - **Member, 1998-1999**
- KGH Research & Development Fund Competition - **Member, Review Committee, 1998**
- NIH Working Committee - Symptom Perception in Asthma - **1998-99**
- Allergy & Immunology Search Committee, Department of Medicine, Queen's University - **Chairman, 1999**
- Scientific Committee, Quebec International Symposium on Cardiopulmonary Rehabilitation – **1999**
- Royal College of Physicians & Surgeons of Canada. Examiner Panel, Respiratory Disease Section - **1999**
- Ministry of Health Task Force Member – Home Oxygen - **1999**
- Chair, Ad Hoc Committee, COPD/Rehabilitation, Canadian Thoracic Society - **2001**
- Chair, Canadian Thoracic Society Consensus Guidelines for the Management of COPD – **2001**
- Chair, Respiratory Research Group, Queen's University – **2002**
- NHLBI Working Group in Clinical Research in COPD (Member) – **2002**
- Global COPD Initiative (GOLD) – **Canadian Representative, 2002**
- Editorial Board – COPD: Journal of Chronic Obstructive Lung Disease – **2002**
- Canadian Consensus Guidelines – **Editor, 2002**
- European Respiratory Society Taskforce on Clinical Exercise Testing – **Member, 2003**
- European Respiratory Society Taskforce on Guidelines for Pulmonary Rehabilitation – **Member, 2004**
- Honorary Editorial Board – The International Journal of Chronic Obstructive Pulmonary Disease– **2005**
- Secretary, Canadian Thoracic Society Executive Committee – **2006**
- American Thoracic Society Dyspnea Statement Guidelines – **2007**
- President Elect, Canadian Thoracic Society – **2008**
- NIH Panel on Airways Disease in the Elderly - **2009**
- CCP Panel on Management of Dyspnea in End-Stage Respiratory Disease – **2009**
- Co-Primary Investigator & Co-Chair of the National Initiative for Knowledge Translation and Implementation of Canadian Thoracic Society Guidelines – **2009**
- Member, European Respiratory Society Clinical Exercise Interpretation Committee – **2009**
- Member, Scientific Committee, ATS Respiratory Structure and Function Assembly – **2009**
- Member European Respiratory Society Physiology Committee – **2009**
- Member, CTS Steering Committee for the Development of a National Respiratory Research Agenda - **2009**
- Board Member, Canadian Lung Association – **2009**
- Member, CIHR-CANCOLD Scientific Advisory Committee - **2009**
- Member, CIHR-ICRH Advisory Board, Respiriology Group – **2010**
- Member, COPD Foundation - **2010**
- Member, Editorial Board, CHEST – **2010-2015**
- Member, Institute Advisory Board (IAB) for the Canadian Institutes of Health Research (CIHR) Institute

of Circulatory and Respiratory Health – **2010 - 2016**

- Member, Medical Advisory Secretariat (MAS) Panel, Ministry of Health – **2010-2011**
- Member, Canadian Thoracic Society National Research Steering Committee – **2011**
- Associate Editor, Canadian Respiratory Journal – **2010**
- European Respiratory Society National Delegate of Canada – **September 2012 – August 2015**
- Chair, Long Term Planning Committee, Canadian Thoracic Society – **April 2012 –**
- Member, Editorial Board, Journal of Applied Physiology – **2013**
- Member, Editorial Board, Journal of COPD – **2013**
- Member, Editorial Board, International Journal of COPD – **2013**
- Member, Editorial Board, COPD Journal of American Lung Foundation – **2014**
- Member, Scientific Steering Committee for CanCOLD, a national longitudinal cohort study in COPD – **2014**
- Member, Advisory Board for the Canadian Institute of Cardiocirculatory & Respiratory Health – **2014**
- Lead, Physiology Platform of Canadian Respiratory Research Network – **2014**
- Member, Editorial Board, Barcelona Respiratory Network Reviews (BRNR) - **2015**
- Member, Editorial Board, COPD: Journal of Chronic Obstructive Pulmonary Disease – **2015**
- **Chair**, Canadian Thoracic Society COPD Guidelines Committee – **2003-2008**
- Member, Canadian Thoracic Society COPD Guideline Committee – **2017 –**
- Member, European Respiratory Society Task Force on Exercise Physiology on Respiratory Muscle Function - **2017**

INVITED REVIEWER

(1) Journals:

American Review of Respiratory Disease & Critical Care Medicine
Journal of Applied Physiology [Editorial Board Member]
Chest [Editorial Board Member]
Medicine and Science in Sports and Exercise
Canadian Respiratory Journal [Associate Editor]
Thorax
Lung
Respiratory Medicine
European Respiratory Journal
Respiration
COPD [Editorial Board Member]
International J of COPD [Editorial board member]
Respiratory Physiology & Neurobiology
Editorial Board: Barcelona Respiratory Network Review (BRNR)
Regulatory, Integrative and Comparative Physiology
Applied Physiology, Nutrition and Metabolism
Respiratory Research

(2) Granting Agencies: (Guest Reviewer)

Ontario Thoracic Society Grants-in-Aid
Ontario Thoracic Society Block Term Grants
Cystic Fibrosis Association Grants
Medical Research Council of Canada
Department of Veterans Affairs, California
Hitchcock Foundation, New Hampshire
British Columbia Thoracic Society
Department of Veterans Affairs, Chicago

National Institute of Health U.S.
 Physicians' Services Incorporated, Ontario
 Canadian Thoracic Society
 Netherlands Asthma Foundation
 Canadian Institute of Health Research (CIHR)
 Canadian Foundation for Innovation

AWARDS

Academic

- Basmajian Award for Excellence in Biomedical Research 1993 - 1994
- Ontario Ministry of Health Career Scientist Award (renewed annually) 1994 - 2004
- Ontario Lung Association Meritorious Service Award 1997
- Distinguished Scientist Honour Award, American College of Chest Physicians 2005
- Dr. Edward Livingstone Trudeau Lecture, New York State Thoracic Society 2007
- Visiting Professor, Yale University 2007
- Jean Jacques Gauthier Award and Honour Lecture, University of Montreal 2008
- John Rankin Visiting Professor and Honour Lecture, University of Madison
Madison, Wisconsin, U.S.A. 2008
- The PK Morgan Honour Lecture, Association of Respiratory Technology &
Physiology (ARTP), United Kingdom 2013
- Excellence in Research and Respiratory Physiology Award from the
Association for Respiratory Technology & Physiology (ARTP). 2013
- Clinician Scientist Award, Department of Medicine 2013 - 2015
- Fellow: European Respiratory Society 2014
- Lung Association/Pfizer Canada COPD Research Award 2014
- Distinguished Achievement Award, Canadian Thoracic Society 2015
- Queen's Department of Medicine Research Achievement Award 2015
- Lung Association/Pfizer Canada COPD Research Award 2015
- Queen's University Health Sciences 2017 Prize for Research Excellence 2017
- Ludwig Engel Visiting Professor Oration for 2017, Sydney, Australia 2017
- 2018 CIHR-ICRH/CTS Distinguished Lecturer Award in Respiratory Sciences 2018
- Brian J. Sproule Lectureship (Alberta Respiratory Centre – University of Alberta) 2018
- Honorary Life Membership: Ontario Thoracic Society 2019
- ATS Keynote Speaker: American Thoracic Society International Conference 2019
- Honorary Lifetime Achievement Award: European Respiratory Society 2019
- Thomas Aldrich Memorial Lecture: Albert Einstein College of Medicine, Bronx NY 2019

INVITED LECTURES/PRESENTATIONS – RESEARCH

1. **Pneumo Club, University of Ottawa**, Ottawa, Ontario. “Control of Breathing in Quadriplegia”. May 5, 1989
2. The Lung Association, Kingston, Ontario. “Chronic Bronchitis and Emphysema”. June 14, 1989
3. **Pneumo Club, Queen's University**, Kingston, Ontario. “Physiological Determinants of Breathlessness in Patients with COPD”, January 19, 1990.
4. **Kingston Chapter of the College of Family Physicians of Canada**, Kingston, Ontario: “Asthma: A Clinical Update”. January 25, 1990.
5. **CME, Queen's University**, Kingston, Ontario. “Aerosols in Asthma: Too Little, Too Late?” April 14, 1990.

6. **Pneumo Club, University of Ottawa**, Ottawa, Ontario. "The Utility of CPAP in Relieving Dyspnea in Patients with Chronic Respiratory Insufficiency". June 8, 1990
7. **Combined Department of Family Medicine**, Kingston, Ontario. "Care of the COPD Patient". November 14, 1990.
8. **ORCS/OLA "Respiratory Update '91"**, Kingston, Ontario. "Breathlessness in Patients with CAL: New Approaches to Management". May 10, 1991. (Broadcast on NOTN Teleconference)
9. **Visiting Professor, University of Ottawa**, Ottawa Civic Hospital, Ottawa, Ontario. Grand Rounds, "Management of the Chronically Breathless Patient". May 15, 1991.
10. **Medical Grand Rounds, Belleville General Hospital, Belleville**, Ontario. "Ambulatory Management of the COPD Patient". November 20, 1991.
11. **Visiting Professor, University of Calgary, Foothills Hospital**, Division of Respiriology, Calgary, Alberta. (1) **Research Seminar**, "Mechanisms of Breathlessness in Patients with Chronic Airflow Limitation", (2) **Pulmonary Rounds**, "Dyspnea Relief in COPD: New Therapeutic Strategies", (3) **Alberta Respiratory Care Society Annual Meeting**, "Alternative Modes of Exercise Training for Pulmonary Patients". November 28-December 1, 1991.
12. **Geriatric Medicine-Cardiorespiratory Disease, CME, Queen's University**, Kingston, Ontario. "The Benefits of Exercise Training in Elderly Patients with Pulmonary Disease". December 4, 1991.
13. **The Lung Association, CME**, Peterborough, Ontario. "Comprehensive Management of COPD". January 16, 1992.
14. **Symposium on COPD, CME, The Lung Association**, Orillia, Ontario. "The Approach to the Dyspneic Patient". February 6, 1992.
15. **Better Breathing '92, OTS Annual Scientific Meeting**, Toronto, Ontario. "Dyspnea Relief in COPD". February 7-8, 1992.
16. **ORCS/OLA "Respiratory Update '92"**, Kingston, Ontario. "The Origin of Breathlessness in the Asthmatic Patient" with Kathy Webb. September 11, 1992.
17. **Respiratory Disease Symposium, The Lung Association**, Cornwall, Ontario. "How to Manage Breathless COPD Patients". October 29, 1992.
18. **Asthma Conference, The Lung Association**, Belleville, Ontario. "What is Asthma?" November 7, 1992.
19. **Department of Medicine Research Seminar, Queen's University**, Kingston, Ontario. "On the Origins of Breathlessness", March 10, 1993.
20. **Pneumo Club, University of Ottawa**, Ottawa, Ontario. (1) "Factors Contributing to Dyspnea Relief During Hyperoxia in CAL", with Dr. D. Bain, (2) "Mechanisms of Dyspnea in Asthma", with Dr. D. Loughheed. April 23, 1993.
21. **Visiting Professor, McMaster University**, Hamilton, Ontario. (1) "Pathogenetic Basis of Breathlessness in COPD", (2) "Towards a Rational Approach to Management of Breathlessness in COPD", April 27, 1993.
22. **CME, The Lung Association**, Trenton, Ontario. "Update on COPD", March 2, 1993.
23. **ALA/ATS International Conference**, San Francisco, California. Guest speaker. "The Assessment and Management of the Dyspneic Patient", Canadian Trainees in Respiriology Education Program. May, 1993.
24. **Lung Association Seminar (CME)**, Kingston, Ontario. Chair and guest lecturer. "Rehabilitation in COPD and the Breathe Easy Program", Educational Programs for Chronic Lung Disease Seminar, September 16th, 1993.
25. **The Lung Association**, Kingston, Ontario. "Exercise and Asthma". Press Conference for the launching of the video "Put Me In Coach", November 4th, 1993.
26. **CME, Queen's University**, Kingston, Ontario. Clinical Day in Respiriology. "Home O₂ treatment. Does it work? Who should receive it?", November 17th, 1993.

27. **Grand Rounds**, Oshawa General Hospital, Oshawa, Ontario. “Advances in Management of COPD”. November 25, 1993.
28. **CME**, Picton, Ontario. “Modern Management of Community Acquired Pneumonia”. December 2, 1993.
29. **Ontario Respiratory Residents Symposium**, Niagara-on-the-Lake, Ontario. “Interpretation of Clinical Exercise Tests”. April 22-23, 1994.
30. **National Centres of Excellence in Respiratory Research**, Montreal, Quebec. Workshop on “Pathophysiologic Aspects of Near Fatal Asthma”, presentation: “Breathlessness in Asthma and the Inspiratory Threshold Load”. April 28-29, 1994.
31. **Basmajian Lecture 1994 to Faculty of Medicine, Queen’s University**, Kingston, Ontario. “On the Origins of Dyspnea”. June 15, 1994.
32. **The Lung Association**, Kingston, Ontario. “Asthma Emergencies”, September 13th, 1994.
33. **The Lung Association**, International Conference on Asthma Education, European Respiratory Society Conference, Nice, France. “Asthma Education Programs in Ontario” with Shelagh Finlayson, September 30-October 1, 1994.
34. **The Lung Association**, Kingston, Ontario. “COPD”, October 12th, 1994.
35. **Visiting Professor, University of Ottawa**, Ottawa, Ontario. (1) **Medical Grand Rounds**. “The Origins of Breathlessness-New Insights”, (2) **Research Seminar**. “Breathlessness and the Hidden Mechanical Load”, October 18-19, 1994.
36. **OLA Governing Council Meeting**, Mississauga, Ontario. “Emphysema - New Research Directions”. October 29, 1994.
37. **CME, Grand Rounds**, Peterborough, Ontario. “Current Concepts in the Management of Obstructive Lung Disease”. November 11, 1994.
38. **Annual Meeting of the Ontario Thoracic Society**, Toronto, Ontario. “The Surgical Management of Bullous Lung Disease - Revisited”. February 9-11, 1995.
39. **Network for Centres of Excellence**, Montreal, Quebec. Workshop on “Exercise hypoxia and ventilatory muscle fatigue”. Presentation entitled “The Physiological Rationale for Lung Reduction Surgery”. February 6-7, 1995.
40. **Visiting Professor, University of Western Ontario**, London, Ontario. (1) “Exercise Physiology in Health”, (2) “Clinical Exercise Interpretation in Pulmonary Disease”, (3) **Research Seminar**. “Thoracic Restriction and Breathlessness in Obstructive and Restrictive Lung Disease”. (4) **Grand Rounds**. “Non-invasive Mechanical Ventilation and Lung Reduction Procedures in CAL”, February 21-23, 1995.
41. **The Lung Association**, Leeds-Grenville Respiratory Health Day, Smiths Falls, Ontario, “COPD - New Treatment Options”, April 5, 1995.
42. **British Columbia Thoracic Society**, Vancouver, BC. “Pharmacologic and Surgical Lung Volume Reduction and its Impact on Exertional Dyspnea in CAL”. April 18-20, 1995.
43. **Visiting Lecturer, Research Rounds, University of British Columbia**, Vancouver BC. “Breathlessness and Neuromechanical Uncoupling in Obstructive Lung Disease”, April 18-20, 1995.
44. **The Lung Association**, Kingston, Ontario. Asthma Emergencies, “Coping with Asthma”, May 8th, 1995.
45. **ATS/ALA International Conference**, Seattle, Washington. **Featured Speaker** for 2 symposia. (1) “Mechanisms and Management of Exertional Dyspnea in Patients with Chronic Airflow Limitation”, and “The Physiology of Lung Volume Reduction: Why Should it Work”, May 22, 1995 (Co-Chairman).
46. **Visiting Professor, University of Toronto**, Toronto, Ontario, **Asthma Rounds**, “The neurophysiological basis of breathlessness in obstructive airway disease”, **Grand Rounds**, “Volume reduction surgery and dyspnea relief in emphysema”, **Research Seminar**, “Symptom Perception in Asthma”, October 11, 1995.

47. **First OTS Southeastern Ontario Conference of Office Management of Respiratory Disorders**, Gananoque, Ontario. (Chair) 2 talks (1) "Exercise Reconditioning in COPD", and (2) "Update on COPD Management", October 13, 1995.
48. **Featured Speaker, Irish Thoracic Society Annual Meeting**, Belfast, Ireland. "Volume Reduction Surgery: A Physiological Rationale", November, 1995.
49. **Dorothy Weiselberg Seminar**, Montreal Chest Institute, Montreal, Quebec. Featured Speaker, "Mechanisms and Management of Breathlessness", December 7-8, 1995.
50. **Featured Speaker, National Symposium on COPD**, Ashford Castle, Ireland. "Advances in Management of the Breathless COPD Patient", March 29-30, 1996.
51. **3rd Annual Respiratory Trainee Symposium**, Niagara-on-the-Lake, Ontario. Invited speaker "Volume Reduction Surgery - A Clinical Overview", April 19-20, 1996.
52. **Visiting Professor, Dalhousie University**, Halifax, Nova Scotia. (1) "Mechanisms of Exertional Breathlessness in Obstructive Lung Disease", (2) "Therapeutic Strategies I", and (3) "Therapeutic Strategies II", April 24-16, 1996.
53. **ATS/ALA International Conference**, New Orleans, LA. **Featured Speaker** for 3 talks. (1) Meet the Professor Seminar "Management of Dyspnea", (2) Clinical Problems Assembly "Exercise Intolerance in COPD", and (3) Postgraduate Course "Idiopathic Interstitial Pneumonia: Current Concepts & Management", "The Role of Exercise Testing", May 11-15, 1996.
54. **Etobicoke General Hospital, Respirology Clinic Day**, Toronto, Ontario. "COPD/Rehabilitation", June 6, 1996.
55. **Maisonneuve/Rosemont Hospital, Montreal, Quebec**. Respiratory Rounds. "Advanced COPD: New Hope". (2) Jewish General Hospital, Montreal. Respiratory Rounds. "Managing Class III COPD". (3) Sacre-Coeur Hospital, Respiratory Research Rounds, "Ventilatory Mechanics and Exertional Breathlessness". (4) Notre-Dame Hospital, Grand Rounds, **Featured Speaker**, "Mechanisms and Management of Breathlessness in COPD", September 4-5, 1996.
56. **Ontario Thoracic Society**, Pembroke, Ontario. September 26, 1996. (1) "COPD: Optimal Management" (2) "Lung Volume Reduction Surgery - Who Benefits?"
57. **Guest Speaker**. 'Day in Respirology', University of British Columbia, Vancouver, (a) Lung Volume Reduction Surgery, (b) Modern Management of COPD. October 18, 1996.
58. **Ontario Thoracic Society**, Clinical Day in Respirology, Windsor, Ontario. (1) "Benefits of Pulmonary Rehabilitation", and (2) "Surgical Management of Emphysema", October 23, 1996.
59. **Research in Progress Lecture, Dept. of Physiology, Queen's University**, "Exertional Breathlessness in Interstitial Lung Disease: Mechanisms". Oct. 1996.
60. **New York State Thoracic Society Annual Scientific Assembly, West Point, New York**. "Exercise Intolerance in COPD: New Insights", January 24, 1997.
61. **OTS Better Breathing Conference**, Role of Nebulized Opiates in the Management of Terminal Breathlessness. February 6, 1997 - Winner of Debate.
62. **Guest Speaker**. McMaster University, Hamilton. Future Research Directions for Lung Volume Reduction Surgery. April 7, 1997.
63. **Lecturer, Distinguished Visiting Speaker Program**, McMaster University, Hamilton, "Dyspnea and the S-Bend". April 8, 1997.
64. **National Centers for Excellence Annual General Meeting**, "Non-Invasive Ventilation as an Adjunct to Exercise in Severe COPD". April 24, 1997.
65. **Featured Speaker, Clinical Problems Assembly**, ALA/ATS International Conference. "Breathlessness, Symptom Intensity, Hyperinflation, and Exercise Limitation in Patients with Chronic Airflow Limitation". May 16-21, 1997.
66. **NIH Workshop - Effective Symptom Control in Advanced Disease**, Rockport, Maryland, U.S.A. (1) "Dyspnea: A Basic Perspective", (2) "Dyspnea in Palliative Care: New Research Directions". September 22, 1997.

67. **ORCS/OLA Respiratory Update '97**, "The Management of Advanced COPD". September, 1997.
68. **CME** Brockville, Ontario. "Effective Symptom Control in Irreversible COPD", October 8, 1997.
69. **Grand Rounds**, Samaritan Hospital, Watertown, NY. November 18, 1997. "Advanced COPD: New Management Strategies".
70. **Atlantic Respiratory Conference**, Halifax, Nova Scotia. (1) "Canadian COPD Guidelines - Why are we Failing to Use Them?" (2) "Symptom Control in Advanced Chronic Obstructive Lung Disease", (3) "Dyspnea of Unexplained Origin - Case Studies". November 21-23, 1997.
71. **International Conference on COPD and Asthma**, Geneva, Switzerland. "Anticholinergics in Advanced COPD". November 28-30, 1997.
72. **Better Breathing '98**, Toronto, February 6-8, 1998. (1) Appropriate Use of Supplemental Oxygen. (2) Are People with Lung Disease Needlessly Denied Home Oxygen?
73. **ATS/ALA International Conference**, Chicago, Illinois. (1) Patients with Chronic Obstructive Lung Disease; Exercise Case Studies, (2) Ventilatory Mechanics, Control of Breathing and Respiratory Sensation in the Severe Asthmatic, (3) Dyspnea in Obstructive Lung Diseases: Mechanical Factors. April 24-29, 1998.
74. **ATS/ALA International Conference**, San Diego, California. (1) Dyspnea Relieving Strategies: Ventilatory Support, (2) Spirometric Predictors of Improvement in Exercise Endurance and Dyspnea after Acute Anticholinergic Therapy in COPD, (3) Dyspnea during Hyperinflation in Asthma, Quadriplegics and Normals. April, 1998.
75. Respiriology Meeting, Kelowna, BC. "Modern Management of COPD". September 30, 1998.
76. **Key Note Speaker**, 'Day in Respiriology', University of British Columbia, Vancouver. "Comprehensive Management of COPD; A-Z". October 2, 1998.
77. Pulmonary Speakers Annual Meeting, Scottsdale, Arizona. "Effective Symptom Control in COPD: The Role of Anticholinergics". October 16, 1998.
78. NIH Symposium; Symptom Perception in Asthma. Bethesda, Maryland. "Nature of the Mechanical Load in Asthma". October 22, 1998.
79. National Heart & Lung Institute of Sweden Annual Meeting, Uppsala, Sweden. "Dyspnea in Cardiopulmonary Disease: Mechanical Factors". October 22, 1998.
80. ACCP International Meeting, Toronto, Ontario. "Dyspnea in Cardiopulmonary Disease: Mechanical Factors". November 11, 1998.
81. ACCP International Meeting, Plenary Session, Toronto, Ontario. "Effects of Added O₂ on Exercise and Dyspnea in COPD". November 13, 1998.
82. Grosshansdorf Hospital, Hamburg, Germany. "The Evaluation of Bronchodilator Efficacy in COPD". November, 1998.
83. **Better Breathing '99**, Toronto, January 27-29, 1999. Approach to Dyspnea Management.
84. "ALA/ATS International Mtg San Diego. "New Innovations in the Management of Exertional Dyspnea: Ventilatory Assistance". April, 1999.
85. World COPD Conference, Paris, May 1999. Assessing Bronchodilator Efficacy in Advanced COPD - Does Spirometric Assessment need Rethinking?
86. Quebec, City, Quebec. "How Bronchodilators Relieve Symptoms in Advanced COPD". June, 1999.
87. Chair – Joint Session on Dyspnea, **European Respiratory Society Annual Meeting, Madrid**, Oct. 1999. Mechanisms of dyspnea in COPD.
88. **8th Congress of Lung Diseases, Sao Paulo Thoracic Society**, Sao Paulo, Brazil. (1) Mechanisms of Dyspnea in Obstructive Lung Disease. (2) Effective Symptom Control in Advanced COPD. (3) Mechanisms of Dyspnea in Restrictive Lung Disease (Interstitial Lung Disease, Stable Congestive Heart Failure). (4) Dyspnea of Unknown Origin. November, 1999.
89. **Icelandic Medical Association**, Reykjavik, Iceland. "Dyspnea in Cardiopulmonary Disease: Mechanical Factors. January 20-24, 2000.

90. **Congress of the “Deutsche Gesellschaft fur Pneumologie”**, Hamburg, Germany. “Differential Therapy of Chronic Airway Obstruction”. March 1-4, 2000.
91. **VII Symposium on Chronic Obstructive Pulmonary Disease**, Barcelona, Spain. “Assessment of Bronchodilator Efficacy in Symptomatic COPD: Is Spirometry Useful?”. March 30-31, 2000.
92. **ATS Postgraduate Course**, Toronto, Ontario. “Case Studies-Cardiopulmonary Exercise Testing in Patients with COPD”. May 5-10, 2000.
93. **ATS Symposium**, Toronto, Ontario. “Improving Exercise Tolerance: What is known? Where are we Heading?” May 5-10, 2000.
94. **ATS COPD Symposium**, Toronto, Ontario. “Dyspnea in COPD”. May 5-10, 2000.
95. **ATS/ALA Symposium**, Toronto, Ontario. Anticholinergic Therapy in COPD. May 5-10, 2000.
96. **German Thoracic Society Mini-Symposium, ATS/ALA International Meeting**, Toronto, Ontario. New clinical outcome measures in COPD. May 5-10, 2000.
97. **ORCS Symposium – Respiratory Trends into the Next Millennium**, Kingston, Ontario. “Benefits of exercise training: Psychological or Physiological?” June 8, 2000.
98. **Pneumoclub**, Ottawa, Ontario. “Effects of hyperoxia on ventilatory limitation during exercise in advanced COPD”. June 9, 2000.
99. **COPD2 International Meeting**, Birmingham, England. (1) Exercise tolerance. (2) Measuring work of breathing in COPD. June 14-17, 2000.
100. **Airways 2000**, Noosa, Australia. (1) “Role of Lung Function in the Assessment of Disease: Do Spirometric Measures need Rethinking?”. (2) Workshop – “Exercise Testing and Understanding the Causes of Dyspnea in COPD”. July 27-29, 2000.
101. **Family Medicine Grand Rounds**, Family Medicine Centre, Queen’s University. Optimal management of the COPD patient. January 30, 2001.
102. **Meakins Christie Workshop**, McGill University. Pharmacological volume reduction in advanced COPD. February 4, 2001.
103. **Exercise and Dyspnea: Round Table Report: Understanding dyspnea in COPD: Mechanisms, measurement and management**. Miami, Florida, February 24-25, 2001.
104. **Update in Pulmonary Medicine – Bi-Annual Clinic Day in Respiriology** – Peterborough, Ontario. New Concepts in the Treatment of COPD. GOLD Guidelines for COPD. April 4, 2001.
105. **Respirology Rounds** – London, Ontario. The impairment-disability interface in COPD. April 24th, 2001.
106. **ATS Annual Meeting**, San Francisco. Is FEV1 the best measure for COPD? Symposium – COPD: New Targets, New Tools. May 22, 2001.
107. **ATS Annual Meeting**, San Francisco. Respiratory system unloading. Symposium – Assessing Ventilatory Function and Capacity – Research Lessons for the Clinical Laboratory. May 22, 2001.
108. **Rehabilitation Symposium**, Quebec. Ventilatory assist during exercise in cardiopulmonary disease. June 7, 2001.
109. **Kingston-Ottawa Pneumoclub**. COPD: Diffusion, dyspnea and disability. Kingston General Hospital, June 15, 2001.
110. **COPD2 International Meeting**. (1) Clinical utility of work of breathing measurements in COPD. (2) Exercise tolerance as a clinical outcome measure in COPD. Birmingham, England, June 21-24, 2001.
111. **Invited Speaker and Chair: Exercise Capacity: The Impact of COPD (Symposium) during 11th European Respiratory Society Annual Congress**. Mechanisms of exercise limitation. Berlin, Germany, Sept. 22-26, 2001.

112. **Invited Speaker and Chair:** Clinical and Functional Correlates in COPD session during 11th European Respiratory Society Annual Congress. Evaluation of bronchodilator responses in patients with advanced COPD. Berlin, Germany, Sept. 22-26, 2001.
113. **Toronto Respiratory Rounds.** Exercise intolerance in COPD: Mechanisms and Management. October 16, 2001.
114. **Peterborough Respiratory Group.** Exercise testing in cardiopulmonary disease. October 22, 2001
115. **American College of Chest Physicians.** Pharmacological volume reduction in advanced COPD. Nov. 406, 2001.
116. **A Global COPD Conference, Management of Exertional Dyspnea.** (1) Dyspnea: the patient's complaint. (2) Management of exertional dyspnea. Kos, Greece, Nov 14- 17, 2001.
117. Queen's University CME. Optimal management of COPD. Kingston. Nov. 21, 2001.
118. Brockville Family Physicians CME. Update in the treatment of COPD. Nov. 27, 2001.
119. **British Thoracic Society Winter Meeting.** The clinical importance of dynamic lung hyperinflation. London, England, Dec. 4-6, 2001.
120. **CIHR New Frontiers Program.** "Research in COPD in Canada: From the cell to the community". Orford, Quebec. Jan 10-12, 2002.
121. **OTS Better Breathing, Toronto. COPD:** New insights into an old disease. Feb 1,2, 2002
122. **Common Primary Care Infections, Queen's CME.** Acute exacerbations of chronic bronchitis. March 6, 2002.
123. **3rd Annual Advances in Respiratory & Critical Care Medicine.** (1) Managing dyspnea in COPD. (2) COPD management: Review 2001. Whistler, B.C., April 5-7, 2002.
124. **COPD Management Review.** Review of bronchodilator efficacy. Rome, Italy, Apr. 19- 21, 2002.
125. **Postgraduate Course, ATS International Mtg.** Case Studies: Cardiopulmonary exercise testing in patients with COPD. Atlanta, May 17-22, 2002.
126. **Postgraduate Course, ATS International Mtg.** Role of respiratory muscle on dyspnea in exercise. Atlanta, May 17-22, 2002.
127. **COPD3 International Mtg, Birmingham, UK.** (1) Exercise testing in COPD: Utilization and interpretation in clinical trials. (2) Exercise and operating lung volumes in COPD. (3) Effect of tiotropium on exercise tolerance in COPD. June 10-14, 2002.
128. **Research in Progress, Queen's University.** (1) Mimicking asthma in the laboratory. (2) The effects of external mechanical hyperinflation in life-threatening asthma. June 18, 2002.
129. **Ottawa-Kingston Pneumoclub, Ottawa.** Update on long acting bronchodilators in COPD. June 21, 2002.
130. **Medical Grand Rounds, St. Michael's Hospital, Toronto.** The optimal management of COPD in 2002. July 3, 2002.
131. **4th Tokyo COPD Symposium, Tokyo, Japan.** Pathophysiologic mechanism and treatment of dyspnea in COPD. July 13, 2002.
132. **Chair, European Respiratory Society Annual Congress: Symposium - Tiotropium and the Treatment of COPD:** The Impact from Lung Function to Lifestyle. (1) Overview of COPD patient presentation. (2) Lung mechanics in COPD: The role of a once-daily inhaled M3 blocker. Sept. 14-18, 2002.
133. COPD Alliance Mtg, Halifax. What's New in the Canadian Thoracic Society COPD Guidelines? Nov. 15-17, 2002
134. **Asian Respiratory Symposium, Bangkok, Thailand.** (1) Role of M₃ receptor blockade. (2) Role of respiratory muscles in COPD. (3) Spiriva and impact on exercise tolerance. Nov 30-Dec 2, 2002.
135. **Swedish Respiratory Society.** (1) Ventilatory mechanics in COPD at rest and during exercise. (2) Exercise in COPD – pharmacological intervention. February 4-8, 2003.

136. **1st Asian COPD Regional Meeting, Shanghai, China.** (1) Ventilatory mechanics in COPD. (2) Exercise intolerance in COPD. February 19-23, 2003.
137. **Currents of Change:** COPD International Congress Meeting. Prague. Lung mechanics and exercise tolerance: Improving your patients' activity levels. March 28-29, 2003.
138. **3rd Cardiopulmonary Rehabilitation Symposium:** Quebec City, Quebec. Evidence-Based Interventions. Highlights of the guidelines. May 11-13, 2003.
139. Toronto Respiriologists. Pharmacotherapy of COPD. June 18, 2003.
140. **Kingston-Ottawa Pneumoclub.** Why the IC might be clinically important. June 20, 2003.
141. COPD: The Important Questions: Outcome Measures. Stresa, Italy. June 26-28, 2003.
142. **Invited Speaker,** Chilean Respiratory Society. Santiago, Chile. (1) Exercise limitation in COPD. (2) Mechanisms of dyspnea in COPD. (3) Alleviating dyspnea and improving exercise tolerance – a case-based approach. August 29-30, 2003.
143. **Invited Speaker & Co-Chair,** European Respiratory Society Annual Congress, Vienna, Austria. Improving exercise tolerance in COPD – A role for pharmacotherapy. Sept. 27 – Oct. 1, 2003.
144. **Invited Speaker,** Lovelace Respiratory Research Institute Annual Symposium. Sante Fe, New Mexico. Session 'New Methods in Treatment and Diagnosis of COPD/Emphysema. New physiological aspects of exercise in COPD. Oct. 12-15, 2003.
145. **CTS Scientific Day at CHEST 2003,** Orlando, Florida. The CTS Guidelines on COPD. Oct. 26, 2003.
146. **Satellite Symposia 2003, CHEST 2003,** Orlando, Florida. Impacting lifestyles: Real world benefits of COPD therapy. Oct. 27, 2003.
147. **“Physiology for the Clinician” CHEST 2003,** Orlando, Florida. Inspiratory capacity in exercise testing. October 28, 2003.
148. **Canadian Master Program in Respiratory Medicine,** Niagara-on-the-Lake. Combination therapy in COPD. November 28-29, 2003.
149. **COPD Genetics & Investigating the Therapeutic Potential of Ariflo.** Philadelphia, U.S.A. Understanding the lung volume effects of Ariflo and the therapeutic implications. December 9-10, 2003.
150. **13th Annual BCTS/BCSAI Case Challenge and CME.** Vancouver, B.C. (1) The optimal management of COPD. (2) Mechanisms of dyspnea in COPD: New insights. (3) From nihilism to optimism: Update in the treatment of COPD. (4) Management of the patient with advanced symptomatic COPD: a case-based approach. January 23-24, 2004.
151. **OTS Better Breathing 2004,** Toronto, Ontario. Lunch with a Professor Series. Practical cardiopulmonary exercise testing. January 30, 2004.
152. **OTS Better Breathing 2004,** Toronto, Ontario. Family Practice Program. The new COPD Consensus Guidelines – What do they mean in your practice? January 31, 2004.
153. **Invited Speaker, 3rd COPD Practice Physicians Mtg,** Nagoya, Japan. Effect of inhaled bronchodilators on exercise capacity in patients with COPD. March 6-7, 2004.
154. **Medical Grand Rounds, Queen's University.** Exercise intolerance in COPD: How bronchodilators help. March 25, 2004.
155. **15th Annual Therapeutics,** Kingston, Ontario. COPD: A preventable and treatable disease: New CTS Guidelines. April 7, 2004.
156. **Societe de Pneumologie de Quebec,** Quebec City, Quebec. (1) Hyperinflation and effort intolerance. (2) Grand Rounds, Laval Hospital. (3) l'Enfant-Jesus Hospital, Department of Medicine Conference: New Canadian Guidelines. April 7-8, 2004.
157. **Lung Function Day,** Lund, Sweden. (1) Spirometry. (2) Assessment of exercise performance. April 14-15, 2004.
158. **Guest Speaker,** Winnipeg Respiriologists, Manitoba. COPD Guidelines: do they really answer the important questions? April 20, 2004.

159. **Ontario Respiratory Care Society, Respiratory Potpourri 2004.** Kingston, Ontario. COPD Consensus Guidelines 2003. May 6, 2004.
160. **ATS 100th International Conference**, Orlando, Florida. Postgraduate Course “Cardiopulmonary Exercise Testing for the Clinician: A Case-Based Approach for Putting Guidelines into Practice.” Case studies: Patients with COPD. May 21-26, 2004.
161. **ATS 100th International Conference**, Orlando, Florida. Postgraduate Course “Dyspnea: New Insights and Approaches to an Old Problem”. Basic Mechanisms: The role of dynamic hyperinflation. May 21-26, 2004.
162. **Invited Speaker/Facilitator, ATS International Conference**, Orlando, Florida. Postgraduate Course: Hyperinflation: The Critical Target in COPD. Importance and consequences of lung hyperinflation: dyspnea and exercise. May 21-26, 2004.
163. **COPD4 International Mtg**, Birmingham, England. Plenary Session. Hyperinflation. June 9-11, 2004.
164. **Ottawa-Kingston Pneumoclub**, Ottawa. Unexplained dyspnea in cancer patients. June 25, 2004.
165. **Symposium “Reducing Trapped Air in COPD – Releasing the Patient”, ERS, Glasgow**, Scotland. Air trapping: linking pathology with outcomes in COPD. Sept 4 – 8, 2004.
166. **COPD Forum for Specialists**, Copenhagen, Denmark. Hyperinflation in COPD. Sept. 24-25, 2004.
167. **Airways Meeting, South Australia.** (1) Effects of bronchodilators on hyperinflation. (2) Exercise performance as a treatment outcome. October 22-23, 2004.
168. **Toronto Respiriologists.** Air trapping: A critical target. November 17, 2004.
169. **Medical Grand Rounds**, Sunnybrook & Women’s Hospital, Toronto. Modern management of COPD. November 18, 2004.
170. **Taiwan Cardiopulmonary Assoc.** (1) Exercise limitation in COPD: mechanical factors. (2) Pharmacological volume reduction and its positive implications. December 2-5, 2004.
171. **Medical Grand Rounds Montreal, Quebec,** Air trapping: The critical target. .
172. **IUPS Symposium, Dyspnea: Mechanisms and Management**, San Diego, CA. Dynamic hyperinflation and dyspnea in asthma. March 29-30, 2005.
173. **Chair, SPIRIVA Expert Forum Plenary Session**, Lisbon, Portugal. April 5-9, 2005.
174. **Implementing Practice Guidelines Workshop, Quebec City**, Quebec. Session: (1) Current Initiatives on D&I of Asthma and COPD Guidelines I. (2) What is the Best Way to Implement Guidelines I April 14-16, 2005.
175. **9th State of the Art Interdisciplinary Review Course, Athens, Greece.** (1) Dyspnea in asthma: mechanical factors. (2) Mechanisms of exercise intolerance in COPD: The role of hyperinflation. (3) Mechanisms of exercise intolerance in COPD: the effect of tiotropium in lung mechanics. April 20-24, 2005.
176. **Satellite Symposium, 4th Quebec International Symposium on Cardiopulmonary Prevention/Rehabilitation** Quebec City. COPD as an inflammatory disease. New strategies to evaluate the response to pharmacologic treatments. May 10, 2005.
177. **Postgraduate Course – COPD: State of the Art for the Clinician and Researcher**”, ATS International Conference, San Diego. Assessment of functional outcome. Postgraduate Course – E13 From Air Trapping to Breathlessness: San Diego, CA, May 20, 2005.
178. **Kingston-Ottawa Pneumoclub, Queen’s University, Kingston.** Ventilatory constraints during exercise in COPD patients stratified by CTS criteria. June 17, 2005.
179. **Thoracic Society of Australia and New Zealand Advanced Course.** (1) Dyspnea: Etiology and measurement. (2) Exercise in respiratory disease. Sydney, Australia, June 24-26, 2005.
180. **European Respiratory Society. Symposium ‘Mechanical Factors Limiting Physical Exercise in Disease’.** How treatment may improve physical performance and dyspnea in COPD. ‘Defining

- Essential Maintenance Therapy in COPD'. Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance. Copenhagen, Sept. 17-21, 2005.
181. **Understanding Airway Diseases: A Celebration of the Firestone Institute.** Chronic airflow limitation. Hamilton, October 5-7, 2005.
 182. **XI Colombian Congress of Pulmonary Medicine.** Symposium "Changing the Course of COPD". Impacting patient-centred outcomes. 2) Flow limitation and air trapping in COPD. Colombia, S. America, October 14, 2005.
 183. **American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR) National Mtg.** Clinical importance of lung hyperinflation. Milwaukee, Wisconsin, October 20-23, 2005.
 184. **Distinguished Scientist Honour Lecture,** American College of Chest Physicians. Dyspnea in obstructive lung disease: New insights. 2) Simplified detection of dynamic hyperinflation, 3) Dyspnea and the patient with COPD Montreal, Quebec, Oct 29 – Nov. 3, 2005.
 185. **Ottawa Gatineau SCPE/CSEP Symposium** 'Respiratory Limitations to Exercise Tolerance in Specific Populations'. Gatineau, Quebec. Nov. 10-12, 2005.
 186. **Assoc. for Respiratory Technology and Physiology (ARTP).** COPD. Brighton, UK, January 26-28, 2006.
 187. **Philippine College of Chest Physicians Annual Conference.** Impacting Patient-Centred Outcomes in COPD: Breathlessness and Exercise Tolerance. Hong Kong, February 27, 2006
 188. **Philippine College of Chest Physicians Annual Conference.** (1) What's new in COPD. (2) Strategies for Improving and Maintaining Exercise Endurance in COPD Patients. (3) Meet the Faculty "A quest for the holy grail in COPD". Mandaluyong City, Philippines, February 28 – March 3, 2006.
 189. **National COPD Symposium, Ho Chi Minh City, Vietnam,** March 3-5, 2006. (1) The Effect of Tiotropium on Lung Hyperinflation, Dyspnea and Exercise Tolerance in COPD. (2) Dynamic Hyperinflation and Exercise Intolerance in COPD, and the Role of Anticholinergics
 190. **5th International Conference on Management and Rehabilitation of Chronic Respiratory Failure** (from ICU to home). Medical pneumonectomy: a great bargain. Stresa, Italy, March 22-25, 2006.
 191. **Postgraduate Seminar for Chest Physicians.** Bronchodilatation and COPD. Ghent, Belgium. March 30, 2006.
 192. **American Thoracic Society Meeting.** Symposium: Update on Cardiopulmonary Exercise Testing: Putting Recent Advances into Practice. Case Studies: Exercise in chronic obstructive pulmonary disease. San Diego, May 19, 2006.
 193. **Canadian Respiratory Leadership Forum.** Pharmacological lung volume reduction in COPD. Montebello, Quebec, June 9-11, 2006.
 194. **American COPD Conference:** Impact and Change in Exercise Tolerance on Activities of Daily Living and Quality of Life in COPD. Dynamic hyperinflation. Orlando, Florida, June 12-13, 2006.
 195. **5th International Conference on COPD.** Session entitled "The diagnostic revolution and what it can offer for the future". What new physiological and exercise testing can offer. Birmingham, UK. June 28-30, 2006.
 196. **European Respiratory Society Symposium:** Management of Dynamic Hyperinflation during Exercise in COPD. Effects of bronchodilators on dynamic hyperinflation. Implications for exercise tolerance. Munich, Germany, Sept 2-6, 2006.
 197. **Pfizer Visiting Professorship in Pulmonology.** Dynamic lung hyperinflation, dyspnea and exercise intolerance in COPD. Yale University, Hartford, Connecticut, November 15, 2006.
 198. **New York State Thoracic Society – Trudeau Lecture at Scientific Assembly.** West Point, NY, February 2-3, 2007.

199. **Respirology Rounds**, London Health Sciences Centre. Feb 2007.
200. **Congress of the South African Thoracic Society.** (1) What's important in respirology physiology? (2) Cardiopulmonary exercise testing. (3) Pathophysiology of COPD. (4) Improving exercise tolerance in COPD. Cape Town, South Africa, March 2 –5, 2007.
201. **Pulmonary Grand Rounds, UCLA**, California, April 20, 2007.
202. **Postgraduate Course - Pulmonary Rehabilitation and the Flight of the Bumblebee: Refining the process and Expanding the Scope.** Approaches to reducing dyspnea. (2) Pathophysiology of COPD and Therapeutic Intervention. Detection of dynamic hyperinflation and incremental cycle ergometry. (3) **Chair**, Mini-Symposium – Dynamic Hyperinflation (DH) in COPD: Evaluation and Treatment. ATS International Conference, May 18, 2007.
203. **Kingston-Ottawa Pneumoclub.** Abnormal ventilatory response to exercise in GOLD 1 COPD. Kingston, June 15, 2007.
204. **Frontiers in Respiratory Medicine.** Dynamic hyperinflation, dyspnea and exercise intolerance in COPD. Maynooth, Ireland, October 13, 2007.
205. American College of Chest Physicians Annual Meeting, Chicago, October 23, 2007. (1) Canadian COPD Guidelines 2007. (2) COPD Treatment II.
206. **University of Western Ontario Visiting Professor.** (1) Respirology Residents' Seminar Series, Pathophysiology of early COPD, (2) Grand Rounds, London Health Sciences Centre, What's new in the 2008 COPD Guidelines? (3) Medical Grand Rounds, St. Joseph's Hospital, What's new in the 2008 COPD Guidelines? London, Ontario, January 23 & 24, 2008.
207. **Asia Pacific COPD Forum 2008.** (1) The Canadian COPD Guidelines: Evolving constructs of care. (2) Managing dyspnea and activity limitation in COPD: An evidence-based approach. Bangkok, Thailand, February 22&23, 2008.
208. **Canadian Society of Hospital Pharmacists.** The prevention and treatment of exacerbations of COPD: Review of the 2007 Canadian Thoracic Society's (CTS) Guidelines. Kingston, Ontario, March 26, 2008.
209. **NIH Exploratory Workshop: Asthma in the Elderly.** Ventilatory constraints during exercise in the elderly. Bethesda, MD, April 7-8, 2008.
210. **Ontario Respiratory Care Society Conference**, "Educate, Medicate, Ventilate and Update: A Respiratory Review". CTS guidelines for COPD management. Kingston, Ontario, April 10, 2008.
211. **Gananoque Family Physicians.** Changing the clinical course of COPD. Gananoque, Ontario, April 24, 2008.
212. **American Thoracic Society Meeting.** (1) Clinical significance of pulmonary hyperinflation in COPD. (2) Static and dynamic hyperinflation: Therapeutic strategies. (3) Exercise responses in cardiopulmonary disorders. Toronto, Ontario, May 16-21, 2008.
213. **Kingston-Ottawa Pneumoclub.** Evaluation of acute bronchodilator reversibility in GOLD Stage I COPD. Ottawa, June 13, 2008.
214. **Jean-Jacques Gauthier Lecturer.** Maximizing dyspnea relief in patients with advanced COPD. Sacre-Coeur Hospital, Montreal, June 18, 2008.
215. **1st. Canadian Respiratory Conf.** Clinical guidelines in airways disease: COPD. Montreal, Quebec, June 19-21, 2008.
216. **Visiting Professor Program, Pfizer Inc.** (1) The rationale for early introduction of anticholinergic therapy in COPD. (2) Improving dyspnea and exercise endurance in advanced COPD: (3) Refining cycle exercise testing protocols to better evaluate bronchodilator efficacy in clinical trials. New York, July 24, 2008.
217. **COPD: The Important Questions.** COPD and Asthma: Similarities and Differences. Physiology of COPD and asthma. Rome, Italy, September 11-13, 2008.

218. **China National Respiratory Congress.** (1) Link between air trapping reduction and impact of COPD clinical course, Uplift rationale and meaning of FEV1 decline rate change. (2) Acquiring long term success in COPD clinical course administration. Xi'an, China, September 18 – 25, 2008.
219. **Meet the Professor Seminar, European Respiratory Society Annual Congress.** MP8 – Mechanisms of exercise intolerance in COPD and their amelioration. Berlin, October 4-8, 2008.
220. **Chair. European Respiratory Society Annual Congress.** Respiratory muscle limitations to exercise tolerance. Berlin, October 4-8, 2008.
221. Ottawa Multi-Therapeutic Day – 3rd Annual “Share the Care Symposium –Helping you Help your Patients”. COPD and smoking cessation: the latest evidence in patient management. Ottawa, October 24, 2008.
222. **Annual John Rankin Memorial Lecturer, University of Wisconsin.** *Grand Rounds:* Improving dyspnea and activity limitation in advanced COPD. *Asthma Rounds:* The origins of dyspnea in asthma. Madison, Wisconsin, November 13-14, 2008.
223. **COPD– Looking at a Better Life for Patients.** From exercise ‘intolerance’ to disability. Rome, Italy, November 20-23, 2008.
224. **OTS Better Breathing Symposium.** “Mild” COPD: Is there a case for earlier intervention? “Toronto, Ontario, January 31, 2009.
225. **COPD: Reactive Past, Preventive Future 2009.** Physiology of COPD in men and women. Vancouver, BC, February 5-7, 2009.
226. **COPD Phenotypes Meeting , Denver** Does hyperinflation denote a distinct phenotype in COPD? Denver, Colorado, March 5-6, 2009.
227. **2009 Canadian Respiratory Conference; A Breath of Fresh Air.** Obesity in COPD. Toronto, Ontario, April 23-25, 2009.
228. **Clinical Year in Review Session, American Thoracic Society** Annual Meeting. Cardiopulmonary Exercise Testing and Pulmonary Rehabilitation. Exercise testing in idiopathic pulmonary fibrosis. 2)，“Ventilatory Limitations at Rest and During Exercise in Obesity”. Mechanisms of exertional dyspnea in obesity. San Diego, California, May 16-20, 2009.
229. **European Respiratory Society:** “Cardiopulmonary Exercise Testing in the Evaluation of the Respiratory Patient”, Postgraduate Course. Clinical evaluation of exertional dyspnea. 2)“Clinical Lessons from Cardiopulmonary Interactions during Exercise”. 3) Cardiopulmonary interactions during exercise in COPD. “New Developments in Exercise Physiology”. Vienna, Austria, Sept. 12-16, 2009.
230. **Centennial Family Physicians CME Program.** COPD: The latest discoveries and the benefits of pulmonary rehabilitation. Kingston, Ontario, September 28, 2009.
231. **Cobourg Physicians CME Program.** COPD: The latest discoveries and the benefits of pulmonary rehabilitation. Cobourg, Ontario, October 7, 2009.
232. **Perth Family Physicians.** COPD: Earlier diagnosis today = a better tomorrow. Perth, Ontario, October 9, 2009.
233. **Winnipeg Respiratory Specialists Annual Meeting.** How respiratory mechanics change with the progression of COPD. Winnipeg, Manitoba, October 19, 2009
234. **Royal Jubilee Hospital Grand Rounds.** The pathophysiology and clinical consequences of mild COPD – the case for earlier intervention. Victoria, BC. October 20, 2009.
235. **Grand Rounds, Royal Colombian Hospital.** The pathophysiology and clinical consequences of mild COPD – the case for earlier intervention. Vancouver, BC, October 20, 2009.
236. **BC Thoracic Society Dinner.** The pathophysiology and clinical consequences of mild COPD – the case for earlier intervention. Vancouver, BC. October 20, 2009.

237. **Vancouver General Hospital**, Breakfast with Respiratory Fellows. Pathophysiology of COPD with a particular emphasis on exercise physiology in COPD and the effects of lung volume reduction surgery. Vancouver, BC. October 21, 2009.
238. **Pulmonary Research Rounds**, University of Alberta Hospital. The impact of obesity on the physiology of COPD and asthma. Edmonton, Alberta. October 21, 2009.
239. **Evening Dinner Program, Edmonton** Respiriologists, GP's, & IM specialists. How respiratory mechanics change with the progression of COPD. Edmonton, Alberta. October 21, 2009.
240. **Grand Rounds, Royal Alexandra Hospital**. The pathophysiology and clinical consequences of mild COPD – the case for earlier intervention. Edmonton, Alberta. October 22, 2009.
241. **Pulmonary Research Round, Foothills Hospital**. The role of cardiopulmonary exercise testing in the clinical evaluations of dyspnea – an integrated approach. Calgary, Alberta, October 22, 2009.
242. **Respiratory Academic Rounds, Foothills Hospital**. The pathophysiology and clinical consequences of mild COPD – the case for earlier intervention. Calgary, Alberta, October 23, 2009.
243. **Cornwall Family Physicians**. COPD: Earlier diagnosis today = a better tomorrow. From diagnosis to the latest discoveries. Cornwall, Ontario, October 28, 2009.
244. **Respirology Grand Rounds, University of Toronto**. COPD: Lessons from body boxes, balloons and bicycles. Toronto, Ontario, November 20, 2009.
245. **COPD Symposium**. The physiology of mild COPD and its clinical consequences. Meakins-Christie Laboratories, McGill University, Montreal, Quebec. January 20, 2010.
246. **Ontario Thoracic Society Better Breathing Meeting**. Respirology Residents' Symposium, Physiology of COPD and it's manipulation. Toronto, Ontario, January 30-31, 2010.
247. **Northern Ontario Multidisciplinary Update for Family Physicians**. COPD. Earlier Diagnosis today = A Better Tomorrow. From Diagnosis to the Latest Discoveries. Sudbury, February 12, 2010.
248. **Canadian Respiratory Congress Mtg**. The physiology of mild COPD during rest and exercise. 2) The future of Canadian respiratory research. Halifax, Nova Scotia. April 30, 2010.
249. **Invited Speaker and Co-Chair**, American Thoracic Society Annual Meeting Postgraduate Course. Case studies in lung disease. New Orleans, Louisiana, May 14-19, 2010.
250. **Eurostage Meeting. Workshop in Respiratory Diseases**. Dispnea e iperinflazione dinamica. Rome, Italy, June 3-4, 2010.
251. **European Respiratory Society Annual Meeting. Postgraduate Course**. Exercise testing for the evaluation of interventions in clinical practice trials. Barcelona, Spain, September 18-22, 2010.
252. **Medicine Grand Rounds**, Royal University Hospital. Pathophysiology and clinical consequences of mild COPD: The case for earlier intervention. Saskatoon, Sask. October 13, 2010.
253. **Evening presentation to Royal University Hospital & Community Respirologists, GP's and Health Council GP's**. Pathophysiology and clinical consequences of mild COPD: The case for earlier intervention. Saskatoon, Sask. October 13, 2010.
254. **Northgate Medical Clinic**. Pathophysiology and clinical consequences of mild COPD: The case for earlier intervention. Regina, Sask. October 14, 2010.
255. **Medicine Grand Rounds**, Regina General Hospital. Pathophysiology and clinical consequences of mild COPD: The case for earlier intervention. Regina, Sask. October 14, 2010.
256. **American College of Chest Physicians Annual Meeting**. (1) Cardiopulmonary exercise testing, an underutilized tool. (2) Role of pharmacotherapy in early COPD. (3) What's new in COPD (Chair). (4) Physiologic advances in understanding COPD. (5) Respiratory mechanics in

- COPD and the impact on patient physical activity. Vancouver, BC, October 31- November 4, 2010.
257. **Brazilian Thoracic Society Annual Meeting.** (1) COPD: Lessons learned from balloons, body boxes and bicycles. (2) The pathophysiology of mild COPD and the case for earlier treatment. (3) Pharmacological lung volume reduction in COPD and its clinical consequences. (4) The impact of obesity on the respiratory system in patients with airway obstruction. (5) New insights into the breathlessness of pregnancy. Curitiba, Brazil, November 16-20, 2010.
 258. **Ontario Thoracic Society Annual Better Breathing Conference** Pro side: debate: Every patient with GOLD stage I COPD should be considered for treatment. . Toronto, Ontario, January 28-30, 2011.
 259. **CanCOLD Seminar.** When obesity and COPD collide: physiological and clinical consequences. Respiratory Epidemiology & Clinical Research Unit, McGill University, Montreal, Quebec, April 7, 2011.
 260. **Leuven University.** COPD: Lessons learned from body boxes, bicycles and balloons. Belgium, April 27, 2011.
 261. **Canadian Respiratory Conference,** Niagara Falls, (1) Physiology for the clinician: understanding why pulmonary rehabilitation works in COPD. (2) Small airways dysfunction in mild COPD: Is it clinically relevant? April 28-30, 2011.
 262. **Scientific Symposium Obesity:** Implications for the Clinical Practice of the Pulmonary, Critical Care and Sleep Physician. Talk: COPD and obesity: Physiological implications and management approaches. American Thoracic Society Annual Meeting, Denver Colorado, May 13-18, 2011.
 263. **Kingston-Ottawa Pneumoclub.** Physiological effects of roflumilast at rest and during exercise in COPD. Kingston, Ontario, June 10, 2011.
 264. **UK Physiological Society Main Meeting.** When obesity and COPD collide: Physiological and clinical consequences. Oxford, UK, July 12-14, 2011.
 265. **European Respiratory Society Annual Meeting.** (1) Postgraduate course “Improving skills in cardiopulmonary exercise testing”. Talk: Practical aspects of end-tidal volume measurements during exercise. (2) Exercise assessment in different diseases. Joint Chair, Poster discussion. (3) Symposium “Obesity and the Lung”. Talk: When obesity and COPD collide: physiological and clinical consequences. Amsterdam, September 24-28, 2011.
 266. **COPD Academy/COPD Medical Seminars.** (1) The progression of COPD. Lessons from balloons, body boxes and bicycles. (2) Modern pharmacotherapy of COPD. (3) Wakayama COPD Society. Dyspnea in COPD patients – mechanism and its treatment. (4) How can we evaluate the efficacy of pharmacotherapy for COPD. Tokyo, Japan. October 16, 2011.
 267. **Spanish National Respiratory Symposium.** The continuum of COPD and the role of bronchodilators. Palma de Mallorca, Spain. February 25, 2012.
 268. **Alberta Respiratory Disease Symposium.** The Continuum of COPD: a physiological perspective. Edmonton, Alberta, March 3, 2012.
 269. **Clinical Rounds, Firestone Institute for Respiratory Health,** McMaster University. The Continuum of COPD: A hyperinflated perspective. Hamilton, Ontario, April 3, 2012.
 270. **Mississauga Respirology Journal Club.** The Continuum of COPD: A hyperinflated perspective. Mississauga, Ontario, April 3, 2012.
 271. **Canadian Respiratory Conference.** Dyspnea and exercise intolerance in COPD: New physiological insights. Vancouver, BC, April 27, 2012.
 272. **Obstructive Lung Disease Symposium, Cedars Sinai Medical Centre.** Obstructive Lung Diseases: Clinical & Pathophysiological Approach to Evaluation and Management in 2012. (1) Speaker: “COPD exacerbations: pathophysiology & treatment. (2) Moderator, Session 2. Los Angeles, California, April 28, 2012.

273. **St. John's Respiriologists. St. John's, Newfoundland, May 1, 2012**
274. **Medical Rounds, St. Clares Hospital.** The prevention of AECOPD. What's New? St. John's, Newfoundland, May 2, 2012.
275. **Halifax Respiriology Rounds.** The continuum of COPD: A hyperinflated perspective. Halifax, Nova Scotia. May 2, 2012.
276. **Medical Rounds, Queen Elizabeth Hospital.** A continuum of COPD. A hyperinflated perspective. Halifax, Nova Scotia. May 3, 2012.
277. **Moncton Respiriologists.** A continuum of COPD. A hyperinflated perspective. Moncton, New Brunswick. May 7, 2012.
278. **American Thoracic Society Annual Meeting.** (1) Prevalence, detection and pulmonary implications of hyperinflation in COPD. (2) Obesity and exercise: What does the clinician and researcher need to know? (3) Facilitator, Thematic Poster Session: Emphysema and COPD: Pathophysiology. San Francisco, California, May 18-23, 2012
279. **Norweigan Respiratory Society Annual Meeting.** (1) Mechanisms and management of dyspnea in COPD: new insights. (2) Clinical assessment of the dyspneic patient: the utility of exercise testing. (3) Improving dyspnea and exercise endurance in COPD: targeting lung hyperinflation. Stavanger, Norway. June 7-9, 2012.
280. **Inspiration 2012: Exploring Frontiers in Respiratory Medicine.** (1) Early physiological changes in COPD. (2) Facilitator Workshop; Dynamic hyperinflation and dyspnea in COPD. Prague, Czech Republic. June 10, 2012.
281. **COPD8 International Meeting.** Session: The Role of Fat in COPD. Title: Influence on mechanics/physiology. Birmingham, UK, June 20-22, 2012.
282. **European Respiratory Society Annual Meeting. Symposium:** Over a Decade of Continuous Innovation in COPD. Title: GOLD Goals 2011 – how did the tiotropium clinical trials contribute? Vienna, Austria. Sept 1-5, 2012.
283. **Lakeridge Health Centre.** Prevention of exacerbations of COPD: what's new? Oshawa, Ontario. September 24, 2012.
284. **American College of Chest Physicians (CHEST) Annual Mtg.** (1) Panel Discussion: Dyspnea: Understanding Mechanisms & Palliative Interventions. Talk: Understanding mechanisms of dyspnea. (2) CTS Debate: COPD GOLD Standards are Fool's Gold. Atlanta, Georgia, October 20-25, 2012.
285. **ERS Research Seminar – Dyspnea: Multidimensional and Multidisciplinary.** (1) Dyspnea during exercise in patients with cardiorespiratory disease. (2) The clinical management of exertional dyspnea in patients with cardiorespiratory diseases. (3) Discussant x 2: Air hunger vs excessive effort/work of breathing & The role afferent feedback from skeletal muscles, heart and lungs in the perception of effort in healthy adults. Paris, France, November 8-9, 2012.
286. **Landmark Scientific Symposium – Obesity and the Lung – Bigger isn't always better".** (1) Mechanisms of dyspnea in COPD (2) The continuum of COPD – physiological perspective. Brisbane, Australia. November 24 & 25, 2012.
287. **OTS Annual Better Breathing Conference.** Revisiting pink puffers, blue bloaters and other "new" phenotypes of COPD in the modern era. Toronto, Ontario. February 1, 2013.
288. **Association for Respiratory Technology & Physiology (ARTP). P K Morgan Memorial Lecture.** (1) Why do we need more respiratory physiology. (2) Meet the Expert Session. Hinckley Island. February 7-9, 2013.
289. **National Society of Respiratory Medicine, Mexico.** (1) The Continuum of COPD: a physiological perspective. (April 3) (2) When obesity and COPD collide: physiological and clinical implications. (April 4) Merida, Mexico. April 1-5, 2013.

290. **American Thoracic Society Annual Meeting.** Postgraduate Course: Update in COPD Management, May 18. Physiological changes in early COPD and relation to management. (May 18) Philadelphia, PA. May 17-22, 2013.
291. **Irish Lung Foundation.** COPD: a physiological continuum. Dublin, Ireland, June 14, 2013.
292. **European Respiratory Society Annual Meeting.** Postgraduate Course: Cardiopulmonary Exercise Testing in the Evaluation of Patients with Respiratory Diseases, September 7. Exercise testing for the evaluation of pharmacological interventions in clinical practice. Barcelona, Spain, September 7-11, 2013.
293. **Third Guangzhou International Congress.** When obesity and COPD interact: physiological implications. Guangzhou, China, October 10-12, 2013.
294. **Invited Speaker:** Lung function and exercise tests – which methods tell us what? 1st World Lung Disease Summit Meeting. Lisbon, Portugal, November 15-17, 2013. Presentation November 16.
295. **Gairdner, UBC & St. Paul’s Hospital 2013 Symposium on COPD:** New Approaches toward Prevention and Cure. Physiological characteristics and phenotypes. Vancouver, BC, December 3-4, 2013.
296. **COPD Istanbul International Conference.** (1) GOLD Grade I-B – physiological characterization. (2) Physiological phenotypes of COPD. (3) When obesity and COPD collide: Physiological and clinical consequences. Istanbul, Turkey, March 7-10, 2014.
297. **24th Annual Therapeutics Update, Queen’s University.** Wheezy like Sunday morning. Puffers are pink: bloaters are blue: With all these new inhalers, what’s a GP to do? Kingston, Ontario, April 12, 2014.
298. **1st Annual Department of Medicine Day.** A Practical Review for Health Care Professionals in Primary Care. Outpatient management of COPD: can specialized clinics and new therapeutic approaches prevent hospitalization of COPD patients? Kingston, Ontario, May 14, 2014.
299. **American Thoracic Society Annual Conference.** Session: COPD: Exercise and Rehabilitation. Wednesday, May 21. San Diego, California. May 16-21, 2014.
300. **Ottawa/Kingston Pneumoclub.** “Mild COPD”: what spirometry conceals, exercise tests reveal! Ottawa General Hospital, Ottawa, Ontario. June 6, 2014.
301. **Primary Care Updates.** Ottawa, Ontario, June 13, 2014.
302. **COPD9 International Conference.** Plenary Session “COPD: The physiologists view”. Birmingham, UK. June 25-27, 2014.
303. **European Respiratory Society Annual Meeting.** (1) Postgraduate Course Cardiopulmonary Exercise Testing. Presentation September 6th, Exercise testing to evaluate therapeutic interventions. (2) Symposium “COPD Management on the Cusp of Change”. Presentation September 7th; Exploring the role of LAMAs in enhancing patient activity and health status in COPD. Munich, Germany, September 6-10, 2014.
304. **CRRN Investigator Meeting, Ottawa,** January 15-16, 2015. Physiological impairment in early COPD. Presented January 15.
305. **Ontario Thoracic Association Annual Better Breathing Conference.** Joint OTS/ORCS Scientific Program: What’s New in Lung Health? Optimizing management of COPD in the modern era. January 30, 2015. Toronto, Ontario January 30-February 1, 2015.
306. **Israel Society of Pulmonology COPD Seminar.** Israel, February 25-27, 2015. (1) “Mild” COPD: what spirometry conceals. (2) Understanding dyspnea and activity limitation across the continuum of COPD: a physiological perspective.
307. **Canadian Respiratory Conference.** (1) Practical Guidelines for COPD Management: the changing landscape. April 24. Title: Modern pharmacotherapy for COPD: Rationalizing treatment choices for the individual. (2) Mild COPD: What spirometry conceals! April 25, 2015. Ottawa, Ontario April 23-25, 2015.

308. **American Thoracic Society Annual Meeting**, May 15-20. (1) Postgraduate Course: New Approaches to Evaluating Function and Exercise in Patients with Pulmonary Disease – General Information. Talk: Tests to evaluate dynamic hyperinflation in pulmonary disease. May 15, 2015. (2) Postgraduate Course: ATS and ERS Statement Updates in Pulmonary Rehabilitation, Skeletal Muscle Dysfunction, Nutrition, Field Testing and Physical Activity. Talk: Mechanisms and measures of dyspnea, May 16, 2015. (3) Symposium: Crossing Specialty Boundaries: COPD, Co-Morbidities and Pulmonary Rehabilitation. Talk: Obesity and COPD: The implications for pulmonary rehabilitation, May 19, 2015.
309. **Kingston-Ottawa Pneumoclub**. GOLD Stage 0 COPD revisited. Kingston, Ontario. June 12, 2015.
310. **2nd Annual Firestone Institute for Respiratory Health Day**. Management in Primary Care Practice. Talk: COPD management in the modern era. Saturday, September 19th, 2015. Hamilton, Ontario.
311. **European Respiratory Society International Congress**, Sept 26-30, 2015. Postgraduate course; Advanced respiratory and cardiovascular testing. Presentation Sept. 26: Measuring dyspnea in health and disease. Amsterdam, Netherlands.
312. **ACCP CHEST**, October 24-29, 2015. (1) Unexplained dyspnea (Oct. 24). (2) Dyspnea in COPD: Pathophysiology and treatment (Oct. 25). (3) Measuring dyspnea in clinical practice (Oct. 26). (4) Cardiac CPET cases (Oct. 27). Montreal, Quebec.
313. **Quebec Respiriologists Association**. University of Montreal. Pathophysiology of COPD. January 16, 2016.
314. **26th Annual Therapeutics Update**. Queen's University. Puffer update: Within our gasp. Kingston, Ontario, February 24th, 2016.
315. **CHEST World Congress 2016**. (1) COPD: Diagnosis. (2) Dyspnea. Shanghai, China April 14-17, 2016.
316. **CHEST International Conference on Respiratory Pathophysiology, Sleep and Breathing**, June 15-17, 2016. Mechanisms of dyspnea in chronic interstitial and obstructive diseases: final common pathways, presented June 15. Rome, Italy.
317. **International Symposium on COPD (University of Florence)**. Florence, Italy, June 23-25, 2016. What spirometry doesn't tell you in mild COPD (presented June 24).
318. **European Respiratory Society International Congress**, September 3-7, 2016. London, England. (1) Measuring exertional dyspnea in health and disease (presented September 3). (2) Chair session Dyspnoea and respiratory muscle/mechanics anomalies in disease (September 5).
319. **RENAISSANCE: Methodology for young pulmonologists**, February 1, 2017, Verona, Italy. Mild COPD: an underestimated and underrated disease.
320. **Horizons in Pneumology – VII Edition**. February 2, 2017, Verona, Italy. Mild COPD: an underestimated and underrated disease.
321. **27th Annual Therapeutics Update, Queen's University**. The lung and the breathless. Kingston, Ontario, March 1, 2017.
322. **Ontario Lung Association BREATHE Workshop**. COPD: What's new? Brockville, Ontario, April 13, 2017.
323. **3rd Annual Update for the Hospitalist**. COPD & PFTs: Interpreting the results. Napanee L&A Country General Hospital, April 19, 2017.
324. **Canadian Respiratory Conference**. Dyspnea: Mechanisms and management in advanced COPD. Montreal, Quebec, April 27-29, 2017. Presented April 28.
325. **Joint CHEST-SGP Congress 2017**. Basel, Switzerland, June 7-9, 2017. Respiratory mechanics and dyspnea. Presented June 8, 2017.
326. **European Respiratory Society Annual Congress**. Postgraduate course: Breathing pattern and dynamic hyperinflation presented September 11th. Symposium: From Small Airways

- Dysfunction to Dyspnoea in COPD. Title: Clinical implications of small airways dysfunction in COPD presented September 13th. Milan, Italy, Sept. 9 – 13, 2017.
327. **Italian Pulmonologists Congress. International Symposium on Pharmacology & Therapeutics of Bronchodilators.** Plenary Session “Controversies surrounding bronchodilators”. October 20th. Assessing the exercise response to a bronchodilator. Rome, Italy, October 19-21, 2017.
 328. **American College of Chest Physicians (CHEST).** Plenary presentation: Exercise testing in COPD (Oct 29). Toronto, Canada, October 27 – Nov 1, 2017.
 329. **Ludwig Engel Honorary Visiting Professor Oration for 2017.** (1) Mechanisms and management of breathlessness in COPD: New insights. (2) 2nd Oration Talk: The Clinical Physiologist: a vanishing phenotype! Sydney, Australia, November 2, 2017.
 330. **The 2017 International COPD Conference (Investigating the Changing Face of COPD).** Maximal bronchodilatation at initiation of therapy vs. progressive bronchodilation? Philadelphia, PA, November 15, 2017.
 331. **1st Symposium on Chronic Lung Diseases of the Center for Innovative Medicine (CIM). From Bench to Bedside.** Personalized pharmacotherapy in COPD. Are we there yet? McGill University Health Centre, Montreal, Quebec, December 4, 2017.
 332. **European Respiratory Society - Clinical Exercise Testing: Advanced.** (1) Respiratory and sensory responses to incremental exercise. (2) Tutorial: Physiological responses to incremental exercise. (3) Presentation and discussion of normal tests. (4) CPET in COPD. (5) Tutorial: Dyspnoea on exertion in cardiopulmonary disease. (6) Case-based discussion: typical cases of respiratory limitation to exercise. (7) Unexplained dyspnea. Rome, Italy, February 22-23, 2018.
 333. **Canadian Respiratory Conference: CIHR-ICRH/CTS Distinguished Lecturer Award in Respiratory Sciences.** Unraveling the Pathophysiology of Breathlessness in COPD (April 14). Vancouver, BC, April 12-14, 2018.
 334. **American Thoracic Society International Meeting.** Principles to practice in pulmonary rehabilitation: A pro/con debate. Presentation: Ventilatory limitation is the major etiology of exercise intolerance in COPD (May 21). San Diego, USA May 19-23, 2018.
 335. **International Dyspnea Society 5th Annual Meeting.** Recent advances in the pharmacological management of breathlessness. McGill University, Montreal, Quebec, June 21-22, 2018.
 336. **European Respiratory Society International Meeting.** (1) Respiratory mechanics and exertional dyspnea in health and disease. Postgraduate course, September 15. (2) Common mechanisms of exertional dyspnea in chronic lung disorders. Symposium September 16. (3) Breathing pattern and dynamic hyperinflation. Skills workshop, September 17. Paris, France, September 14-19, 2018.
 337. **Medical Grand Rounds, Queen’s University.** When you can’t breathe, nothing else matters. Kingston, Ontario. October 25, 2018.
 338. **Brian J. Sproule Lectureship (Alberta Respiratory Centre).** The pathophysiology of dyspnea in chronic lung diseases. University of Alberta, Edmonton, Alberta. November 14, 2018.
 339. **Keynote Speaker, American Thoracic Society International Conference.** Unravelling the mystery of breathlessness in COPD. Presented May 20, 2019. Dallas, Texas, May 17-22, 2019.
 340. **European Respiratory Society International Congress.** (1) Respiratory mechanics and exertional dyspnea in health and disease. Postgraduate Course: Sept 28. (2) Group assignment. Postgraduate Course: Sept 28. (3) Breathing patterns and dynamic hyperinflation x 3 presentations. Skills Workshop: Oct 1. Madrid, Spain, September 28 – October 2, 2019.
 341. **The Thomas Aldrich Memorial Lecture.** Dyspnea in COPD: New insights and clinical implications. Albert Einstein College of Medicine/Montefiore Health, Bronx, New York. September 12, 2019.
 342. **The Lung Association COPD Workshop.** Perth, Ontario October 17, 2019.

343. **2019 International COPD Conference.** Why and how to diagnose hyperinflation. Philadelphia, Pennsylvania. November 5, 2019
344. **Comprehensive Day for Family Doctors.** Chronic obstructive pulmonary disease – matching treatment to patients. Ottawa, Ontario February 28th, 2020.

Training in Respiratory Physiology Doctoral [Supervisor]

1. Matthew James, M.Sc., Queen's University: 2018-
Principal Supervisor
Thesis Title: Fentanyl vs. bronchodilators and their impact on exercise performance in moderate to advanced COPD.
2. Kate Milne, M.Sc., UBC: 2018-
Principal Supervisor. Co-Supervisors: Dr. J.A. Neder, Dr. C. D'Arsigny
Mechanisms of exertional dyspnea in chronic thromboembolic pulmonary hypertension.
3. Nicolle Domink, Ph.D., Post-Doctorate Queen's University: 2016/7 -
Principal Supervisor
Thesis/Project Title: Night time lung function, respiratory mechanics and early morning symptoms in COPD: Impact of bronchodilator therapy.
Present Position: Assistant Professor (Term Adjunct) – Queen's University: 2014/9 –
4. Daniel Langer, Ph.D. – Post-Doctorate - Queen's University: 2013/3 - 2014/8
Principal Supervisor
Thesis/Project Title: Effects of inspiratory muscle training on dyspnea during endurance cycle exercise in patients with COPD.
Present Position: Assistant Prof Dept. of Physiotherapy, Leuven, Belgium
5. Bader Al-Ghamdi, M.D. - Certificate - Queen's University: 2013/1 – 2013/12
Principal Supervisor
Thesis/Project Title: Mechanisms of dyspnea in interstitial lung disease.
Present Position: Pulmonary Consultant, Chief of Residency Program, King Abdulaziz Medical City, National Guard Health Affiras-Jeddah, Saudi Arabia.
6. Casey Ciavaglia - Doctorate Equivalent - Queen's University: 2012/9 – 2014/7
Principal Supervisor
Thesis/Project Title: The effect of exercise test modality on dyspnea perception in obese patients with COPD.
Present Position: Research Associate, Queens University
7. Azmy Faisal, Ph.D. - Post-doctorate - Queen's University: 2012/7 – 2014/7
Principal Supervisor
Thesis/Project Title: Mechanisms of dyspnea: insights from brain functional magnetic resonance imaging.
Present Position: Post-Doc Fellow
8. Amany Elbehairy, M.D. - Doctorate - University of Alexandria, Egypt: 2012/7 –
Co-Supervisor
Thesis/Project Title: Mild COPD: mechanisms of dyspnea and activity restriction.

Present Position: Clinical Research Fellow

9. Ling Yang, M.D. - Post-doctorate - Xinhua Hospital, Shanghai, China: 2012/3 – 2013/7
Principal Supervisor
Thesis/Project Title: Respiratory physiology across the continuum of COPD.
Present Position: Associate Professor- Xinhua Hospital, Shanghai, China:
10. Roberto Chin - Doctorate - Queen's University: 2010/7 – 2012/8
Principal Supervisor
Thesis/Project Title: Exercise limitation in mild COPD: the role of respiratory mechanical factors.
Present Position: Medical Student
11. Jordan Guenette, Ph.D. - Post-doctorate - University of British Columbia: 2010/2 – 2012/8
Principal Supervisor
Thesis/Project Title: Physiology of early COPD.
Present Position: Assistant Professor, Dept. of Physiotherapy, University of British Columbia
12. Natya Raghavan, M.D. - Post-doctorate - Queen's University: 2010/1 – 2013/12
Principal Supervisor
Thesis/Project Title: Respiratory physiology in early COPD.
Present Position: Assistant Professor, Division of Respiriology, McMaster University
13. Naparat Amornputtisathaporn, M.D. - Post-doctorate - Mahidol University: 2009/7 – 2010/7
Principal Supervisor
Thesis/Project Title: Respiratory physiology in early COPD.
Present Position: Staff Respiriologist, Mahidol University, Thailand
14. Athavudh Deesomchok, M.D. - Post-doctorate - Chiang Mai University, Thailand: 2008/1 – 2009/6
Principal Supervisor
Thesis/Project Title: Pathophysiology of asthma.
Present Position: Staff Respiriologist, Assoc Professor, Chiang Mai University, Thailand
15. Josuel Ora, M.D. - Post-doctorate - Univerista di Roma: 2007/7 – 2009/12
Principal Supervisor
Thesis/Project Title: Effects of obesity on dyspnea and exercise tolerance in COPD.
Present Position: Assistant Professor, Pulmonology , Univerista di Roma
16. Karin Wadell, Ph.D. - Post-doctorate - Umea University, Sweden: 2006/7 – 2008/9
Principal Supervisor
Thesis/Project Title: Mechanisms of dyspnea relief following supervised multimodality exercise training in patients with COPD.
Present Position: Assistant Professor, Dept. of Physiology, Umea University
17. Dennis Jensen, Ph.D. - Doctorate - Queen's University: 2004/7 -2008/8
Principal Supervisor
Thesis/Project Title: Chemical and mechanical adaptations of the respiratory system at rest and during exercise in healthy human pregnancy: implications for respiratory sensation.
Present Position: Assocate Professor, Dept. of Kinesiology, McGill University

18. Pierantonio Laveneziana, M.D. - Bachelor's - Universita di Firenze, Florence Italy: 2005/7 – 2007/7
Principal Supervisor
Thesis/Project Title: Ventilatory and perceptual responses to exercise in obese patients with COPD.
Present Position: Associate Professor, Physiology and Medicine, Pierre & Marie Curie University, Paris
19. Dror Ofir, Ph.D. - Doctorate - Queen's University: 2004/7 – 2008/11
Principal Supervisor
Thesis/Project Title: Ventilatory constraints and breathlessness during exercise in the elderly, in the obese, and in those with mild airflow limitation.
Present Position: Researcher, Israel Navy, Tel Aviv
20. Justin Travers, M.D., Clinical Fellow: 2006/7 – 2007/6
Project Title: (1) Sensory and mechanical responses to simulated exacerbations of COPD. (2) Dyspnea in cancer.
Present Position: Respiriologist, Wellington, New Zealand
21. Farzad Saberi, M.D., Clinical Fellow: 2004/7 -
Present Position: Respiriologist, Burnaby, BC
22. Kayvan Amjadi, M.D., Cameron Gray Fellowship, Alexander Stewart Fellowship: 2004/7
Thesis/Project Title: Effect of nebulized furosemide on the severity of dyspnea during exercise in patients with COPD.
Present Position: Respiriologist, University of Ottawa, Ottawa, Canada.
23. Michelle (Peters) Tryon, M.Sc.: 2003/7 – 2005/6
Thesis/Project Title: The effects of supplemental oxygen and bronchodilators on exertional dyspnea and exercise performance in normoxic COPD patients.
Present Position: Pharmacist, Kingston General Hospital, Kingston, Canada.
24. “Kevin” Zhi He, M.Sc.: 2003/7 –2005/5
Thesis/Project Title: Reliability of laboratory exercise testing in a population of patients with chronic obstructive pulmonary disease.
Present Position: Research Assistant Professor of Biostatistics, University of Michigan, USA.
25. Krishna Sharma, M.D., Clinical Fellow: 2001/7 – 2003/6
Present Position: Respiriologist, University of Ottawa, Ottawa, Canada.
26. Christopher Parker, M.D., Clinical Fellow: 2001/7 – 2003/6
Thesis/Project Title: Pathophysiology of dyspnea during moderate exacerbations of COPD.
Present Position: Associate Professor, Queen’s University, Kingston, Canada
27. Susan Revill, Ph.D.: 2000/9 – 2000/11
Project/Thesis Title: Assessment of patients prior to pulmonary rehabilitation.
Present Position: Research Clinical Scientist, Glenfield Hospital NHS Trust, UK
28. Gisella Palumbo, M.Sc.: 2000/7 – 2002/6
Thesis/Project Title: Mechanisms of dyspnea during lung hyperinflation in chronic obstructive pulmonary disease.

29. Stephen Chao, M.D., Clinical Fellow: 1999/7 – 2000/2
Present Position: Respiriologist, Windsor, Canada
30. Marc Newton, M.D., Clinical Fellow: 1998/7 – 1999/6
Project Title: Lung volume responses to bronchodilators in COPD.
Present Position: Respiriologist, Owen Sound, Canada
31. Joseph Giustino, M.D., Clinical Fellow: 1997/7 – 1998/6
Project Title: Mechanisms of exertional breathlessness in patients with chronic airflow limitation and congestive heart failure.
Present Position: Respiriologist, Ladner, BC
32. Harry Hong, M.D., Cameron Gray Fellowship: 1996/7 – 1998/6
Project Title: Respiratory sensation during chest wall restriction and dead space loading in exercising men.
Present Position: Respiriologist, Surrey, BC
33. Christine D’Arsigny, M.D., Clinical Fellow: 1996/7 – 1997/6
Project Title: (1) Mechanisms of exertional dyspnea in patients with stable congestive heart failure.
(2) Skeletal muscle function in patients with COPD.
Present Position: Associate Professor, Queen’s University, Kingston, Canada
34. Satish Raj, M.D.: 1997
Project Title: Mechanisms of exertional dyspnea in patients with stable congestive heart failure.
Present Position: Cardiologist, University of Calgary, Calgary, Alberta
35. Douglas Bain, M.D., Clinical Fellow: 1995-1997
Project Title: Factors contributing to relief of exertional breathlessness during hyperoxia in nonhypoxic COPD.
Present Position: Respiriologist, Toronto East General Hospital, Toronto, Canada.
36. Laurence Chau, M.S.: 1994/7 – 1996/6
Project Title: (1) Pulmonary rehabilitation in COPD. (2) Qualitative aspects of dyspnea in COPD. (3) Qualitative aspects of dyspnea in ILD.
Present Position: Respiriologist, Oakville, Canada
37. Neil Shinder, M.D.: 1994/7 – 1996/6
Present Position: Respiriologist, Rockland Lung & Sleep Disorders, Nanuet, NY.
38. John Bertley, M.D.: 1993/9 – 1995/6
Project Title: (1) Perceptual responses to endogenous opioid blockade during exercise in chronic airflow limitation. (2) The effect of nebulized morphine on breathlessness and exercise performance in COPD. (3) Qualitative aspects of dyspnea in COPD.
Present Position: Respiriologist, St. Catherine’s, Canada
39. Diane Lougheed, M.D.: 1991/7 – 1993/7
Project Title: (1) Mechanisms of dyspnea in asthma: the role of lung hyperinflation. (2) Respiratory sensation during induced bronchoconstriction in quadriplegia.

Present Position: Professor, Queen's University, Kingston, Canada

PUBLICATIONS

H-index: 82; citations: 27,701

Doctoral Thesis

O'Donnell, D.E. Mechanisms of dyspnea in patients with chronic airflow limitation. Doctorate in Medicine (DM) awarded by the National University of Ireland, July 1989.

Published Papers

1. O'Donnell D, Kelly CP, Cotter P, Clancy L. Use of oxygen-driven nebulizer delivery systems for beta-2 agonists in chronic bronchitis. *Irish J Med Sci* 1985; 154(5): 198-200.
2. Fitzgerald DJ, O'Donnell D, Brennan M, O'Malley K, O'Brien E. Accuracy and reliability of the DelMar Avionics Pressureometer III. *J Hypertension* 1985; 3(Suppl 3): 359-361.
3. O'Donnell DE, Cotter P, Kennedy N, Clancy L. An open steady-state pharmacokinetic study to compare Provent and Phyllocontin in asthmatic patients. *Br J Clin Practice* 1986; 40(8): 318-322.
4. O'Donnell DE, Sanii R, Anthonisen NR, Younes M. The effect of airway dynamic compression on breathing pattern and respiratory sensation in severe COPD. *Am Rev Respir Dis* 1987; 135(4): 912-918.
5. O'Donnell DE, Sanii R, Anthonisen NR, Younes M. External resistive loading in severe COPD: an evaluation of ventilatory mechanics and compensatory responses. *Am Rev Respir Dis* 1987; 136: 102-107.
6. Kelly CP, O'Donnell D, West B, Clancy L. Small cell and squamous cell lung carcinomas: sequential occurrence at a single site. *Thorax* 1987; 42: 821-822.
7. O'Donnell DE, Sanii R, Younes M. External mechanical loading in conscious humans: role of upper airway mechanoreceptors. *J Appl Physiol* 1988; 65: 541-548.
8. O'Donnell DE, Sanii R, Giesbrecht G, Younes M. The effect of continuous positive airway pressure on respiratory sensation in patients with COPD during submaximal exercise. *Am Rev Respir Dis* 1988; 138:1185-1191.
9. O'Donnell DE, Sanii R, Younes M. Improvement in exercise endurance in patients with chronic airflow limitation using CPAP. *Am Rev Respir Dis* 1988; 138: 1510-1514.
10. Mahler DA, O'Donnell DE. Alternative modes of exercise training for pulmonary patients. *J Cardiopulm Rehab* 1991; 11: 58-63.
11. O'Donnell DE, Webb K. Breathlessness in patients with severe chronic airflow limitation: physiological correlates. *Chest* 1992; 102: 824-831.
12. O'Donnell DE. Quest for Cures, Respiratory Research at Queen's University. The Lung Association, The Lung Letter, Vol 6, No 2, Spring & Autumn 1992.
13. O'Donnell DE, Sanii R, Loveridge B, Younes M. Steady-state ventilatory responses to expiratory resistive loading in quadriplegics. *Am Rev Respir Dis* 1993; 147: 54-59.
14. Loughheed MD, Webb K, Forkert L, O'Donnell DE. Breathlessness during acute bronchoconstriction in asthma: pathophysiological mechanisms. *Am Rev Respir Dis* 1993; 148: 1452-1459.
15. O'Donnell DE, Webb K. Exertional breathlessness in patients with chronic airflow limitation: the role of lung hyperinflation. *Am Rev Respir Dis* 1993; 48(5): 1351-1357. PMID 8239175. Cited by 494.

16. O'Donnell DE, Webb K, McGuire MA. Older patients with COPD: benefits of exercise training. *Geriatrics* 1993; 48(1): 59-66.
17. Luce K, O'Donnell DE, Morton AR. A combination of calcitonin and biphosphonate for the emergency treatment of severe tumour-induced hypercalcemia [*Letter to the Editor*]. *Calcif Tissue Int* 1993; 52: 70-71.
18. O'Donnell DE. Breathlessness in COPD: mechanisms and management. *Chest* 1994; 106: 904-912.
19. O'Donnell DE. Breathlessness in advanced COPD: therapeutic strategies. *Ontario Thoracic Reviews* 1994; 6: 1-7.
20. Chau LL, O'Donnell DE. Investigation of hemoptysis. *Medicine North America* 1995; 333-345.
21. Chau LL, O'Donnell DE. Cough variant asthma. *Can J Asthma Management* 1995; 2(1): 4-6.
22. Loughheed MD, Webb K, O'Donnell DE. Breathlessness during induced hyperinflation in asthma: Role of the inspiratory threshold load. *Am J Respir Crit Care Med* 1995; 152(3): 911-920.
23. O'Donnell DE, McGuire M, Samis L, Webb K. Impact of exercise reconditioning on breathlessness in severe chronic airflow limitation. *Am J Respir Crit Care Med* 1995; 152(6): 2005-2013.
24. Lemoine JR, O'Donnell DE. Focus on Respiratory Health. *Asthma and COPD* 1996; 1: 1-4.
25. O'Donnell DE, Webb KA, Bertley JC, Conlan AA. Mechanisms of relief of exertional breathlessness following unilateral bullectomy and lung volume reduction surgery in advanced chronic airflow limitation. *Chest* 1996; 110: 18-27.
26. O'Donnell DE. Volume reduction surgery in patients with chronic airflow limitation: a physiological rationale. *Seminars in Respiratory and Crit Care Med* 1996; 6: 509-516.
27. O'Donnell DE. Towards the alleviation of chronic breathlessness. *Ontario Thoracic Reviews* 1996; 8: 5-7.
28. O'Donnell, DE, Chau LL, Bertley J, Webb KA. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiological mechanisms. *Am J Respir Crit Care Med* 1997; 155: 109-115. PMID: 9001298. Cited by 328.
29. O'Donnell DE, Bain DJ, Webb KA. Factors contributing to relief of exertional breathlessness during hyperoxia in chronic airflow limitation. *Am J Respir Crit Care Med* 1997; 155: 530-535.
30. Kern DG, Durand KTH, Crausman RS, Never A, Kuhn III C, Loughheed MD, O'Donnell DE, Munt PW, Vanderslice RR. Chronic interstitial lung disease in nylon flocking industry workers – Rhode Island, 1992-96. *Medical Morbidity/Mortality Review, Centre of Disease Control, Atlanta*, 1997; 46(38): 897-900.
31. D'Arsigny C, O'Donnell DE. Will exercise help my COPD patient? *Med North America* 1997; 20: 40-46.
32. Chau LKL, Webb KA, Jackson AC, O'Donnell DE. Vocal cord paresis and respiratory muscle weakness: an unusual presentation of chronic polyneuropathy. *Can Respir J* 1998; 5(2): 125-129.
33. Shinder N, Polson A, Pringle E, O'Donnell DE. Neuralgic amyotrophy: a rare cause of bilateral diaphragmatic paralysis. *Can Respir J* 1998; 5(2): 139-142.
34. O'Donnell DE, Chau LK, Webb KA. Qualitative aspects of exertional dyspnea in interstitial lung disease. *J Appl Physiol* 1998; 84(6): 2000-2009.
35. O'Donnell DE, McGuire M, Samis L, Webb KA. Effects of general exercise training on ventilatory and peripheral muscle strength and endurance in chronic airflow limitation. *Am J Respir Crit Care Med* 1998; 157: 1489-1497.
36. D'Arsigny C, Ford S, O'Donnell DE. Localized upper airway obstruction in a patient with acquired immunodeficiency syndrome. *Postgrad Med J* 1998; 74(876): 604-606.
37. O'Donnell, DE. Dyspnea in advanced chronic obstructive pulmonary disease. *J Heart Lung Transplant* 1998; 17(6): 544-554.

38. O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation and endurance during exercise in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1998; 158: 1557-1565. PMID: 4817708. Cited by 489.
39. O'Donnell DE. "Symptoms at the End of Life" NIH Workshop Report. Contributed section on "Dyspnea: basic perspective". 1998.
40. Bain DJ, Webb KA, O'Donnell DE. Pulmonary arteriovenous malformation as a cause of severe exertional dyspnea. *Int J Clin Practice* 1999; 53(2): 142-144.
41. O'Donnell DE, D'Arsigny C, Raj S, Abdollah H, Webb KA. Ventilatory assistance improves exercise endurance in patients with stable congestive heart failure. *Am J Respir Crit Care Med* 1999; 160: 1804-1811.
42. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in COPD. *Am J Respir Crit Care Med* 1999; 160: 524-549. PMID: 16430725. Cited by 465.
43. Banzett RB, Dempsey JA, O'Donnell DE, Wambolt MZ. NHLBI Workshop Summary: Symptom perception and respiratory sensation in asthma. *Am J Respir Crit Care Med* 2000; 162: 1178-1182.
44. American Thoracic Society; Meek P, Schwartzstein RM, Adams L, Altose MD, Breslin EH, Carrieri-Kohlman V, Gift A, Hanley MV, Harver A, Jones PW, Killian K, Knebel A, Lareau SC, Mahler DA, O'Donnell DE, Steele B, Stuhlberg M, Titler M. Dyspnea. Mechanisms, assessment, and management: a consensus statement. *Am J Respir Crit Care Med* 1999; 159: 321-340.
45. Giustino J, Sutherland K, Webb K, O'Donnell DE. Severe exertional dyspnea in localized emphysema. *Can Respir J* 1999; 6(6): 535-539.
46. Newton M, Webb KA, O'Donnell DE. Testing for exercise limitation in obstructive lung disease [*Letter to the Editor*]. *Chest* 1999; 115(6): 1755-1757.
47. O'Donnell DE. Assessment of bronchodilator efficacy in symptomatic COPD: Is spirometry useful? *Chest* 2000; 117: 42-47.
48. O'Donnell DE, Hong HH, Webb KA. Respiratory sensation during chest wall restriction and deadspace loading in exercising men. *J Appl Physiol* 2000; 88(5): 1859-1869.
49. O'Donnell DE. Pulmonary rehabilitation: The neglected option for treatment of chronic airflow limitation [*Editorial*]. *Ontario Thoracic Reviews*. 2000; 12(3): 2.
50. O'Donnell DE, D'Arsigny C, Webb KA. Effects of hyperoxia on ventilatory limitation during exercise in advanced COPD. *Am J Respir Crit Care Med* 2001; 163: 892-898. PMID: 1128762. Cited by 261.
51. O'Donnell DE. Ventilatory limitations in chronic obstructive pulmonary disease. *Med Sci Exer* 2001; 33(7): S647-655.
52. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in COPD. *Am J Respir Crit Care Med* 2001; 164: 770-777. PMID: 11349351. Cited by 718.
53. O'Donnell DE, Forkert L, Webb KA. Evaluation of bronchodilator responses in patients with "irreversible" emphysema. *Eur Respir J* 2001; 18: 914-920.
54. Loughheed MD, Flannery J, Webb KA, O'Donnell DE. Respiratory sensation and ventilatory mechanics during induced bronchoconstriction in spontaneously breathing low cervical quadriplegia. *Am J Respir Crit Care Med* 2002; 166: 370-376.
55. O'Donnell DE, D'Arsigny C, Fitzpatrick M, Webb KA. Exercise hypercapnia in advanced chronic obstructive pulmonary disease: the role of lung hyperinflation. *Am J Respir Crit Care Med* 2002; 166: 663-668. (*with accompanying editorial by J Dempsey, p.634-635*).
56. Newton M, O'Donnell DE, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. *Chest* 2002; 121(4): 1042-1050.
57. O'Donnell DE. Exercise and dyspnea. *Eur Respir Rev* 2002; 12: 36-39.
58. O'Donnell DE. Exercise tolerance as a clinical outcome measure in COPD. *Eur Respir Rev* 2002; 12: 303-304.

59. O'Donnell DE. Clinical utility of work of breathing measurements in COPD. *Eur Respir Rev* 2002; 12: 383-385.
60. Simpson JA, Labugger R, Hesketh G, D'Arsigny C, O'Donnell D, Matsumoto N, Collier CP, Iscoe S, Van Eyk JE. Differential detection of skeletal troponin I isoforms in serum of a patient with rhabdomyolysis: markers of muscle injury? *Clin Chem* 2002; 48: 1112-1114.
61. O'Donnell DE, Webb KA. Evaluation of bronchodilator responses in patients with "irreversible" emphysema [*Letter*]. *Eur Respir J* 2002; 19(5): 982-983.
62. Voduc N, O'Donnell DE. Tiotropium in the treatment of chronic obstructive pulmonary disease: review of clinical trials. *J New Developments Clin Med* 2003; 21(1): 37-48.
63. O'Donnell DE, Hernandez P, Aaron S, Bourbeau J, et al. Canadian Thoracic Society COPD Guidelines: Summary of highlights for family doctors. *Can Respir J* 2003; 10: 183-185.
64. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for the management of chronic obstructive pulmonary disease. *Can Respir J* 2003; 10: 11A-33A.
65. Fitzpatrick M, McLean H, Urton AM, Tan T, O'Donnell DE, Driver HS. Effect of nasal or oral breathing route on upper airway resistance during sleep. *Eur Respir J* 2003; 22: 827-832.
66. Voduc N, O'Donnell DE. Should your patients have cardiopulmonary exercise testing? *J Respir Dis* 2003; 24(3): 106-117.
67. Fukuchi Y, O'Donnell DE, Conlan AA. Update in COPD. In: *Medical Review*, Osaka, Japan. 2003:1-7.
68. O'Donnell DE. The clinical utility of cardio-pulmonary exercise testing. *Ontario Thoracic Reviews* 2003; 15: 2-7.
69. O'Donnell DE, Mahler D. Symptom-based diagnosis – how practical in practice? *RespirAsia* 2003; 6: 3-6.
70. Sharma K, O'Donnell DE. COPD: Helping patients breathe easy. *Parkhurst Exchange*. January 2003: 90-91.
71. O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in COPD. *Eur Respir J* 2004; 24: 86-94. PMID: 15293609. Cited by 324.
72. O'Donnell D, Flüge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. *Eur Respir J* 2004; 23:832-840. PMID: 15218994. Cited by 744.
73. O'Donnell DE. What is unique about the new Canadian COPD Guidelines? *Can Respir J* 2004; 11(3); 200-203.
74. O'Donnell DE. Lung mechanics in COPD: the role of tiotropium. *Eur Respir Rev* 2004; 13: 40-44.
75. Raghavan R, Ellis AK, Wobeser W, Sutherland KB, O'Donnell DE. Hemopneumothorax in a COPD patient treated with non-invasive positive pressure ventilation (NIPPV): the risk of attendant anticoagulation. *Can Respir J* 2004; 11(2): 159-162.
76. Voduc N, Webb KA, D'Arsigny C, McBride I, O'Donnell DE. McArdle's disease presenting as unexplained dyspnea in a young woman. *Can Respir J* 2004; 11(2): 163-167.
77. O'Donnell DE, Aaron S, Bourbeau J, et al. State of the Art Compendium: Canadian Thoracic Society recommendations for the management of chronic obstructive pulmonary disease. *Can Respir J* 2004; 11(Suppl B): 7B-59B.
78. Aaron SD, Vandemheen K, Fergusson D, FitzGerald M, Maltais F, Bourbeau J, Goldstein R, McIvor A, Balter M, O'Donnell DE. The Canadian Optimal Therapy of COPD Trial: Design, organization and patient recruitment. *Can Respir J* 2004; 11(8): 581-585.
79. Amjadi K, O'Donnell DE. I can't catch my breath. *Can J Diagnosis* 2004;21(1):35-38.
80. O'Donnell, DE, Webb KA. Mechanisms of dyspnea during dynamic lung hyperinflation in COPD. *ORCS/OTS Research Review* 2004;1:4-11.
81. O'Donnell DE. Breathing new life into COPD. *Can J of CME*. 2004;16(8):79-82.

82. Jensen D, Wolfe LA, O'Donnell DE, Davies GAL. Chemoreflex control of breathing during wakefulness in healthy men and women. *J Appl Physiol* 2005; 98: 822-828.
83. Jensen D, Wolfe LA, Slatkovska L, Webb KA, Davies GAL, O'Donnell DE. Effects of human pregnancy on the ventilatory chemoreflex response to carbon dioxide. *Am J Physiol (Regulatory, Integrative and Comparative Physiology)* 2005; 288: 1369-1375.
84. Parker CM, Voduc N, Aaron SD, Webb KA, O'Donnell DE. Physiological changes during symptom recovery from moderate exacerbations of COPD. *Eur Respir J* 2005; 26(3): 420-428. **(with accompanying editorial by R Rodriguez-Roisin, p.376-378)**
85. Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciruba FC, Richter K, Kesten S, O'Donnell D. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. *Chest* 2005; 128(3): 1168-1178.
86. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenkroger D, Bethke TD. Roflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trial. *Lancet* 2005; 366: 563-571.
87. Saberi F, O'Donnell DE. The role of tiotropium, a long-acting anticholinergic bronchodilator, in the management of COPD. *Treat Respir Med* 2005; 4(4): 275-281.
88. O'Donnell DE, Parker CM. COPD exacerbations. 3: Pathophysiology. *Thorax* 2006; 61: 354-361.
89. Peters MM, Webb KA, O'Donnell DE. Combined physiological effects of bronchodilators and hyperoxia on dyspnea and exercise performance in normoxic COPD. *Thorax* 2006; 61: 559-567. **(with accompanying editorial by R Casaburi, p.551-552)**
90. Loughheed MD, Fisher T, O'Donnell DE. Dynamic hyperinflation during bronchoconstriction in asthma. Implications for symptom perception. *Chest* 2006; 130: 1072-1081.
91. O'Donnell DE, Sciruba F, Celli B, Mahler DA, Webb K, Kalberg CJ, Emmett A, Knobil K. Effects of fluticasone-salmeterol combination on lung hyperinflation and exercise endurance in chronic obstructive pulmonary disease. *Chest* 2006; 130: 647-656.
92. Tschakovsky ME, Saunders NR, Webb KA, O'Donnell DE. Muscle blood-flow dynamics at exercise onset: do the limbs differ? *Med Sci Sports Exer* 2006; 38(10): 1811-1818.
93. O'Donnell DE, Hamilton AL, Webb KA. Sensory-mechanical relationships during high intensity, constant work rate exercise in COPD. *J Appl Physiol* 2006; 101: 1025-1035. **(with accompanying editorial by K Killian, p.1013-1014)**
94. O'Donnell DE. Introduction. In: Hyperinflation: A Critical Target in COPD. *Proc Am Thorac Soc* 2006; 3(2): 175. **(Guest Editor)**
95. O'Donnell DE. Hyperinflation, dyspnea and exercise intolerance in chronic obstructive pulmonary disease. *Proc Am Thorac Soc* 2006; 3(2): 180-184.
96. O'Donnell DE. Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance. *Eur Respir Rev* 2006; 15(99): 37-41.
97. O'Donnell DE, Laveneziana P. The clinical importance of dynamic lung hyperinflation in COPD. *COPD* 2006; 3(4): 219-232.
98. Nici L, Donner C, Wouters E, Zuwallack R, Abrosino N, Bourbeau J, Carone M, Celli B, O'Donnell D, et al. American Thoracic Society/European Respiratory Society Statement on Pulmonary Rehabilitation. *Am J Respir Crit Care Med* 2006; 173: 1390-1413.
99. O'Donnell DE, Laveneziana P. Lung hyperinflation in COPD: the impact of pharmacotherapy. *Eur Respir Rev* 2006; 15(100): 85-89.
100. O'Donnell DE, Laveneziana P. Physiology and consequences of lung hyperinflation in COPD. *Eur Respir Rev* 2006; 15(100): 61-67.
101. O'Donnell DE. Is sustained pharmacological lung volume reduction now possible in COPD? *[Editorial]*. *Chest* 2006; 129(3): 501-503.
102. Jensen D, Webb K, Wolfe LA, O'Donnell DE. Effects of human pregnancy and advancing gestation on exertional breathlessness. *Respir Physiol Neurobiol* 2007; 156: 85-93.

103. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell DE, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. *Ann Intern Med* 2007; 146(8): 545-555.
104. ERS Task Force: Palange P, Ward SA, Carlsen K-H, Casaburi R, Gallagher CG, Gosselink R, Puente-Maestu L, O'Donnell DE, Schols AM, Sing S, Whipp BJ. Recommendations on the use of exercise testing in clinical practice. *Eur Respir J* 2007; 29: 185-209. PMID: 17197484. Cited by 314.
105. Ofir D, Laveneziana P, Webb KA, O'Donnell DE. Ventilatory and perceptual responses to cycle exercise in obese women. *J Appl Physiol* 2007; 102: 2217-2226. (*with accompanying editorial by R.B. Banzett and S.H. Loring, p.2090-2091*)
106. Laveneziana P, O'Donnell DE. The role of spirometry in evaluating therapeutic responses in advanced COPD. *Dis Manage Health Outcomes* 2007; 15(2): 91-100.
107. O'Donnell DE, Banzett RB, Carrieri-Kohlman V, Casaburi R, Davenport PW, Gandevia SC, Gelb AF, Mahler DA, Webb KA. Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. *Proc Am Thor Soc* 2007; 4: 145-168.
108. O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk DD, Balter M, Ford G, Gervais A, Goldstein R, Hodder R, Kaplan A, Keenan S, Lacasse Y, Maltais F, Road J, Rocker G, Sin D, Sinuff T, Voduc N. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007 update. *Can Respir J* 2007; 14(Suppl B): 5B-32B. PMID: 17885691. Cited by 283.
109. Parker CM, Laveneziana P, O'Donnell DE. Ventilatory constraints during exercise in chronic obstructive pulmonary disease. *Appl Physiol Nutr Metab* 2007; 32: 1225-1238.
110. Jensen D, Webb KA, O'Donnell DE. Chemical and mechanical adaptations of the respiratory system at rest and during exercise in human pregnancy. *Appl Physiol Nutr Metab* 2007; 32: 1239-1250.
111. Travers J, Laveneziana P, Webb KA, Kesten S, O'Donnell DE. Effect of tiotropium bromide on the cardiovascular response to exercise in COPD. *Respir Med* 2007; 101: 2017-2024.
112. O'Donnell DE, Laveneziana P. Dyspnea and activity limitation in COPD: mechanical factors. *COPD* 2007; 4(3): 225-236.
113. O'Donnell DE, Ofir D, Laveneziana P. Patterns of cardiopulmonary response to exercise in lung diseases. *Eur Respir Monograph* 2007; 40: 69-92.
114. O'Donnell DE (Member of Respiratory Review Panel). *Respiratory (Asthma and COPD) Guidelines for Family Practice*. Toronto, MUMS Guidelines Clearinghouse: 2007.
115. Travers J, Dudgeon DJ, Amjadi K, McBride I, Dillon K, Laveneziana P, Ofir D, Webb KA, O'Donnell DE. Mechanisms of exertional dyspnea in patients with cancer. *J Appl Physiol* 2008; 104: 57-66.
116. Ofir D, Laveneziana P, Webb KA, Lam YM, O'Donnell DE. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2008; 177(6): 622-629. (*with accompanying editorial by P Calverley, p.564-565*)
117. Jensen D, Amjadi K, Harris-McAllister V, Webb KA, O'Donnell DE. Mechanisms of dyspnea relief and improved exercise endurance after furosemide inhalation in COPD. *Thorax* 2008; 63: 606-613.
118. Jensen D, Duffin J, Lam M, Simpson JA, Webb KA, Davies G, Wolfe LA, O'Donnell DE. Physiological mechanisms of hyperventilation during human pregnancy. *Respir Physiol Neurobiol* 2008; 161: 76-86.
119. Green HJ, Bombardier EM, Iqbal S, D'Arsigny C, O'Donnell DE. Organization of metabolic pathways in vastus lateralis of patients with chronic obstructive lung disease. *Am J Physiol: Regul Integr Comp Physiol* 2008; 295: R935-R941.
120. Laveneziana P, Wadell K, Webb KA, O'Donnell DE. Exercise limitation in chronic obstructive pulmonary disease. *Curr Respir Med Rev* 2008; 4: 257-268.

121. Laveneziana P, Jensen D, Webb KA, O'Donnell DE. Pharmacological treatment in chronic obstructive pulmonary disease. *Curr Respir Med Rev* 2008; 4: 304-314.
122. Green HJ, Burnet M, Duhamel TA, D'Arsigny C, O'Donnell DE, Webb KA. Abnormal sarcoplasmic reticulum Ca^{2+} - sequestering properties in skeletal muscle in chronic obstructive pulmonary disease. *Am J Physiol Cell Physiol* 2008; 295: C350-C357.
123. O'Donnell DE, Hernandez P, Kaplan A, Aaron S, Bourbeau J, Marciniuk D, Balter M, Ford G, Gervais A, Lacasse Y, Maltais F, Road J, Rocher G, Sin D, Sinuff T, Voduc N. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary care. *Can Respir J* 2008; 15(Suppl A): 1A-8A.
124. Aaron SD, Fergusson D, Marks GB, Suissa S, Vandemheen KL, Doucette S, Maltais F, Bourbeau F, Bourbeau JF, Goldstein RS, Balter M, O'Donnell D, FitzGerald M; on behalf of the Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Counting, analyzing and reporting exacerbations of COPD in randomized controlled trial. *Thorax* 2008; 63: 122-128.
125. Jensen D, Webb KA, Davies GAL, O'Donnell DE. Mechanical ventilatory constraints during incremental cycle exercise in human pregnancy: implications for respiratory sensation. *J Physiol* 2008; 586: 4735-4750.
126. O'Donnell DE, Webb KA. Point-Counterpoint: The major limitation to exercise performance in COPD is dynamic hyperinflation. *J Appl Physiol* 2008; 105: 753-755, discussion: 755-757.
127. O'Donnell DE, Webb KA. Last Word on Point-Counterpoint: The major limitation to exercise performance in COPD is 1) inadequate energy supply to the respiratory and locomotor muscles, 2) lower limb muscle dysfunction, 3) dynamic hyperinflation. *J Appl Physiol* 2008; 105: 765.
128. Ofir D, Laveneziana P, Webb K, Lam Y-M, O'Donnell DE. Sex differences in the perceived intensity of breathlessness during exercise with advancing age. *J Appl Physiol* 2008; 104: 1583-1593.
129. Green HJ, Burnett ME, D'Arsigny CL, O'Donnell DE, Ouyang J, Webb KA. Altered metabolic and transporter characteristics of vastus lateralis in chronic obstructive lung disease. *J Appl Physiol* 2008; 105: 870-886.
130. Franssen FME, O'Donnell DE, Goossens GH, Blaak EE, Schols AM. Obesity and the lung: 5. Obesity and COPD. *Thorax* 2008; 63(12): 1110-1117.
131. Kaplan A, Hernandez P, O'Donnell D. Less smoke, more fire: What's new for you in the latest COPD guidelines? *Can Fam Physician* 2008; 54: 737-739.
132. O'Donnell DE. Chronic obstructive pulmonary disease: The importance of early diagnosis. *Can Respir J* 2008; 15(Suppl C): 34C-35C.
133. O'Donnell DE. Dynamic lung hyperinflation and its clinical implication in COPD. *Rev Mal Respir* 2008; 25(10): 1305-1318.
134. O'Donnell DE. Bronchodilator therapy in COPD: physiological effects. *Breathe* 2008; 4(4): 342-344.
135. O'Donnell, D.E. New Canadian Thoracic Society's guidelines aim for improved prevention and control in COPD. (Panel: Bourbeau J, Hernandez P, Marciniuk D, O'Donnell DE (*editorial overview*)). *Journal Club on Respiriology (MedNet)* 2008:1-16.
136. Martinez FJ, O'Donnell DE, Anzueto AR. Altering the course of disease is crucial in COPD. *Pulmonary Reviews* 2008; 13(9): 15-17.
137. O'Donnell DE. COPD revisited: new guidelines mean more patients will be treated. *Parkhurst Exchange* 2008; 16(12): 60-61.
138. O'Donnell DE, Laveneziana P, Ora J, Webb KA, Lam Y-M, Ofir D. Evaluation of acute bronchodilator reversibility in symptomatic GOLD stage I COPD. *Thorax* 2009; 64: 216-223.
139. O'Donnell DE, Travers J, Webb KA, He Z, Lam M, Hamilton A, Kesten S, Maltais F, Magnussen H. Reliability of ventilatory parameters during cycle ergometry in multicentre trials in COPD. *Eur Respir J* 2009; 34(4): 866-874.

140. Jensen D, Webb KA, Davies GAL, O'Donnell DE. Mechanisms of activity-related breathlessness in healthy human pregnancy. *Eur J Appl Physiol* 2009; 106: 253-265.
141. Jensen D, Ofir D, O'Donnell DE. Effects of pregnancy, obesity and aging on the intensity of perceived breathlessness during exercise in healthy humans. *Respir Physiol Neurobiol* 2009; 167(1): 87-100.
142. O'Donnell DE, Ora J, Webb KA, Laveneziana P, Jensen D. Mechanisms of activity-related dyspnea in pulmonary diseases. *Respir Physiol Neurobiol* 2009; 167(1): 116-132.
143. Green HJ, Burnett ME, D'Arsigny C, Iqbal S, Ouyang J, Webb KA, O'Donnell DE. Muscle fiber type characteristics in females with chronic obstructive pulmonary disease: a preliminary study. *J Mol Histol* 2009; 40: 41-51.
144. Laveneziana P, O'Donnell DE, Ofir D, Agostoni P, Padeletti L, Ricciardi G, Palange P, Duranti R, Scano G. Effect of biventricular pacing on ventilatory and perceptual responses to exercise in patients with stable chronic heart failure. *J Appl Physiol* 2009; 106: 1574-1583.
145. Laviolette L, O'Donnell DE, Webb KA, Hamilton AL, Kesten S, Maltais. Performance during constant work rate cycling exercise in women with COPD and hyperinflation. *COPD* 2009; 6: 340-351.
146. Ora J, Laveneziana P, Ofir D, Deesomchok A, Webb KA, O'Donnell DE. Combined effects of obesity and COPD on dyspnea and exercise tolerance. *Am J Respir Crit Care Med* 2009; 180: 964-971.
147. Green HJ, Burnett ME, D'Arsigny CL, Webb KA, McBride I, Ouyang J, O'Donnell DE. Vastus lateralis Na⁺-K⁺-ATPase activity, protein, and isoform distribution in chronic obstructive pulmonary disease. *Muscle Nerve* 2009; 40: 62-68.
148. Laveneziana P, Palange P, Ora J, Martolini, D, O'Donnell DE. Bronchodilator effect on ventilatory, pulmonary gas exchange, and heart rate kinetics during high-intensity exercise in COPD. *Eur J Appl Physiol* 2009; 107(6): 633-643.
149. Camp PG, O'Donnell DE, Postma DS. Chronic obstructive pulmonary disease in men and women: myths and reality. *Proc Am Thorac Soc* 2009; 6: 535-538.
150. O'Donnell DE. Cardiopulmonary exercise testing and pulmonary rehabilitation. In: Ware LB. Clinical year in review I: Interstitial lung disease, pulmonary vascular disease, pulmonary infections and cardiopulmonary exercise testing and pulmonary rehabilitation. *Proc Am Thorac Soc* 2009; 6: 491-493.
151. Green HJ, Bombardier E, Burnett ME, D'Arsigny CL, Iqbal S, Webb KA, Ouyang J, O'Donnell DE. Cellular assessment of muscle in COPD: case studies of two males. *Int J Gen Med* 2009; 2: 227-242.
152. O'Donnell DE. The ins and outs of indications: COPD revisited. *Parkhurst Exchange* 2009, April (1): 9.
153. Ora J, Jensen D, O'Donnell DE. Exertional dyspnea in chronic obstructive pulmonary disease: mechanisms and treatment approaches. *Curr Opin Pulm Med* 2010; 16(2): 144-149.
154. O'Donnell DE, Ora J, Laveneziana P. Clinical benefits of maximal bronchodilation in chronic obstructive pulmonary disease (Part 1). *Hot Topics Respir Med* 2010; 12: 25-32.
155. Jensen D, Webb KA, O'Donnell DE. The increased ventilatory response to exercise in pregnancy reflects alterations in the respiratory control systems ventilatory recruitment threshold for CO₂. *Respir Physiol Neurobiol* 2010; 171(2): 75-82.
156. Raghavan N, Ora J, Webb KA, O'Donnell DE. "Mild" COPD – is there a case for earlier treatment? *Ann Respir Med* 2010; 1(1): 23-30.
157. Ora J, O'Donnell DE. Modern management of chronic obstructive pulmonary disease. *Minerva Pneumologica* 2010; 49: 1-16.
158. Ora J, Jensen D, O'Donnell DE. Exertional dyspnea in chronic obstructive pulmonary disease: mechanisms and treatment approaches. *Curr Opin Pulm Med* 2010; 16(2): 144-149.

159. Mahler DA, Selecky PA, Harrod CG, Benditt JO, Carrieri-Kohlman V, Curtis JR, Manning HL, Mularski RA, Varkey B, Campbell M, Carter ER, Chiong JR, Ely EW, Hansen-Flaschen J, O'Donnell DE, Waller A. American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. *Chest* 2010; 137(3): 674-691.
160. O'Donnell DE, Ora J. The impact of obesity on dynamic respiratory mechanics, dyspnea and exercise tolerance in COPD. *Can Respir J* 2010;17(Suppl A): 30A-31A.
161. Deesomchok A, Fisher T, Webb K, Ora J, Lam Y-M, Lougheed M, O'Donnell D. Effects of obesity on perceptual and mechanical responses to bronchoconstriction in asthma. *Am J Respir Crit Care Med* 2010; 181(2): 125-133.
162. Laviolette L, Sava F, O'Donnell DE, Webb KA, Hamilton AL, Kesten S, Maltais F. Effect of obesity on constant workrate exercise in hyperinflated men with COPD. *BMC Pulm Med* 2010; 10: 33.
163. Marciniuk DD, Brooks D, Butcher S, Debigare R, Dechman G, Ford G, Pepin V, Reid D, Sheel AW, Stickland MK, Todd DC, Walker SL, Aaron SD, Balter M, Bourbeau J, Hernandez P, Maltais F, O'Donnell DE, Bleakney D, Carlin B, Goldstein R, Muthuri SK; the CTS COPD Committee Expert Working Group. Optimizing pulmonary rehabilitation in chronic obstructive pulmonary disease – practical issues: A Canadian Thoracic Society Clinical Practice Guideline. *Can Respir J* 2010; 17(4): 159-168.
164. Deesomchok A, Webb KA, Forkert L, Lam Y-M, Jensen D, O'Donnell DE. Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity. *COPD* 2010; 7(6): 428-437.
165. Guenette JA, Jensen D, O'Donnell DE. Respiratory function and the obesity paradox. *Curr Opin Clin Nutr Metab Care* 2010; 13(6): 618-624.
166. Boulet L-P, Devlin H, O'Donnell DE. The Physicians' Practice Assessment Questionnaire on asthma and COPD. *Respir Med* 2010; 105(1): 8-14.
167. Guenette JA, Jensen D, O'Donnell DE. Obesity and COPD. *A Focus on COPD* 2010; 1(5): 4-7.
168. Guenette JA, O'Donnell DE. Pulmonary edema in athletes: methodology or meaningful physiology? [*Comment on point:counterpoint*]. *J Appl Physiol* 2010; 109(4): 1277-1278.
169. O'Donnell DE: Prioritizing research at the Canadian Thoracic Society and beyond. *Can Respir J* 2010; 17(1): 9-10 (**President's Page**).
170. Hodder R, Marciniuk DD, O'Donnell DE: COPD Management: new bronchodilators. *A Focus on COPD (Highlights of the ERS Annual Congress 2009)*. 2010; 1(1): 16-18
171. O'Donnell DE. The clinician/scientist in respirology – a vanishing phenotype. *Can Respir J* 2010; 17(3): 104-107 (**President's Page**).
172. O'Donnell DE. Summer round-up. *Can Respir J* 2010; 17(4): 152-154 (**President's Page**).
173. O'Donnell DE. The Lung Association Leadership Conference – an opportunity for change. *Can Respir J* 2010; 17(5): 209-210 (**President's Page**).
174. O'Donnell DE. Research officially recognized as a core activity of the Lung Association. *Can Respir J* 2010; 17(6): 263-264 (**President's Page**).
175. Laviolette L, O'Donnell D, Maltais F. Letter to the Editor. *COPD* 2010; 7(6): 443-444.
176. O'Donnell DE, Deesomchok A, Lam Y-M, Guenette JA, Amornputtisathaporn N, Forkert L, Webb KA. Effects of body mass index on static lung volumes in patients with airway obstruction. *Chest* 2011; 140: 461-468.
177. Marciniuk DD, Goodridge D, Hernandez P, Rucker G, Balter M, Bailey P, Ford G, Bourbeau J, O'Donnell DE, Maltais F, Mularski RA, Cave AJ, Mayers I, Kennedy V, Oliver TK, Brown C. Canadian Thoracic Society COPD Committee Dyspnea Expert Working Group. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease. A Canadian Thoracic Society clinical practice guideline. *Can Respir J* 2011; 18(2): 69-78.

178. Ora J, Laveneziana P, Wadell K, Preston M, Webb KA, O'Donnell DE. Effect of obesity on respiratory mechanics during rest and exercise in COPD. *J Appl Physiol* 2011; 111: 10-19. (***with accompanying editorial by BD Johnson and TG Babb***)
179. O'Meara P, Guenette J, Raghavan N, Amornputtisathaporn N, deMetz C, Nolan RL, O'Donnell DE. Mechanisms of dyspnoea relief following radiation treatment in a patient with severe COPD. *Eur Respir J* 2011; 38(3): 728-730.
180. Raghavan N, Webb KA, Amornputtisathaporn N, O'Donnell DE. Recent advances in pharmacotherapy for dyspnea in COPD. *Curr Opin Pharmacol* 2011; 11(3): 204-210.
181. Guenette JA, Webb KA, Jensen D, Ofir D, Raghavan N, O'Donnell DE. Sex differences in exertional dyspnea in patients with mild COPD: Physiological mechanisms. *Respir Physiol Neurobiol* 2011; 177(3): 218-227.
182. Raghavan N, Guenette JA, O'Donnell DE. The role of pharmacotherapy in mild to moderate COPD. *Ther Adv Respir Dis* 2011; 5(4): 245-254.
183. Jensen D, O'Donnell DE. The impact of human pregnancy on perceptual responses to chemoreflex vs exercise stimulation of ventilation: a retrospective analysis. *Respir Physiol Neurobiol* 2011; 175(1): 55-61.
184. O'Donnell DE, Casaburi R, Vincken W, Puente-Maestu L, Swales J, Lawrence D, Kramer B; on behalf of INABLE study investigators. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. *Respir Med* 2011; 105(7): 1030-1036.
185. Jensen D, Li R, O'Donnell DE, Luo Y-M. Effects of dead space loading on neuromuscular and neuro-ventilatory coupling of the respiratory system during exercise in health: implications for dyspnea and exercise tolerance. *Respir Physiol Neurobiol* 2011; 179: 219-226.
186. Laveneziana P, Webb KA, Ora J, Wadell K, O'Donnell DE. Evolution of dyspnea during exercise in COPD: impact of critical volume constraints. *Am J Respir Crit Care Med* 2011; 184(12): 1367-1373.
187. Guenette JA, Raghavan N, Harris-McAllister V, Preston ME, Webb KA, O'Donnell DE. Effect of adjunct fluticasone propionate on airway physiology during rest and exercise in COPD. *Respir Med* 2011; 105: 1836-1845.
188. Tan WC, Bourbeau J, Hernandez P, Chapman K, Cowie R, Fitzgerald M, Aaron S, Marciniuk D, Maltais F, O'Donnell D, Goldstein R, Sin D, Chan-Yeung M, Manfreda J, Anthonisen N, Tate R, Sears M, Siersted H, Becklake M, Ernst P, Bowie D, Sweet L, Van Til L. Canadian prediction equations of spirometric lung function for Caucasian adults 20 to 90 years of age: Results from the Canadian Obstructive Lung Disease (COLD) study and the Lung Health Canadian Environment (LHCE) study. *Can Respir J* 2011; 18(6): 321-326.
189. Guenette JA, Mureika JR, O'Donnell DE. Is the men's marathon world record 25 years behind the women's record? [*Comment*]. *J Appl Physiol* 2011; 110: 285.
190. Marciniuk DD, Hernandez P, Balter M, Bourbeau J, Chapman KR, Ford GT, Lauzon JL, Maltais F, O'Donnell DE, Goodridge D, Strange C, Cave AJ, Current K, Mathuri S. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: A Canadian Thoracic Society clinical practice guideline. *Can Respir J* 2012; 19(2): 109-116.
191. Guenette JA, Loughheed MD, Webb KA, O'Donnell DE. Can an 86-year-old woman with advanced lung disease be a world class athlete? *Respir Physiol Neurobiol* 2012; 181(2): 162-166.
192. Raghavan N, Lam Y-M, Webb KA, Guenette JA, Amornputtisathaporn N, Raghavan R, Tan WC, Bourbeau J, O'Donnell DE. Components of the COPD Assessment Test (CAT) associated with a diagnosis of COPD in a random population sample. *COPD* 2012; 9(2): 175-183.
193. Jensen D, Alshail A, Viola R, Dudgeon DJ, Webb KA, O'Donnell DE. Inhaled fentanyl citrate improves exercise endurance during high-intensity, constant work-rate cycle exercise in COPD. *J Pain Symptom Manage* 2012; 43(4): 706-719.

194. O'Donnell DE, Guenette J, Maltais F, Webb K. Decline of inspiratory capacity in COPD: the impact on breathing pattern, dyspnea, and ventilatory capacity during exercise. *Chest* 2012; 141(3): 753-762.
195. Guenette JA, Webb KA, O'Donnell DE. Does dynamic hyperinflation contribute to dyspnea during exercise in patients with COPD? *Eur Respir J* 2012; 40(2): 322-329. (*with accompanying editorial by Luo, Hopkinson and Polkey*)
196. Parshall MB, Schwartzstein R, Adams L, Banzett RB, Manning H, Bourbeau J, Calverley, PM, Gift A, Harver A, Lareau SC, Mahler DA, Meek PM, O'Donnell DE; the ATS Committee on Dyspnea. An official American Thoracic Society statement: update on the mechanisms, assessment and management of dyspnea. *Am J Respir Crit Care Med* 2012; 185(4): 435-452.
197. O'Donnell DE, Bredenbrocker D, Brose M, Webb KA. Physiological effects of roflumilast at rest and during exercise in COPD. *Eur Respir J* 2012; 39(5): 1104-1112. (*selected for reviewer comment "outside the blue" by BP Mieczkowski, Am J Respir Crit Care Med 2013;187(4):447*)
198. Vozoris NT, O'Donnell DE. Prevalence, risk factors, activity limitation and health outcomes of an obese population-based sample with chronic obstructive pulmonary disease. *Can Respir J* 2012; 19(3): e18-e24.
199. Laveneziana P, Guenette JA, Webb KA, O'Donnell DE. New physiological insights into dyspnea and exercise intolerance in COPD patients. *Expert Rev Respir Med* 2012; 6(6): 651-662.
200. O'Donnell DE, O'Donnell CDJ, Webb KA, Guenette JA. Respiratory consequences of mild-to-moderate obesity: impact on exercise performance in health and in chronic obstructive pulmonary disease. *Pulm Med* 2012; article ID 818925.
201. O'Donnell DE, Webb KA, Guenette JA. Letter to the Editor. *Chest* 2012; 141(2): 569.
202. Guenette JA, Raghavan N, O'Meara P, de Metz CE, O'Donnell DE. Chest radiotherapy to achieve lung volume reduction [*Letter*]. *Eur Respir J* 2012; 39(3): 792.
203. Jensen D, O'Donnell DE. Opioids for the amelioration of dyspnea in COPD: a much neglected topic [*Letter to the Editor*]. *J Pain Symptom Manage* 2012; 44(4): e1-2.
204. Wadell K, Webb KA, Preston ME, Amornputtisathaporn N, Samis L, Patelli J, Guenette JA, O'Donnell DE. Impact of pulmonary rehabilitation on the major dimensions of dyspnea in COPD. *COPD* 2013; 10(4): 425-435.
205. Guenette JA, Chin RC, Cory JM, Webb KA, O'Donnell DE. Inspiratory capacity during exercise: measurement, analysis and interpretation. *Pulm Med* 2013; article ID956081.
206. Guenette JA, Webb KA, O'Donnell DE. Effect of fluticasone/salmeterol combination on dyspnea and respiratory mechanics in mild to moderate COPD. *Respir Med* 2013; 107(5): 708-716.
207. Thomas M, Decramer M, O'Donnell DE. No room to breathe: the importance of lung hyperinflation in COPD. *Prim Care Respir J* 2013; 22(1): 101-111.
208. Chin RC, Guenette JA, Cheng S, Raghavan N, Amornputtisathaporn N, Cortes-Telles A, Webb KA, O'Donnell DE. Does the respiratory system limit exercise in mild chronic obstructive pulmonary disease? *Am J Respir Crit Care Med* 2013; 187(12): 1315-1323. (*with accompanying editorial by JA Dempsey, p.1282-1283*)
209. Tan WC, Bourbeau J, Hernandez P, Chapman KR, Cowie R, Fitzgerald JM, Aaron S, Marciniuk D, Maltais, F, Buist AS, O'Donnell DE, Sin DD; the CanCOLD Collaborative Research Group. Bronchodilator responsiveness and reported respiratory symptoms in an adult population. *PLOS One* 2013; 8(3): E58932.
210. Elbehairy AF, Webb KA, Neder JA, O'Donnell DE. Should mild COPD be treated? Evidence for early pharmacological intervention. *Drugs* 2013; 73(18): 1991-2001.
211. Marciniuk DD, Johnson BD, Neder A, O'Donnell DE. Cardiopulmonary exercise testing [*Editorial*]. *Pulm Med* 2013; article ID 686104, 1 page.
212. O'Donnell DE. COPD: Management of "The Frequent Exacerbator". *Asthma Plan of Action eNewsletter*. Spring 2013:1-3. <http://www.on.lung.ca/page.aspx?pid=1313/>

213. Ciavaglia CE, Guenette J, Ora J, Webb KA, Neder A, O'Donnell DE. Does exercise test modality influence dyspnea perception in obese patients with COPD? *Eur Respir J* 2014; 43(6): 1621-1630. PMID: 24311769
214. Tan WC, Bourbeau J, Hernandez P, Chapman KR, Cowie R, FitzGerald JM, Marciniuk DD, Maltais F, Buist AS, O'Donnell DE, Sin DD, Aaron SD for the CanCOLD Collaborative Research Group. Exacerbation-like respiratory symptoms in individuals without chronic obstructive pulmonary disease: results for a population-based study. *Thorax* 2014; 69(8): 709-717. PMID: 4706040
215. Guenette JA, Chin RC, Cheng S, Dominelli P, Raghavan N, Webb KA, Neder JA, O'Donnell DE. Respiratory neuromuscular and sensory-mechanical adaptations to exercise in GOLD Grade I COPD. *Eur Respir J* 2014; 35(1): 51-69. PMID: 24507837
216. O'Donnell DE, Laveneziana P, Webb K, Neder JA. Chronic obstructive pulmonary disease: clinical integrative physiology. *Clin Chest Med* 2014; 35(1): 51-69. PMID: 24507837
217. Tan WC, Bourbeau J, O'Donnell D, Aaron S, Maltais F, Marciniuk D, Hernandez P, Cowie R, Chapman K, Buist AS, Sin D, Fitzgerald JM; the CanCOLD Collaborative Research Group. Quality assurance of spirometry in a population-based study – Predictors of good outcome in spirometry testing. *COPD* 2014; 11(2): 143-151. PMID: 24666210
218. O'Donnell DE, Maltais F, Porszasz J, Webb KA, Albers FC, Deng Q, Iqbal A, Paden HA, Casaburi R; the 205.440 study investigators. The continuum of physiological impairment during treadmill walking in patients with mild-to-moderate COPD: patient characterization phase of a randomized clinical trial. *Plos One* 2014; 9(5): e96574. PMID: 24788342
219. O'Donnell DE, Ciavaglia C, Neder JA. When obesity and COPD collide: physiological and clinical consequences. *Ann Am Thoracic Soc* 2014; 11(4): 635-644. PMID: 24625243
220. Cortés-Télles A, Forkert L, O'Donnell DE, Morán-Mendoza O. Idiopathic pulmonary fibrosis: New insights on functional characteristics at diagnosis. *Can Respir J* 2014; 21(3): e55-e60. PMID: 24712014
221. Laveneziana P, Webb KA, Wadell K, Neder JA, O'Donnell DE. Does expiratory muscle activity influence dynamic hyperinflation and exertional dyspnea in COPD? *Respir Physiol Neurobiol* 2014; 199: 24-33. PMID: 24793133
222. O'Donnell DE, Gebke KB. Activity restriction in mild COPD: a challenging clinical problem. *Int J COPD* 2014; 9: 577-588. PMID: 24940054
223. O'Donnell DE, Gebke KB. Examining the role of activity, exercise and pharmacology in mild COPD. *Postgrad Med* 2014; 126(5): 135-145. PMID: 25295658
224. Bourbeau J, Tan WC, Benedetti A, Aaron SD, Chapman KR, Coxson HO, Cowie R, FitzGerald M, Goldstein R, Hernandez P, Leipsic J, Maltais F, Marciniuk D, O'Donnell D, Sin DD, for the CanCOLD Study Group. Canadian Cohort Obstructive Lung Disease (CanCOLD): fulfilling the need for longitudinal observational studies in COPD. *COPD* 2014; 11(2): 125-132.
225. Langer D, Ciavaglia CE, Neder JA, Webb KA, O'Donnell DE. Lung hyperinflation in chronic obstructive pulmonary disease: mechanisms, clinical implications and treatment. *Expert Rev Respir Med* 2014; 8(6): 731-749. PMID: 25159007
226. Guenette JA, Chin RC, Cheng SD, Dominelli PB, Raghavan N, Webb KA, Neder JA, O'Donnell DE. Mechanisms of exercise intolerance in Global Initiative for Chronic Obstructive Lung Disease grade 1 COPD. *Eur Respir J* 2014; 44(5): 1177-1187. PMID: 25142487
227. Ciavaglia CE, Guenette JA, Langer D, Webb KA, Neder JA, O'Donnell DE. Differences in respiratory muscle activity during cycling and walking do not influence dyspnea perception in obese patients with COPD. *J Appl Physiol* 2014; 117(11): 1292-1301. PMID: 25301894
228. Casaburi R, Maltais F, Porszasz J, Albers F, Deng Q, Iqbal A, Paden HA, O'Donnell DE; the 205.440 investigators. Effects of tiotropium on hyperinflation and treadmill exercise tolerance in

- mild-moderate chronic obstructive pulmonary disease. *Ann Am Thorac Soc* 2014; 11(9): 1351-1361. PMID: 25289942
229. Tan WC, Bourbeau J, Aaron S, FitzGerald JM, Hernandez P, Cowie R, Chapman KR, Marciniuk D, Maltais F, Buist S, O'Donnell D, Sin DD; the CanCOLD Collaborative Research Group. Exacerbations in non-COPD patients: truth or myth – authors' response [*Letter*]. *Thorax* 2014; 69(11): 1050-1051. PMID: 24996635
 230. O'Donnell DE. Adult survivors of preterm birth: What spirometry conceals, exercise tests reveal [*Editorial*]. *Ann Am Thorac Soc* 2014; 10: 1606-1607. PMID: 25549025
 231. O'Donnell DE, Neder JA, Webb KA, Elbehairy AF. Reply: Effects of mild chronic obstructive pulmonary disease on gas exchange during cycling and walking [*Letter*]. *Am J Respir Crit Care Med* 2015; 192(9): 1138-1139.
 232. Gagnon P, Casaburi R, Saey D, Porszasa J, Provencher S, Milot J, Bourbeau J, O'Donnell DE, Maltais F. Cluster analysis in patients with GOLD 1 Chronic Obstructive Pulmonary Disease. *PLoS One* 2015; 10(4): e0123626. PMID: 25906326
 233. Elbehairy AF, Raghavan N, Cheng S, Yang L, Webb KA, Neder JA, Guenette JA, Mahmoud MI, O'Donnell DE; the Canadian Respiratory Research Network. Physiological characterization of the chronic bronchitis phenotype in GOLD grade 1B COPD. *Chest* 2015; 147(5): 1235-1245. PMID: 25393126
 234. Green ME, Natajara N, O'Donnell DE, Williamson T, Kotecha J, Khan S, Cave A. Chronic obstructive pulmonary disease in primary care: an epidemiologic cohort study from the Canadian Primary Care Sentinel Surveillance Network. *CMAJ Open* 2015; 3(1): E15-E22. PMID: 25844366
 235. Neder JA, Arbex FF, Alencar MC, O'Donnell CD, Cory J, Webb KA, O'Donnell DE. Exercise ventilatory inefficiency in mild to end-stage COPD. *Eur Respir J* 2015; 45(2): 377-387. PMID: 25359345
 236. Dominelli PB, Foster GE, Guenette JA, Haverkamp HC, Eves ND, Dominelli GS, Henderson WR, O'Donnell DE, Sheel, AW. Quantifying the shape of the maximal expiratory flow-volume curve in mild COPD. *Respir Physiol Neurobiol* 2015; 219: 30-35.
 237. Oliveira MF, Zelt JT, Jones JH, Hirai DM, O'Donnell DE, Verges S, Neder JA. Does impaired O₂ delivery during exercise accentuate central and peripheral fatigue in patients with coexistent COPD-CHF? *Front Physiol* 2015; 5: 514. PMID: 25610401
 238. Faisal A, Webb KA, Guenette JA, Jensen D, Neder JA, O'Donnell DE; the Canadian Respiratory Research Network. Effect of age-related ventilatory inefficiency on respiratory sensation during exercise. *Resp Physiol Neurobiol* 2015; 205: 129-139. PMID: 25447683
 239. Mahler DA, O'Donnell DE. Recent advances in dyspnea. *Chest* 2015;147(1):232-241. PMID: 25560861
 240. Vozoris NT, O'Donnell DE. Smoking, activity level and exercise test outcomes in a young population sample without cardiopulmonary disease. *J Sports Med Phys Fitness* 2015; 55: 787-796. PMID: 25611081
 241. Medeiros WM, Fernandes MCT, Azevedo DP, de Freitas FF, Amorim BC, Chiavegato LD, Hirai DM, O'Donnell DE, Neder JA. Oxygen delivery-utilization mismatch in contracting locomotor muscle in COPD: peripheral factors. *Am J Physiol Regul Integr Comp Physiol* 2015; 308: R105-R111. PMID: 25477423
 242. Neder JA, Ramos RP, Ota-Arakaki JS, Hirai DM, D'Arsigny CL, O'Donnell DE. Exercise intolerance in pulmonary arterial hypertension: the role of cardiopulmonary exercise testing. *Ann Am Thorac Soc* 2015; 12(4): 604-612. PMID: 25897744
 243. Elbehairy A, Ciavaglia C, Webb K, Guenette J, Jensen D, Mourad S, Neder JA, O'Donnell DE; the Canadian Respiratory Research Network. Pulmonary gas exchange abnormalities in mild COPD: implications for exercise intolerance. *Am J Resp Crit Care Med* 2015; 191(12): 1384-1394. PMID: 25826478 (*with an accompanying editorial by P Calverley, p.1346-1347*)

244. Tan W, Sin D, Bourbeau J, Hernandez P, Cowie R, Fitzgerald M, Marciniuk D, Maltais F, Buist S, Road J, Hogg J, Kirby M, Coxson H, Hague CJ, Leipsic J, O'Donnell D, Aaron S; the CanCOLD Collaborative Research Group. Characteristics of COPD in never-smokers and ever-smokers in the general population: results from the CanCOLD study. *Thorax* 2015; 70(9): 822-829. PMID: 26048404.
245. Neder JA, Langer D, Ciavaglia C, Webb K, O'Donnell C, Cory J, O'Donnell DE. Ventilation distribution heterogeneity at rest as a marker of exercise impairment in mild to advanced COPD. *COPD* 2015; 12(3): 249-256. PMID: 25230258
246. O'Donnell DE, Webb KA, Neder JA. Lung hyperinflation in COPD: applying physiology to clinical practice. *COPD Research and Practice* 2015; 1: 4. [doi.10.1186/s40749-015-0008-8]
247. Currow DC, Abernethy AP, Carrieri-Kohlman V, Disler R, Higginson I, Jolley C, Maddocks M, Morelot-Panzini C, Moxham J, Mularski RA, Noble S, O'Donnell D, Parshall MB, Pattinson K, Phillips J, Ross J, Schwartzstein RM, Similowski T, Simon S, Smith T, Wells A, Yates P, Yorke J, Johnson MJ. The need to research refractory breathlessness. *Eur Respir J* 2016; 47(1): 342-343. PMID: 26721965
248. Oliveira MF, Alencar MC, Arbex F, Souza A, Sperandino P, Medina L, Medeiros WM, Hirai DM, O'Donnell DE, Neder JA. Effects of heart failure on cerebral blood flow in COPD: Rest *and* exercise. *Respir Physiol Neurobiol* 2016; 221: 41-48. PMID: 26528895
249. Vozoris N, Wang X, Fischer HD, Gershon AS, Bell CM, Gill SS, O'Donnell DE, Austin P, Stephenson AL, Rochon PA. Incident opioid use among older adults with chronic obstructive pulmonary disease: a population-based cohort study. *Br J Clin Pharmacol* 2016; 81(1): 161-170. PMID: 26337922
250. O'Donnell DE, Neder JA, Elbehairy AF. Physiological impairment in mild COPD. *Respirology* 2016; 21(2): 211-223. PMID: 26333038
251. Faisal A, Alghamdi BJ, Ciavaglia CE, Elbehairy AF, Webb KA, Ora J, Neder JA, O'Donnell DE. Common mechanisms of dyspnea in chronic interstitial and obstructive lung disorders. *Am J Respir Crit Care Med* 2016; 193(3): 299-309. PMID: 26407036 (*With accompanying editorial by C.J. Jolley and J. Moxham, p. 236-238*).
252. Puente-Maestu L, Palange P, Casaburi R, Laveneziana P, Maltais F, Neder JA, O'Donnell DE, Onorati P, Porszasz J, Rabinovich R, Rossiter HB, Singh S, Troosters T, Ward S. Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. *Eur Respir J* 2016; 47(2): 429-460. PMID: 26797036
253. Neder JA, O'Donnell DE. Update on non-surgical lung volume reduction procedures. *Can Respir J*, 6-2016. doi: 10.1155/2016/6462352. PMID: 27445557
254. Neder JA, Jones JH, Zelt JT, Ramos RP, Ota-Arakaki JS, Hirai DM, Sperandio PA, Alencar MC, Arbex FF, O'Donnell DE. Pulmonary artery wedge pressure and exercise oscillatory ventilation in pre-capillary pulmonary hypertension. *Int J Cardiol*, published online November 10, 2015 as doi:10.1016/j.ijcard.2015.11.020. (Correspondence) 2016;164-166. PMID: 26577023.
255. Vozoris NT, Gill S, O'Donnell DE. Opioids in COPD: the "whole picture" includes results from real-world, population-based observational studies [*Letter to the Editor*]. *Br J Clin Pharmacol*, published online November 23, 2015 as doi: 10.1111/bcp.12838. 2016;81(4):797-798. PMID: 26592364.
256. Davis C, Sheikh K, Pike D, Svenningsen S, McCormack DG, O'Donnell DE, Neder JA, Parraga G. Ventilation heterogeneity in never-smokers and COPD: comparison of pulmonary functional magnetic resonance imaging with the poorly communicating fraction derived from plethysmography. *Acad Radiol* published online January 8, 2016 as doi: 10.1016/j.acra.2015.10.022. 2016;23(4):398-405. PMID: 26774739

257. Vozoris N, O'Donnell DE. The need to address increasing opioid use in elderly COPD patients. *Expert Rev Respir Med* published online January 18, 2016 as doi: 10.1586/17476348.2016.1143776. 2016;10(3):245-248. PMID: 26783198
258. Oliveira MF, Arbex F, Alencar MC, Souza A, Sperandio PA, Medeiros W, Mazzuco A, Borghi-Silva A, Medina LA, Santos R, Hirai DM, Mancuso F, Almeida D, O'Donnell DE, Neder JA. Heart failure impairs muscle blood flow and endurance exercise tolerance in COPD. *COPD: J of COPD*, published online January 20, 2016:1-9. Doi: 10.3109/15412555.2015.1117435. 2016;13(4):407-415. PMID: 26790095
259. Neder J A, Hirai D, Jones J, Zelt J, Berton D, O'Donnell DE. A 56-yr old otherwise healthy woman presenting with lightheadedness and progressive shortness of breath. *Chest* (accepted February 1, 2016). 2016 Jul;150(1):e23-27. PMID: 27396797
260. Neder JA, Alharbi A, Berton D, Alencar MC, Arbex F, Hirai D, Webb KA, O'Donnell DE. Exercise ventilatory inefficiency adds to lung function in predicting mortality in COPD. *COPD: J of COPD*, published online April 14, 2016 as doi:10.3109/15412555.2016.1158801. 2016 13(4):416-424. PMID: 27077955
261. Lange P, Halpin D, O'Donnell DE, MacNee W. Diagnosis, assessment and phenotyping of COPD: beyond FEV₁. *Int J COPD*. 2016;11 (Suppl 1st World Lung Disease Summit):3-12. PMID: 26937185.
262. Alencar MC, Arbex F, Souza A, Mazzuco A, Sperandio P, Rochon A, Hirai D, Mancuso F, Berton D, Borghi-Silva A, Almeida D, O'Donnell D, Neder JA. Does exercise ventilatory inefficiency predict poor outcome in heart failure patients with COPD? *J Cardiopulmon Rehab Prevention* (accepted October 2015). 2016 Nov/Dec;36(6):454-459.
263. Bourbeau J, Chapman K, Aaron S, O'Donnell D, Tan W, Maltais F, Hernandez P, Marciniuk D, Sin D, Fitzgerald M, Zhi Li P, Benedetti A, Labonte L, Gershon A. Undiagnosed COPD contributes to the burden of health care utilization: data from the CanCOLD Study. *Am J Crit Care Med* (accepted December 2015). *Am J Respir Crit Care Med* published online February 2, 2016 as doi: 10.1164/rccm.201509-1795OC. 2016;194(3):285-298. PMID: 26836958
264. Neder J, Ramos R, Ota J, Ferreira E, Hirai D, Sperandio P, Alencar MC, Arbex F, Berton D, D'Arsigny C, O'Donnell D. Post-exercise PETCO₂: Insights into ventilation-gas exchange coupling in chronic thromboembolic pulmonary hypertension. *Eur Respir J*. Published online April 13, 2016 as doi: 10.1183/13993003.01948-2015. 2016;48(1):252-254. PMID: 27076589.
265. Scioscia G, Blanco I, Arismendi E, Burgos F, Gistau C, Barbaro MPF, Celli B, O'Donnell D, Agusti A. Different dyspnea perception is different in COPD patients with frequent and infrequent exacerbations. *Thorax* (accepted pending revision February 7, 2016, revision submitted June 7, 2016). Doi:10.1136/thoraxjnl-2016-208332. PMID: 27586869. **(With accompanying editorial by Ridsdale HA, Hurst JR: Dyspnoea perception and susceptibility to exacerbation in COPD. Thorax Online First, November 4, 2016 as 10.1036/thoraxjnl-2016-209318).**
266. O'Donnell DE, Webb KA, Langer D, Elbehairy AF, Neder JA, Dudgeon DJ. Respiratory factors contributing to exercise intolerance in breast cancer survivors: a case-control study. *J Pain Symptom Management*, published online March 11, 2016 as doi: 10.1016/j.painsymman.2016.01.004. 2016;52(1):54-63. PMID: 26975626
267. Gershon AS, Hwee J, Chapman KR, Aaron SD, O'Donnell DE, Stanbrook M, Bourbeau J, tan W, Su J, Victor JC, To T. Factors associated with undiagnosed and overdiagnosed COPD. *Eur Resp J* 2016;48(2):561-564. PMID: 27338199
268. Tan WC, Leipsic J, Hague C, Bourbeau J, Sin DD, Coxson HO, Kirby M, Raju R, Road J, O'Donnell DE, Aaron SD, Maltais F, Hernandez P, Cowie R, Chapman KR, Marciniuk D, Fitzgerald JM, Hogg JC; the CanCOLD Collaborative Research Group. The natural history of CT-based bronchiolitis and emphysema in never-, ever- and current smokers: A population-based CanCOLD Study. *Thorax* 1-2016

269. Elbehairy A, Guenette J, Faisal A, Ciavaglia C, Webb K, Jensen D, Ramsook A, Neder JA, O'Donnell D. Mechanisms of exertional dyspnea in symptomatic smokers without COPD. *Eur Respir J* 2016;48(3):694-705. Doi: 10.1183/13993003.00077-2016. PMID: 27492828
270. Gupta N, Pinto L, Benedetti A, Li PZ, Tan W, Aaron S, Chapman K, FitzGerald JM, Hernandez P, Marciniuk D, Maltais François, O'Donnell D, Sin D, Walker B, Bourbeau J. The COPD Assessment Test: can it discriminate across COPD subpopulations? *Chest* (Accepted June 7, 2016). 2016;150(5):1069-1079. PMID: 27364603
271. O'Donnell DE, Webb KA, Harle I, Neder JA. Pharmacological management of breathlessness in COPD: Recent advances and hopes for the future. *Exp Resp Rev* published online May 12, 2016 as doi: 10.1080/17476348.2016.1182867. 2016;10(7):823-834. PMID: 27115291
272. Vozoris N, Wang X, Fischer HD, Bell CM, O'Donnell DE, Austin PC, Stephenson AL, Gill SS, Rochon PA. Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. *Eur Resp J*. (Accepted April 2016: doi:10.1183/13993003.01967.2015). 2016;48(3):683-693. PMID: 27418553
273. Arbex FF, Alencar MC, Souza A, Mazzuco A, Sperandio PA, Rocha A, Hirai DM, Mancuso F, Berton DC, Borghi-Silva A, Almeida DR, O'Donnell DE, Neder JA. Exercise ventilation in COPD: influence of systolic heart failure. *COPD* published online May 12, 2016 as doi: 10.1080/15412555.2016.1174985. 2016;13(6):693-699 PMID: 27172093
274. Soares de Souza A, Sperandio PA, Mazzuco A, Alencar MC, Arbex FF, Oliveira MF, O'Donnell DE, Neder JA. Influência da insuficiência cardíaca nos volumes pulmonares de repouso em pacientes com DPOC [Influence of heart failure on resting lung volumes in patients with COPD]. *Journal Brasileiro de Pneumologia* (Accepted May 10, 2016). 2016;42(4):273-278. PMID: 27832235
275. Tan WC, Leipsic J, Hague C, Bourbeau J, Li PZ, Zhen L, Sin DD, Coxson HO, Kirby M, Hogg JC, Raju R, Road J, O'Donnell DE, Maltais F, Hernandez P, Cowie R, Chapman KR, Marciniuk D, FitzGerald JM, Aaron SD; the Canadian Respiratory Research Network and the CanCOLD Collaborative Research Group. Qualitative assessment of computed tomography (CT) thoracic scans and its relationship to patient-related outcomes in the population. *Chest* (submitted January 2016).
276. O'Donnell DE, Elbehairy AF, Faisal A, Webb KA, Neder JA, Mahler DA. Exertional dyspnoea in COPD: The clinical utility of cardiopulmonary exercise testing. *Eur Resp Rev* (Submitted June 1, 2016). 2016;25(141):333-347. **Erratum in: Eur Resp Rev.2016.Dec25(142)513.** PMID: 27581832
277. O'Donnell DE, Neder JA, Harle I, Moran-Mendoza O. Chronic breathlessness in patients with idiopathic pulmonary fibrosis – a major challenge for caregivers. *Expert Rev Respir Med*. DOI: 10.1080/17476348.2016.1251843. 2016;10(12):1295-1303. PMID: 27766905
278. Dominelli PB, Foster GE, Guenette JA, Haverkamp HC, Eves ND, Dominelli GS, Henderson WR, O'Donnell DE, Sheel AW. Reply to Topalovic and Janssens re: Quantifying the shape of the maximal expiratory flow-volume curve to address flow limitation (*Letter*). *Respir Physiol Neurobiol* 2016;227:68. PMID: 26899171.
279. Rocha A, Arbex F, Alencar MC, Sperandio P, Hirai DM, Berton DC, O'Donnell DE, Neder JA. Physiological and sensory consequences of exercise oscillatory ventilation in heart failure-COPD. *International J of Cardiol*. 2016;224:447-453. PMID: 27701063
280. O'Donnell. Lung hyperinflation in COPD: What the clinician needs to know. *Ontario Thoracic Review* 2016;28(2):1-21.
281. Vozoris NT, O'Donnell DE, Bell CM, Gill SS, Rochon PA. Opioids in COPD: a cause of death or a marker of illness severity? *Eur Resp J* 2016;48:1521-1522. PMID: 27799397
282. Selman J, Jose, A, Farias M, Leitao L, Wandalsen G, Berton D, O'Donnell D, Lanza F, Neder JA, Dal Corso S. Pulmonary ventilation during stepping and running: implications for exercise

- induced bronchoconstriction in asthmatic children. *Pediatric Pulmonology* (Submitted November 2016).
283. Elbehairy AF, Guenette JA, Faisal A, Ciavaglia CE, Webb KA, Jensen D, Ramsook AH, Neder JA, O'Donnell DE on behalf of the Canadian Respiratory Research Network. Physiological impairment in smokers at risk for COPD: clinical consequences. 8-2016. *Eur Resp J*.
 284. Smid D, Franssen F, Gonik M, Miravittles M, Casanova C, Cosio B, de Lucas-Ramos P,..... O'Donnell DE, Webb KA, et al. CWR collaboration. Redefining cut-points for symptom burden of GOLD COPD classification. *NEJM* (submitted October 23, 2016).
 285. Tan WG, Hague CJ, Leipsic J, Bourbeau , Zheng L, Li P, Sin D, Coxson H, Kirby M, Hogg J, Road J, O'Donnell D, Maltais F, Hernandez P, Cowie C, Chapman K, Marciniuk D, Fitzgerald M, Aaron S. Findings on thoracic computed tomography scans and respiratory outcomes in persons with and without chronic obstructive pulmonary disease: a population-based cohort study (PONE-D-16-33170R1). *PLOS ONE*. (Accepted November 2016). 2016 Nov 18;11(11):e0166745. doi: 10.1371/journal.pone.0166745. PMID: 27861566
 286. Ryerson CJ, Camp PG, Eves ND, Schaeffer M, Syed N, Dhillon S, Jensen D, Maltais F, O'Donnell DE, Raghavan N, Roman M, Stickland MK, Assayag D, Bourbeau J, Dion G, Fell CD, Hambly N, Johansson KA, Kalluri M, Khalil N, Kolb M, Manganas H, Moran-Mendoza O, Provencher S, Ramesh W, Rolf JD, Wilcox PG, Guenette JA. High oxygen delivery to preserve exercise capacity in patients with idiopathic pulmonary fibrosis treated with Nintedanib. *Methodology of the HOPE-IPF Study*. *Ann Am Thorac Soc* 2016;13(9):1640-1647. PMID: 27348402.
 287. Vozoris NT, O'Donnell DE, Gill SS. Opioids and adverse outcomes in elderly chronic obstructive pulmonary disease patients. *Eur Resp J* 2016: doi:10.1183/13993003.01690-2016. 2016;48(6):1818. PMID: 27903697
 288. O'Donnell DE, Casaburi R, Frith P, Kirsten A, De Sousa D, Hamilton A, Xue W, Maltais F. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD. *Eur Resp J* (Accepted Dec 2016; published online 2017 April 19:49(4). pii 1601348. doi:10.1183/13993003.01348-2016). PMID: 28424359
 289. Neder JA, Berton DC, Arbex FF, Alencar MC, Rocha A, Sperandio P, Palange P, O'Donnell DE. Physiological and clinical relevance of exercise ventilatory efficiency in COPD. *Eur Respir J* 2017 March 8:49(3). pii: 1602036; doi:10.1183/13993003.02036-2016. PMID: 28275174.
 290. Walter Barbosa G, Neder JA, Utida K, O'Donnell DE, DeTarso Muller P. Impaired exercise ventilatory efficiency in smokers with low transfer factor but normal spirometry. *Eur Resp J* 2017 March 8:49(3). pii :1602511; doi: 10.1183/13993003.02511-2016. PMID: 28275177.
 291. Elbehairy AF, Faisal A, Guenette JA, Jensen D, Webb KA, Ahmed R, Neder JA, O'Donnell DE on behalf of the Canadian Respiratory Research Network. Resting physiological correlates of reduced exercise capacity in smokers with mid airway obstruction. *COPD*. (Published online April 2017 – dx.doi.org/10.1080/1541255.2017.1281901). 2017;14(3)267-275. PMID: 28368706.
 292. Hirai D, Jones J, Zelt J, da Silva M, Bentley R, Edgett B, Gurd B, Tschakovsky M, O'Donnell DE, Neder JA. Oral N-Acetylcysteine and exercise tolerance in mild chronic obstructive pulmonary disease. *J Appl Physiol* (Published online March 2017 May 1:122(5):1351-1361. doi:10.1152/jappphysiol.00990.2016. PMID: 28255088.
 293. Vozoris N, O'Donnell D, Bell C, Gill S, Rochon P. Incident opioid use is associated with risk of respiratory harm in non-palliative COPD. *Eur Resp J* 2017:49 93). pii:1602529. doi: 10.1183/13993003.02529-2016. PMID: 28275179
 294. Neder A, Berton DC, Muller PT, Elbehairy AF, Rocha A, Palange P, O'Donnell DE; Canadian Respiratory Research Network (CRRN). Ventilatory inefficiency and exertional dyspnea in early chronic obstructive pulmonary disease. *Ann Amer Thorac Soc* 2017 Jul 14(Suppl 1):S22-S29. doi: 10.1513/AnnalsATS.201612-1033FR. PMID: 28345959.

295. Hanania NA, Taskin DP, Kerwin EM, Donohue JF, Denenberg M, O'Donnell DE, Quinn D, Siddiqui S, Orevillo C, Maes A, Reisner C. Long term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension Delivery Technology in patients with chronic obstructive pulmonary disease. *Resp Med* 2017;126:105-115. (Published online March 2017 – doi: /10.1016/j.rmed.2017.03.015). PMID: 28427541.
296. O'Donnell DE, Elbehairy AF, Berton DC, Domnik, NJ, Neder JA. Advances in the evaluation of respiratory pathophysiology during exercise in chronic lung diseases. *Front Physiol* (Published online 2017;Feb 22:8:82 – doi:10.3388/fphys.2017.00082) PMID: 28275353.
297. Hirai D, Zelt J, Jone JH, Castanhas L, Bentley R, Early W, Staples P, Tschakovsky M, McCans J, O'Donnell DE, Neder JA. Dietary nitrate supplementation and exercise tolerance in patients with heart failure with reduced ejection fraction. *Am J of Physiol: Integrative & Comparative Physiology*. 2017;312(1):R13-R22. Accepted Oct 2016: doi: 10.1152/ajpregu.00263.2016) PMID: 27784687
298. Jones JH, Zelt JT, Hirai DM, Fisher JT, O'Donnell DE, Neder JA. Emphysema on thoracic CT and exercise ventilatory inefficiency in mild-to-moderate COPD. *COPD Journal* 2017;14(2):210-218 (Accepted Oct 2016). Published online December 20: doi: 10.1080/15412555.2016.1253670. COPD. PMID: 27997255
299. Scioscia G, Blanco I, Arismendi E, Burgos F, Gistau C, Foschino Barbaro MP, Celli B, O'Donnell DE, Agusti A. Different dyspnoea perception in COPD patients with frequent and infrequent exacerbations. *Thorax* 2017;72(2):117-121. PMID: 27586869.
300. Elbehairy AF, Hockmann K, Ciavaglia CE, Faisal A, Hill E, Webb KA, Neder JA, O'Donnell DE. Unraveling the cause of severe exertional dyspnea in a heavy smoker. *Annals of Am Thorac Soc* (accepted May 2017). Published online as doi:10.1513/AnnalsATS.201705-382CC. 2017;14(12):1849-1855.
301. Langer D, Ciavaglia C, Faisal A, Webb KA, Neder JA, Gosselink R, Topalovic M, Ivanova A, O'Donnell DE. Mechanisms of exertional dyspnea relief after inspiratory muscle training in patients with COPD. *J Appl Physiol* (Submitted December 2017) *in review* .
302. Elbehairy AF, Parraga G, Webb KA, Neder JA, O'Donnell DE; Canadian Respiratory Research Network (CRRN). Mild chronic obstructive pulmonary disease: Why spirometry is not sufficient! *Expert Rev of Respir Med*. 2017;11(7):549-563. Accepted May 2017. doi.org/10.1080/17476348.2017.1334553. PMID: 28548545.
303. O'Donnell DE, Elbehairy AF, Webb KA, Neder JA. The link between reduced inspiratory capacity and exercise intolerance to COPD. *Ann Am Thoracic Soc* 2017;14(Suppl 1):S30-S39. PMID: 28398073.
304. Vozoris N, Rochon P, Austin P, Lee D, Stephenson A, O'Donnell D, Gill S, Anderson P. Adverse cardiac events associated with incident opioid drug use among older adults with COPD. *Eur J Clin Pharmacol* Accepted June 29, 2017. doi:10.1007/s00228-017-2278-3. PMID: 28664359.
305. Rocha A, Arbex FF, Sperandio PA, Souza A, Biazim L, Mancuso F, Berton DC, Hochhegger B, Alencar MCN, Nery LE, O'Donnell DE, Neder JA. Excess ventilation in COPD-heart failure overlap: Implications for dyspnea and exercise intolerance. *Am J Resp Crit Care Med*. 2017;196(10): 1264-1274. 10.1164/rccm.201704-0675OC. PMID: 28665692. (***With accompanying editorial by Arce SC, De Vito EL. Universidad de Buenos Aires, Argentina. Am J Resp Crit Care Med 2017;196(10):1233-1234.***)
306. deSousa Sena R, Ahmed A, Tan W, Li P, Labonte L, Aaron S, Benedetti A, Chapman K, Walker B, Fitzgerald M, Hernandez P, Maltais F, Marciniuk D, O'Donnell D, Sin D, Bourbeau J. Work productivity loss in mild to moderate COPD: Lessons learned from CanCOLD study. *Eur Resp J*. 2017 Sep 12;50(3),1701154. doi: 10.1183/13993003.01154-2017. PMID: 28899939.
307. Rodrigues A, Da Silva ML, Berton DC, Cipriano Jr G, Pitta F, O'Donnell DE, Neder JA. Maximal inspiratory pressure: does the choice of reference values actually matter? *Chest* 2017;152(1):32-

39. Published online December 8, 2016 as doi: 10.1016/j.chest.2016.11.045. PMID: 27940276. *(With accompanying editorial by Polkey MJ, Man WD-C, London, England. Chest 2017;152(1):6-7).*
308. Calzetta L, Ora J, Cavalli F, Rogliani P, O'Donnell DE, Cazzola M. Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. *Respir Med* 2017 Aug; 129:189-198. doi: 10.1016/j.med.2017.06.020. PMID: 28732830.
309. Washko GR, Coxson HO, O'Donnell DE, Aaron SD. CT imaging of chronic obstructive pulmonary disease: insights, disappointments, and promise. *Lancet Respir Med*. Published online September 28 2017 as doi:10.1016/S2213-2600(17)30345-4. PMID: 28965820.
310. Smid DE, Franssen FME, Casanova C, Cosio B, Gonik M, de Lucas P, Marin JM, O'Donnell DE, Ogata Y, Webb KA, Xie G, Yoshikawa M, Zogg S, Spruit MA. Redefining cut-points for high symptom burden of the GOLD classification in 18577 patients with chronic obstructive pulmonary disease. *J Am Med Dir Assoc* (Accepted September 2017).
311. Lacasse Y, Bernard S, Series F, Nguyen VH, Bourbeau J, Aaron S, Maltais F... O'Donnell DE for International Nocturnal Oxygen (INOX) Research Group. Multicentre, randomized, placebo-controlled trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease: a study protocol for the INOX trial. *BMC Pulm Med* 2017;17(1):8.
312. O'Donnell DE. Maximal bronchodilation at initiation of therapy vs progressive bronchodilatation: The PRO Argument. *Annals of Amer Thoracic Soc*. Submitted November 2017.
313. O'Donnell DE. Activity related dyspnoea in chronic pulmonary diseases: New mechanistic insights. *Tanoffos* 2017;16(Suppl 1):S5-S6. PMID: 29158746.
314. O'Donnell DE. "Mild" COPD: What spirometry conceals! *Tanoffos* 2017;16(Suppl 1):S4. PMID: 29158745
315. Bourbeau J, Bhutani M, Hernandez P, Marciniuk DD, Aaron SD, Balter M, Beauchesne M-F, D'Urzo A, Goldstein R, Kaplan A, Maltais F, O'Donnell DE, Sin DD. CTS Position Statement: Pharmacotherapy in patients with COPD – An update. *Cdn J Resp Crit Care & Sleep Med*. 2017;1(4):222-241.
316. Maltais F, O'Donnell D, Iturri JBG, Bautista J, Kirsten AM, Singh D, Hamilton A, Tetzlaff K, Zho Y, Casaburi R. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in COPD. *Therapeutic Advances in Resp Dis*. 2018;12:1-19. PMID: 29439648.
317. Zelt J, Jones JH, Hirai DM, King TJ, Berton DC, Pyke KE, O'Donnell DE, Neder JA. Systemic vascular dysfunction is associated with emphysema burden in mild COPD. *Respiratory Medicine*. 2018;136:29-36. PMID: 29501244.
318. Vozoris N, Wang X, Austin PC, O'Donnell DE, Aaron SD, To TM, Gershon AS. Incident diuretic drug use and adverse respiratory events among older adults with COPD. *Brit J Clin Pharmacol* 2018;84(3):579-589. PMID: 29139564.
319. O'Donnell DE, Elbehairy AF, Faisal A, Neder JA, Webb KA. Canadian Respiratory Research Network (CRRN). Sensory-mechanical effects of a dual bronchodilator and its anticholinergic component in COPD. *Respir Physiol Neurobiol* 2018;247:116-125. PMID: 28993264.
320. Kirby M, Tanabe N, Tan WC, Zhou G, Obeidat M, Hague CJ, Leipsic J, Bourbeau J, Sin DD, Hogg JC, Coxson HO...O'Donnell DE, for the CanCOLD Collaborative Research Group and the Canadian Respiratory Research Network. Total airway count on computed tomography and the risk of chronic obstructive disease progression. *Am J Resp Crit Care Med* 2018;197(1):56-65. PMID: 28886252.
321. Bravo DM, Gimenes AC, Amorim BC, Alencar MC, Berton DC, O'Donnell DE, Nery LE, Neder JA. Excess ventilation in COPD: Implications for dyspnoea and tolerance to interval exercise. *Respir Physiol & Neurobiology*. 2018;250:7-13. PMID: 29382565.

322. Langer D, Ciavaglia C, Faisal A, Webb KA, Neder JA, Gosselink R, Dacha S, Topalovic M, Ivanova A, O'Donnell DE. Inspiratory muscle training reduces diaphragm activation and dyspnea during exercise in COPD. *J Appl Physiol* 2018;125(2):381-392. PMID: 29543134.
323. Elbehairy AF, Webb KA, Laveneziana P, Domnik NJ, Neder JA, O'Donnell DE on behalf of the Canadian Respiratory Research Network (CRRN). Acute bronchodilator therapy does not reduce wasted ventilation during exercise in COPD. *Resp Physiol & Neurobiology* 2018;252-253:64-71. PMID: 29578103.
324. Degani-Costa L, O'Donnell D, Webb K, Aranda L, Carlstron J, Cesar T, Plachi F, Berton D, Neder JA, Nery L. A simplified approach to select exercise endurance intensity for interventional studies in COPD. *COPD: Journal of Chronic Obstructive Pulmonary Disease* 2018;15(2):139-147. PMID: 29485343.
325. Porszasz J, Carraro N, Cao R, Gore A, Ma S, Jiang T, Maltais F, Ferguson GT, O'Donnell DE, Shaikh A, Rossiter HB, Casaburi R. Effect of tiotropium on spontaneous expiratory flow-volume curves during exercise in GOLD 1 and 2 COPD. *Respir Physiol & Neurobiol* 2018;251:8-15. PMID: 29438808.
326. Johnson KM, Tan WC, Bourbeau J, Sin DD, Sadatsafavi M: Canadian Cohort of Obstructive Lung Disease (CanCOLD) study and the Canadian Respiratory Research Network. The diagnostic performance of patient symptoms in screening for COPD. *Respir Res* 2018;19(1):147. PMID: 30075717.
327. Elbehairy A, Faisal A, Ciavaglia C, Kwok C, Reid K, Vincent S, Domnik N, Neder JA, O'Donnell D. Severe exertional dyspnea in an ex-smoker with a large apical bulla. *Ann Am Thorac Soc* 2018;15(10):1221-1228. PMID: 30772494.
328. Vozoris N, Austin P, Stephenson A, O'Donnell D, Gershon A, Gill S, Rochon P. Serotonergic antidepressant use and morbidity and mortality among older adults with COPD. *Eur Resp J* 2018;52(1):pii147. PMID: 29946006.
329. Neder JA, Rocha A, Alencar MCN, Arbex F, Berton DC, Oliveira MF, Sperandio PA, Nery LE, O'Donnell DE. Current challenges in managing comorbid heart failure and COPD. *Exp Rev of Cardiovascular Ther.* 2018;9:653-673. PMID: 30099925.
330. O'Donnell DE. Dyspnea in COPD: Physical and psychological consequences, unmet needs and future directions. *International J of COPD*. Submitted.
331. O'Donnell DE. Increasing physical activity in chronic obstructive pulmonary disease one step at a time. *Am J Crit Care Med.* 2018;198(8):977-978. PMID: 29758168.
332. Elbehairy AF, O'Donnell CD, Elhameed, AA, Vincent SG, Milne KM, Webb KA, Neder JA, O'Donnell DE on behalf of the Canadian Respiratory Research Network (CRRN). Low resting diffusion capacity, dyspnea and exercise intolerance in COPD. *J Appl Physiol* 2019 Aug 1. Doi:10.1152/jappphysiol.00341.2019. PMID: 3169329.
333. Laveneziana P, Albuquerque A, Aliverti A, Babb T, Barreiro E, Dres M, Dube BP, Fauroux B, Gea J, Guenette J, Hudson A, Kabitz H-J, Laghi F, Langer D, Luo Y-M, Neder JA, O'Donnell DE, Polkey M, Rabinovich R, Rossi A, Series F, Similowski T, Spengler C, Vogiatzis I, Verges S. ERS Statement on respiratory mechanics and muscle testing at rest and during exercise. *Eur Resp J.* 2019 Jun 13;53(6).pii:18-1214.doi.10.1183/13993003.01214-2018. PMID: 30956204.
334. Selman JP, Lanza FC, Wandalsen GF, Sole D, O'Donnell DE, Neder JA, Dal Corso S. Ventilatory demand during stepping and running: implications for exercise-induced bronchoconstriction in children. *Respiratory Care.* 2019 Apr;64(4):445-452. PMID: 30723167.
335. Neder JA, Marillier M, Bernard AC, O'Donnell DE. Transfer coefficient of the lung for carbon dioxide and the accessible alveolar volume: clinically useful if used wisely. *Breathe.* 2019;15(1):69-76. PMID: 30838063.
336. Souza A, Sperandio PA, Mazzuco A, Alencar MC, Arbex FF, Oliveira M, Medeiros W, Rocha A, Nery LE, O'Donnell DE, Neder JA. Effects of bi-level positive airway pressure on ventilatory and

- perceptual responses to exercise in comorbid heart failure-COPD. *Respir Physiol Neurobiol* 2019;Aug;266:18-26. PMID: 31005600.
337. Maltais F, Aumann J-L, Kirsten A-M, Nadreau E, Macesic H, Jin X, Hamilton A, O'Donnell D. Dual bronchodilatation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD. *Eur Resp J.* 2019;Mar 28;53(3). PMID: 30655277.
 338. Elbehairy AF, McIsaac H, Hill E, Neder JA, Harle I, O'Donnell DE. The impact of an innovative advanced breathlessness clinic on dyspnea in patients with severe COPD and ILD: A retrospective analysis. *Respir Care.* 2019. Doi:10.4187/respcare.06950. PMID: 31719189.
 339. Rocha A, Arbex FF, Sperandio P, Mancuso F, Marillier M, Bernard AC, Alencar MCN, O'Donnell DE, Neder JA. Exercise intolerance in comorbid COPD-heart failure: the role of impaired aerobic function. *Eur Resp J.* 2019;Apr18;53(4). PMID: 30765506.
 340. Saint-Pierre M, Ladha J, Berton DC, Reimao G, Castelli G, Marillier M, Bernard AC, O'Donnell DE, Neder JA. Is the slow vital capacity clinically useful to uncover airflow limitation in subjects with preserved FEV1/FVC ratio? *CHEST* 2019 Sep;156(3):497-506. Doi: 10.1016/j.chest.2019.02./001. PMID: 30768928.
 341. Criner GJ, Martinez FJ, Aaron S, Agusti A, Anzueto A, Bafadhel M, Barnes PJ, Bourbeau J, Chen R, Ewig J, Fabbri LM, Frith P, Halpin DMG, Han M, Montes de Oca M, Nishimura M, O'Donnell D, Papi A, Pavord I, Roche N, Rodriuez-Roisin R, Salvi S, Singh D, Sin DD, Stockley R, Lopez Varela MV, Vestbo J, Vogelmeier CF, Washko G, Wedzicha JA, Celli BR. Current controversies in chronic obstructive pulmonary disease: A report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. *Ann Am Thorac Soc* 2019, Jan 19;16(1):29-39. PMID. 30427736.
 342. Tan WC, Bourbeau J, Aaron SD, Hogg JC, Maltais F, Hernandez P, Marciniuk DD, Chapman KR, To T, FitzGerald JM, Walker BL, Road J, Zheng J, Zhou G, Yau T, Benedetti A, O'Donnell D, Sin DD: CanCOLD Collaborative Research Group. The effects of marijuana smoking on lung function in older people. *Eur Resp J.* doi:10.1183/13993003.00826-2019. PMID: 31537703.
 343. Hanania NA, O'Donnell DE. Activity-related dyspnea in chronic obstructive pulmonary disease: Physical and psychological consequences, unmet needs, and future directions. *International J COPD* 2019;14:1127-1138. PMID: 31213793.
 344. Paine NJ, Bacon SL, Bourbeau J, Tan WC, Lavoie KL: CanCold Study Investigators, Aaron SD, Chapman KR, FitzGerald JM, Hernandez P, Marciniuk DD, Maltais F, O'Donnell DE, Sin D, WalkerBL: Canadian Respiratory Research Network and the Can COLD Collaborative Research Group. Physiological stress is related to poor health behaviours in COPD and non-COPD patients: Evidence from the Can COLD study. *Resp Med* 2019: Jan:146:1-9. PMID: 30665505.
 345. Shorofsky M, Bourbeau J, Kimof R, Jen R, Malhotra A, Ayas N, Tan W, Aaron S, Sin D, Road J, Chapman K, O'Donnell D, Maltais F, Hernandez P, Walker B, Marciniuk D, Kamiska M. Impaired sleep quality in COPD is associated with exacerbations: The CanCOLD Cohort Study. *CHEST* 2019. Doi:10.1016/j.chest.2019.04.132. PMID: 31150638.
 346. Neder JA, Berton DC, O'Donnell DE. Uncovering the beneficial effects of inhaled bronchodilator in COPD: beyond forced spirometry. *J Bras Pneumol* 2019;45(3):e20190168. Doi:10.1590/1806-3713/e20190168. PMID: 31271606.
 347. Neder JA, Berton DC, Marillier M, Bernard A-C, O'Donnell DE on behalf of the Canadian Respiratory Research Network. Inspiratory constraints and ventilatory inefficiency are superior to breathing reserve in the assessment of exertional dyspnea in COPD. *COPD: J of Chronic Obstructive Pulmonary Disease.* 2019 Apr;16(2):174-181. PMID: 31272243.
 348. Muller P, Barbosa GW, O'Donnell DE, Neder JA. Cardiopulmonary and muscular interactions: Potential implications for exercise (in)tolerance in symptomatic smokers without COPD. *Frontiers in Physiology: Integrative Physiology.* 2019:10:359. Doi: 10.3389/phys.2019.00859. PMID: 31354517.

349. Neder JA, Marillier M, Bernard AC, James MD, Milne KM, O'Donnell DE. The integrative physiology of exercise training in patients with COPD. *COPD*. 2019 Apr;16(2):182-195. PMID: 31094224.
350. Neder JA, Berton DC, O'Donnell DE. Why we should never ignore an "isolated" low lung diffusing capacity. *J Bras Pneumol* 2019;45(4):e20190241. Doi.org/10.1590/1806-3713/e20190241. PMID: 31508675.
351. Berton DC, Marques RD, Palmer B, O'Donnell DE, Neder JA. Effects of lung deflation induced by tiotropium/olodaterol on the cardiocirculatory responses to exertion in COPD. *Respir Med* 2019 Oct;157:59-68. PMID: 31522031.
352. Neder JA, Berton DC, Marillier M, Bernard A-C, O'Donnell DE; on behalf of the Canadian Respiratory Research Network. The role of evaluating inspiratory constraints and ventilatory inefficiency in the investigation of dyspnea of unclear etiology. *Resp Med* 2019;158:6-13.
353. Vozoris NT, You Z, Li P, Austin PC, Stephenson AL, Gill SS, O'Donnell DE, Gershon AS, Rochon, PA. Prescription synthetic oral cannabinoid use among older patients with chronic obstructive pulmonary disease: A population-based cohort study. *Drugs & Aging*. Doi.org/10.1007/s40266-019-00707-3. PMID: 31552597.
354. Neder JA, Dipaolo M, O'Donnell DE, Palange P. On the complexities of measuring exercise "ventilatory efficiency" in obstructive lung diseases. *Pediatric Pulmonology*. Doi.1002/ppul.24556. PMID: 31682324.
355. O'Donnell DE, Milnd KM, James MD, de Torres JP, Neder JA. Dyspnea in COPD: New mechanistic insights and management implication. *Adv Ther* 2019. Doi:10.1007/s12326-019-01128-9. PMID: 31673990.
356. Langer D, Demeyer H, Ivano A, Webb KA, Neder JA, O'Donnell DE. The link between reduced inspiratory muscle strength, exertional dyspnea and exercise intolerance in COPD. Submitted 2019.
357. O'Donnell DE, Milne KM, James MD, Vincent SG. New insights into the origins of breathlessness in COPD: Clinical implications. Submitted, 2019.
358. Domnik NJ, James ME, Scheeren R, Ayoo G, Di Luch A, Webb K, Ciavaglia C, Garvey J, Crinion S, Driver H, O'Donnell DE. Effects of acclidinium bromide/fomoterol on nighttime respiratory mechanics in chronic obstructive pulmonary disease. Submitted, 2019.
359. Milne KM, IbrahimMasthan M, Webb KA, Vincent SG, James MD, Elbehairy AF, Neder JA, O'Donnell DE. Impact of inhaled fentanyl on exertional dyspnea in moderate interstitial lung disease. Submitted, 2019.
360. Maltais F, O'Donnell DE, Hamilton A, Zhao Y, Casaburi R. Comparative measurement properties of constant work rate cycling and the endurance shuttle walking test in COPD: The TORRACTO Clinical Trial. *Therapeutic Advances in Respir Dis*. Submitted 8.8.2019.
361. Vozoris NT, Pequeno P, Ping L, Austin PC, O'Donnell DE, Gershon AS. Predictors of opioid-related adverse cardiopulmonary events in older adults with COPD. *Drugs & Aging*. Accepted August 2019.
362. O'Donnell DE, Neder JA. Chronic respiratory diseases: The dawn of precision rehabilitation. *Respirology* 2019 Sep;24(9):826-827. PMID: 31271250.
363. Neder JA, O'Donnell DE. On the practical challenges of diagnosing obstruction in the presence of restriction. *J Bras de Pneumologia*. 2019 In press.
364. Tracey L, Lewthwaite H, Abdallah SJ, Murray S, Wilkinson-Maitland CA, Donovan A, Maltais F, O'Donnell DE, Bourbeau J, Smith BM, Jensen D on behalf of the Canadian Respiratory Research Network (CRRN). Physiological and perceptual responses to exercise according to locus of symptom limitation in COPD. *Respir Physiol and Neurobiol*. Doi:10.1016/j.resp.2019.103322. PMID: 3162879.

365. Costa CM, Neder JA, Verrastro CG, Ribeiro P, Ramos R, Ferreira EM, Nery LE, O'Donnell DE, Pereira CAC, Ota-Arakaki J. Uncovering the mechanisms of exertional dyspnoea in combined pulmonary fibrosis and emphysema. *Eur Respir J* 2019; Oct 24: doi: 10.1183/13993003.01319-2019. PMID: 31649067.
366. Bourbeau J, Pinto L, Tan W, Li P, Aaron S, Benedetti A, Chapman K, Fitzgerald M, Heernandez P, Maltais F, Marciniuk D, O'Donnell D, Sin D, et al. Identification and definition of asthma-COPD overlap: The CanCOLD study. *Respirology*. Accepted.
367. Plachi F, Baizan F, Frohlich LF, Gass R, Mendes N, Schroeder E, Berton D, O'Donnell D, Neder A. Exertional dyspnoea-ventilation relationship to discriminate respiratory from cardiac impairment. *European Resp J*. doi:10.1183/13993003.01518-2019. PMID: 31744838.
368. O'Donnell DE, Neder JA. The enigma of dyspnea in COPD: A physiological perspective. *Respirology*. Doi:10.1111/resp.13736. PMID: 31769135.
369. Bourbeau J, Pinto L, tan W, Li P, Aaron S, Benedetti A, Chapman K. Fitzgerald M, Hernandez P, Maltais F, Marciniuk D, O'Donnell D, Sin D, et al. Identification and definition of asthma-COPD overlap: The CanCOLD study. *Respirology*. Submitted.
370. Jensen D, Lewthwaite H, O'Donnell DE, et al. Normative peak cardiopulmonary exercise test responses in adults 40 years and over (the "Work"). *Medicine & Science in Sports & Exercise*. 2019. Submitted.

Accolades

- Casaburi R, Rennard SI. Exercise limitation in chronic obstructive pulmonary disease: The **O'Donnell** Threshold. *Am J Respir Crit Care Med* 2015; 191(8): 873-875. [EDITORIAL]

Collaborator

- There are 31 papers in PubMed that cite the **ECLIPSE** Investigators, including D. O'Donnell (last accessed February 10, 2016).

Book Chapters

1. O'Donnell DE, Webb K. Breathlessness in patients with severe chronic airflow limitation: Physiological Correlations. In: RC Bone, TL Petty (eds). *Year Book of Pulmonary Disease*. St. Louis: Mosby-Year Book, Inc., 1994, p.136-139.
2. O'Donnell DE, Webb KA. Exercise reconditioning in chronic airflow limitation. Eds. Torg, Shepherd, IN: *Current Therapy in Sports Medicine*, 3rd Edition, 1995 pg 678-684. O'Donnell DE. Exertional breathlessness in chronic respiratory diseases. *Lung Biology in Health and Disease Series*, "Dyspnea", Marcel Dekker, Ed. D. Mahler. 1998;11:97-147.
3. O'Donnell DE, Webb KA. Measurement of respiratory volume and flow. IN: *Principles and Practice of Intensive Care Monitoring*, Ed. M. Tobin. 1998, chap. 4, p. 63-80
4. O'Donnell DE. "Physiology of Interstitial Lung Disease". IN: *Interstitial Lung Disease*, 3rd Edition, Ed's. Swartz and King. 3rd Edition (Published by B.C. Decker). 1998:51-71.
5. O'Donnell DE. The etiology of dyspnea during exercise in COPD. In: *Pulmonary Critical Care Update*. CD-Rom. www.uptodate.com. 2000.
6. O'Donnell DE. The assessment and management of dyspnea in the clinical management of COPD. In: "Management of COPD". *Lung Biology in Health and Disease Series*. Eds. Similowski T, Whitelaw WA, Derenne J-P. 2002;Chap 7:113-170.
7. O'Donnell DE, Webb KA, McGuire M. Controlling breathlessness and cough in COPD. In: *Comprehensive Reference Guide for the Health Professional Taking Care of Patients with COPD*. Eds. J. Bourbeau, D. Nault, E. Borycki. Chp 9;2002:pp 149-170.

8. O'Donnell DE, Webb KA, Reville SM. Mechanical ventilation during exercise in COPD. In: *Advancing the Frontiers of Cardiopulmonary Rehabilitation*. Eds. J. Jobin, F. Maltais, P. Poirier, P. LeBlanc, C. Simard. Chp. 11, pp 91-105, Champaign, Human Kinetics. 2002.
9. O'Donnell DE. Exercise limitation and clinical exercise testing in chronic obstructive lung disease. In: *Clinical Exercise Testing: Progress in Respiratory Research*. Eds. J. Zebello, I. Weisman. Karger Series, 2002;32:138-158.
10. O'Donnell DE, Fitzpatrick M. Physiology of interstitial lung disease. In: *Interstitial Lung Disease*. 4th Edition. Ed. Swartz & King. B.C. Decker, 2003, pp 54-75.
11. O'Donnell DE, Webb KA. Exercise. In: *Chronic Obstructive Pulmonary Disease, 2E*. Eds. Calverley, MacNee, Rennard & Pride. Edward Arnold (Publishers) Ltd. 2003, Chp. 18:243-269.
12. Voduc N, O'Donnell DE. Drug therapy in chronic obstructive pulmonary disease. In: *Drug Advances*. Ed. J. Gray. 2003;1:31-44.
13. O'Donnell DE, Voduc N. Management of advanced chronic obstructive pulmonary disease. In: *Non-Neoplastic Advanced Lung Disease*. Ed. J.R. Maurer. Marcel Dekker Inc. 2003;176:117-179.
14. O'Donnell DE, M. Fitzpatrick. Assessment of disability: What test or combination of tests should be used?" In: *Chronic Obstructive Pulmonary Disease: Critical Debates*. Eds. M. Pearson, W. Wedzicha. Blackwell Science. 2003;Chp 5:63-83.
15. O'Donnell DE, Webb KA. Exercise Testing. In: *Pharmacotherapy in COPD*. Ed. B. Celli. Marcel Dekker, 2004;182:chp 3:45-71.
16. Voduc N, Webb KA, O'Donnell DE. Physiological basis of dyspnea. In: *Pulmonary Rehabilitation*. Eds. Donner CF, Ambrosino A, Goldstein R. 2005;Chp.13:124-135.
17. Loughheed MD, O'Donnell DE. Dyspnea in asthma. In: *Dyspnea: Mechanisms, Measurement and Management*. Marcel Dekker Inc. Eds. D. Mahler, D.E. O'Donnell. *Lung Biology in Health & Disease* 2005;208:59-86, Chpt 4.
18. O'Donnell De, Voduc N. Mechanisms of dyspnea in restrictive lung disorders. In: *Dyspnea: Mechanisms, Measurement and Management*. Marcel Dekker, Inc. Eds. D. Mahler, D.E. O'Donnell. *Lung Biology in Health & Disease* 2005;208:87-114, Chpt. 5.
19. O'Donnell DE, Webb. Mechanisms of dyspnea in chronic obstructive pulmonary disease. In: *Dyspnea: Mechanisms, Measurement and Management*. Marcel Dekker, Inc. Eds. D. Mahler, D.E. O'Donnell. *Lung Biology in Health & Disease* 2005;208:29-58, Chpt. 3.
20. O'Donnell DE, Mahler DA. Effective bronchodilator and inhaled corticosteroids on dyspnea in COPD. In: *Dyspnea: Mechanisms, Measurement and Management*. Marcel Dekker Inc. Eds. D. Mahler, D.E. O'Donnell. *Lung Biology in Health & Disease* 2005;208:283-300, Chpt. 12.
21. Voduc N, O'Donnell DE. Pulmonary rehabilitation. In: *Dyspnea in Advanced Disease*. Eds. S. Booth, D. Dudgeon. Oxford University Press 2005:137-155: Chpt. 9
22. Peters M, O'Donnell DE. Dyspnea in chronic obstructive pulmonary disorder. In: *Dyspnea in Advanced Disease*, Ed. S. Booth , D. Dudgeon. Oxford University Press. 2005;55-74: Chpt. 4.
23. Parker CM, O'Donnell DE. Dynamic hyperinflation, dyspnea and exercise intolerance in chronic obstructive pulmonary disease. In: *Essentials of COPD*. 2005;5:3-30.
24. Travers J, Laveneziana P, O'Donnell DE. Physiological assessment of COPD. Chapter 3: In: *COPD: A Guide to Diagnosis and Clinical Management*. Eds. N.A. Hanania and A. Sharafkhaneh. Baylor College of Medicine, Houston, Texas. Humana Press, 2007.
25. Parker CM, O'Donnell DE. Pathophysiology of acute exacerbations of COPD. In: *Chronic Obstructive Pulmonary Disease Exacerbations*. Ed. W. Wedzicha and F. Martinez. Informa Health Care:New York, 2008;7:75-88.
26. Laveneziana P, Ora J, Webb KA, O'Donnell DE. Lung volumes in COPD. In: *COPD: Outcomes and Biomarkers*. Eds. Cazzola M, Martinez FJ, Page CP. Series on "Lung Biology in Health and Disease" edited by C. Lenfant. Informa Healthcare USA Inc., New York. Publication date January 2010.

27. Parker CM, Fitzpatrick MF, O'Donnell DE. Physiology of interstitial lung disease. In: *Interstitial Lung Disease*. Fifth Edition. MI Schwarz & TE King eds. Hamilton, ON: BC Decker Inc. 2011;61-79.
28. Loughheed MD, Ora J, O'Donnell DE. Long-acting muscarinic antagonists in asthma and COPD. In: *Advances in Combination Therapy for Asthma and COPD*. Ed. J. Lotvall. Wiley-Blackwell. 2011;11:268-295.
29. O'Donnell DE, Laveneziana P, Neder JA. Lung function. *Eur Resp Monograph*, 2013;62:127-145.
30. Mahler D, O'Donnell DE. Section 1: Mechanisms of Dyspnea. The neurobiology of dyspnea: An overview. In: *Dyspnea: Mechanisms, Measurement and Management*. Third Edition. Lung Biology in Health & Disease Series. Eds. D. Mahler, D.E. O'Donnell. Marcel Dekker Inc. Chpt 1;3-10:2014.
31. Jensen D, O'Donnell DE. Section 1: Mechanisms of Dyspnea. Pregnancy/obesity. In: *Dyspnea: Mechanisms, Measurement and Management*. Third Edition. Lung Biology in Health & Disease Series. Eds. D. Mahler, D.E. O'Donnell. Marcel Dekker Inc. Chpt 4;39-54:2014.
32. O'Donnell DE, Webb KA. Section 1: Mechanisms of Dyspnea. Mechanisms of dyspnea during exercise in chronic obstructive pulmonary disease. In: *Dyspnea: Mechanisms, Measurement and Management*. Third Edition. Lung Biology in Health & Disease Series. Eds. D. Mahler, D.E. O'Donnell. Marcel Dekker Inc. Chpt. 5;55-68:2014.
33. O'Donnell DE, Webb KA, Mahler D. Section 3: Management. Effect of bronchodilators and inhaled corticosteroids on dyspnea in chronic obstructive pulmonary disease. In: *Dyspnea: Mechanisms, Measurement and Management*. Third Edition. Lung Biology in Health & Disease Series. Eds. D. Mahler, D.E. O'Donnell. Marcel Dekker Inc. Chpt 12;161-176:2014.
34. Laveneziana P, Webb KA, O'Donnell DE. Static and dynamic hyperinflation in chronic obstructive pulmonary disease. In: *Mechanics of Breathing: New Insights from New Technologies*. Aliverti A, Pedotti A, Eds. Springer Press. Chpt 7:73-98, 2014.
35. O'Donnell DE, Laveneziana P, Webb KA, Neder JA. Chronic obstructive pulmonary disease: Clinical integrative physiology. In: *Clinics in Chest Medicine*. Barnes PJ, ed. 35(1);51-69:2014.
36. O'Donnell DE. Mechanisms and consequences of resting lung hyperinflation in COPD. In: *Hyperinflation of the Lung and its Management*. Siafakas N, O'Donnell DE, Eds. Chpt A2;18-27, 2015.
37. O'Donnell DE. Dynamic lung hyperinflation. In: *Hyperinflation of the Lung and its Management*. Siafakas N, O'Donnell DE, Eds. Chpt A3:18-39, 2015.
38. Webb KA, O'Donnell DE. Pharmacotherapy of lung hyperinflation. In: *Hyperinflation of the Lung and its Management*. Siafakas N, O'Donnell DE, Eds. Chpt C1:76-85, 2015.
39. Neder JA, Rocha A, Arbex FF, Oliveira M, Alencar MCN, O'Donnell DE. Cardiovascular comorbidity in chronic lung disease: The role of cardiopulmonary exercise testing. *Chronic Lung Disease and Cardiac Disease: Cardiovascular Complications*. Bhatt SP (Ed) 2018. In press.
40. Neder JA, Tomlinson AR, Babb TG, O'Donnell DE. Integrating the whole: Cardiopulmonary exercise testing. *Pulmonary Function Testing: Principles and Practice*. Kaminsky DA, Irvin CJ (Eds). Human Press. Chapter 11:219-248.
41. Rocha A, Arbex FF, Sperandio PA, Mancuso F, Alencar MCN, Souza A, Biazim L, O'Donnell DE, Neder JA. Heart or Lungs? Uncovering the causes of exercise intolerance in a patient with chronic cardiopulmonary disease. *Annals of Amer Thorac Society*. The Clinical Physiologist. Section Editors: Kreit J, Swenson E. 2018;15(9)1096-1104. PMID: 30168743.
42. O'Donnell DE, Neder JA. Preface: Why clinical physiology remains vital in the modern era. *Clinics in Chest Medicine* – 40(2);xiii-xiv:2019. PMID: 31078224.
43. Neder JA, Berton DC, Muller PT, O'Donnell DE. Incorporating lung diffusing capacity for carbon monoxide in clinical decision making in chest medicine. *Clinical Respiratory Physiology*. *Clinics in Chest Medicine* 40(2);285-305:2019. PMID: 31078210.

44. O'Donnell DE, James MD, Milne KM, Neder JA. The pathophysiology of dyspnea and exercise intolerance in chronic obstructive pulmonary disease. *Clinical Respiratory Physiology. Clinics in Chest Medicine* 40(2);343-366:2019. PMID: 31078214.
45. Neder JA, Rocha A, Berton DC, O'Donnell DE. Clinical and physiologic implications of negative cardiopulmonary interactions in coexisting chronic obstructive pulmonary disease-heart failure. *Clinical Respiratory Physiology. Clinics in Chest Medicine* 40(2);421-438:2019. PMID: 31078219.
46. O'Donnell DE, Milne KM, Vincent SG, Neder JA. Unraveling the causes of unexplained dyspnea: The value of exercise testing. *Clinical Respiratory Physiology. Clinics in Chest Medicine* 40(2);471-499:2019. PMID: 31078223.

Books/Monographs/Editorials

1. Dyspnea: Mechanisms, Measurement and Management. Eds. D. Mahler, D.E. O'Donnell. Marcel Dekker Inc., Lung Biology in Health & Disease 2005;208.
2. Exercise Physiology in COPD: The Impact of Tiotropium. Eur Respir Rev Monograph. Ed. D.E. O'Donnell, 2004.
3. Fisher JT, O'Donnell DE (Editors). Special Issue: The clinical physiology and integrative neurobiology of dyspnea: Introduction to the Special Issue of Respir Physiol Neurobiol 2009;167(1):1.
4. Dyspnea: Mechanisms, Measurement and Management. Third Edition. Eds. D. Mahler, D.E. O'Donnell. Marcel Dekker Inc., Lung Biology in Health & Disease. 2014.
5. O'Donnell DE, Laveneziana P, Neder J. Lung function. European Respiratory Monograph. Outcomes in Clinical Trials. Eds. Kolb M, Vogelmeier CF. 2013;62:127-145.
6. Adult survivors of preterm birth: what spirometry conceals, exercise tests reveal. *Ann Am Thorac Soc* 2014 Dec 11(10):1606-1607. PMID: 25549025.
7. O'Donnell DE. Hyperinflation of the Lung and its Management. Eds. Siafakas N, O'Donnell DE. 2015 Publisher: Novartis (Hella) Saci
8. Molgat-Seon Y, Guenette J, Schaeffer M, Ryerson C, Marillier M, Verges S, O'Donnell D, Neder JA. Pattern of cardiopulmonary responses to exercise in fibrotic interstitial lung diseases. *Clinical Exercise Testing: ERS Monograph*. Palange P, Laveneziana P, Neder JA, Ward SA (Eds). 2018, p128-145.
9. O'Donnell DE, Elbehairy AF, Domnik NJ, Vincent S, Guenette JA, Webb KA, Neder JA. Patterns of cardiopulmonary responses to exercise in COPD. *Clinical Exercise Testing: ERS Monograph*. Palange P, Laveneziana P, Neder JA, Ward SA (Eds). 2018, p107-127.
10. Neder JA, Berton D, Rocha A, Arbex F, Alencar MC, Degani-Costa LH, Ferreira E, Ramos R, O'Donnell D. Abnormal patterns of response in incremental cardiopulmonary exercise testing. *Clinical Exercise Testing: ERS Monograph*. Palange P, Laveneziana P, Neder JA, Ward SA (Eds). 2018, p 34-58.
11. O'Donnell D, Elbehairy A, Berton D, Domnik N, Webb K, Neder JA. Exercise testing in the evaluation of pharmacotherapy in COPD. *Clinical Exercise Testing: ERS Monograph*. Palange P, Laveneziana P, Neder JA, Ward SA (Eds). 2018, p235-250.
12. O'Donnell DE, Neder JA (Editors). *Clinical Respiratory Physiology. Clinics in Chest Medicine* 40(2):2019. (Elsevier).
13. O'Donnell D, Neder JA. Editorial on: Invited Review Series "Rehabilitation in chronic respiratory diseases". *Chronic respiratory diseases: The dawn of precision rehabilitation. Respirology*, 2019 July 4.doi.10.1111/resp.13640. PMID: 31271250

Online Presentation/Publications

1. Citation: O'Donnell D (2012). "The continuum of COPD: a physiological perspective", in Barnes P, (ed). Advances in Chronic Obstructive Pulmonary Disease (COPD): New mechanisms, management strategies and treatments. The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd., London. (Online at <http://hstalks.com/?t=BL1413315-ODonnell>).

Abstracts

1. Harrington K, O'Donnell DE, Butler J, O'Brien ET, O'Malley K. Beta-adrenoreceptors in myocardial infarction. *Journal of the Irish College of Physicians and Surgeons*, October 1985; Vol 14.
2. O'Donnell DE, Kelly CP, Clancy L. Sequential occurrence at a single site of histologically distinct neoplasms Oral presentations to Royal Academy of Medicine, Ireland, and the Irish Thoracic Society. Abstract: *Irish Journal of Medical Science* 1985; 154:128.
3. Fitzgerald DJ, O'Donnell DE, O'Malley K, O'Brien ET. Assessment of non-invasive automatic ambulatory blood pressure recorder: DelMar Avionics pressurometer. *Journal of Irish College of Physicians and Surgeons*, October 1985; Vol 14.
4. O'Donnell DE, Kelly CP, Clancy L. Nebulizer delivery systems in the management of chronic bronchitis. Oral presentation to the Irish Thoracic Society. Abstract: *Irish Journal of Medical Science* 1985; 154:125.
5. O'Donnell DE, Sanii R, Anthonisen NR, Younes M. The extent of dynamic compression in patients with COPD who are flow-limited at rest. Oral presentation to the American Thoracic Society, May 1986. Abstract: *Am Rev Respir Dis* 1986; A31.
6. O'Donnell DE, Sanii R, Anthonisen NR, Younes M. The effect of dynamic airway compression on respiratory sensation and breathing pattern in severe COPD. Abstract: *Am Rev Respir Dis* 1986; A193.
7. O'Donnell DE, Sanii R, Younes M. Oral presentation to the American Thoracic Society. Ventilatory responses to inspiratory resistance loading in conscious humans: contribution of the oropharynx. Abstract: *Am Rev Respir Dis* 1987; 135:A253.
6. O'Donnell DE, Sanii R, Younes M. Oral presentation to the American Thoracic Society. Elastic loading in conscious humans: role of the oropharyngeal and laryngeal mechanoreceptors. Abstract: *Am Rev Respir Dis* 1987; 135:A252.
9. Long GR, Unruh H, Younes M, Patton N, O'Donnell DE, Herchfield E. Management of tuberculous pericarditis. *Am Rev Respir Dis* 1987; 135:A44.
10. O'Donnell DE, Sanii R, Younes M. Effect of CPAP on respiratory sensation in exercising patients with COPD. *Am Rev Respir Dis* 1988; 137:337.
11. O'Donnell DE, Sanii R, Younes M. Improvement in exercise endurance in patients with COPD using CPAP. *Am Rev Respir Dis* 1988; 137:337.
12. O'Donnell DE, Sanii R, Loveridge B, Younes M. Steady-state responses in quadriplegics to expiratory resistive loading. *Am Rev Respir Dis* 1989; 139:A321.
13. O'Donnell DE, Sanii R, Loveridge B, Younes M. Sensory threshold detection of expiratory resistive loads following cervical cord injury. *Am Rev Respir Dis* 1989; 139:A321.
14. Sanii R, O'Donnell DE, Loveridge B. Ventilatory response to acute wheelchair exercise in cervical cord-injured and able-bodied subjects. *Am Rev Respir Dis* 1989; 139:A87.
15. Loveridge B, Sanii R, O'Donnell DE. Effects of upper limb endurance training on ventilatory responses to exercise in quadriplegia. *Am Rev of Respir Dis* 1989; 139:A87.
16. Dubo H, Loveridge B, Sanii R, O'Donnell DE, et al. Upper limb endurance training in quadriplegia. *Clin Invest Med* 1989; 12:R504.

17. Webb K, Fox L, Wigle R, Forkert L, Munt P, O'Donnell DE. Physiological determinants of breathlessness in patients with COPD. *Am Rev Respir Dis* 1990; 141:A535.
18. Webb K, Fox L, Muir C, O'Donnell DE. Ipratropium Bromide reduces exertional dyspnea in patients with severe chronic airflow limitation (CAL). *Chest* 1990; 98:113S.
19. Fox L, Webb K, O'Donnell DE. Respiratory sensation, ventilation and gas exchange following CPAP delivery to patients with advanced COPD at rest. *Am Rev Respir Dis* 1990; 141:A507.
20. Webb K, Fox L, Wigle R, Forkert L, Munt P, O'Donnell DE. The influence of breathlessness on exercise training responses among patients with COPD undergoing pulmonary rehabilitation. *Am Rev Respir Dis* 1990; 141:A507.
21. Webb K, Fox L, O'Donnell DE. Ventilatory responses to endurance exercise training in patients with severe chronic airflow limitation (CAL). *Chest* 1990; 98:57S.
22. Webb K, McGuire M, O'Donnell DE. The impact of endurance training on dyspnea in patients with chronic airflow limitation. Presented at the 3rd International Conference on Pulmonary Rehabilitation and Home Ventilation Proceedings, March 1991.
23. O'Donnell DE, Webb K. Exercise limitation in patients with chronic airflow limitation: the role of dynamic lung hyperinflation. *Med Sci Sports Exer* 1991; 23:4.
24. O'Donnell DE, Webb K. Mechanisms of dyspnea relief following exercise endurance training in patients with chronic airflow limitation. *Clin Invest Med* 1991; 4:A115.
25. O'Donnell DE, Webb K. Dynamic hyperinflation and dyspnea in patients with chronic airflow limitation. *Am Rev Respir Dis* 1991; 143:A594.
26. Loughheed MD, Webb K, Forkert L, O'Donnell DE. Breathlessness during acute bronchoconstriction: the role of hyperinflation. *Am Rev Respir Dis* 1992; 145(4):A631.
27. Loughheed MD, Webb K, O'Donnell DE. Mechanisms of breathlessness in asthma. Slide presentation to Glaxo's Canadian Respiratory Resident Research Competition and published in Proceedings, June 1993.
28. Loughheed MD, Webb K, O'Donnell DE. Effect of CPAP on breathlessness and ventilatory mechanics during acute bronchoconstriction. Slide presentation to Canadian Thoracic Society 1993 Annual Meeting, September 1993. *Clin Invest Med* 1993, Vol 16, No 4, B129:802.
29. Bain DJ, Webb KA, O'Donnell DE. Factors contributing to dyspnea relief during hyperoxia in chronic airflow limitation (CAL). *Am Rev Respir Dis* 1993; 147(4):A548.
30. O'Donnell DE, Webb KA. The efficacy of adjunct high dose anticholinergic therapy in relieving breathlessness in patients with severe chronic airflow limitation (CAL). *Am Rev Respir Dis* 1994; 149(4, Part II):A286.
29. Loughheed MD, Webb KA, O'Donnell DE. Breathlessness during induced hyperinflation in asthma: the role of inspiratory threshold load. 1994: Abstract published in proceedings of the AGM for Respiratory Health Network Centres of Excellence in Canada.
32. Webb K, Bertley J, McGuire M, Samis L, O'Donnell DE. The effect of exercise reconditioning on perception of breathlessness and leg effort in severe chronic airflow limitation (CAL). *Am Rev Respir Dis* 1994; 149(4, Part II):A597.
33. Loughheed MD, Webb KA, O'Donnell DE. A comparison of the effects of CPAP and IPAP on breathlessness during acute bronchoconstriction in asthma. *Am Rev Respir Dis* 1994; 149(4, Part II):A1086.
34. Chau LKL, Bertley JC, Webb KA, Conlan AA, O'Donnell DE. Bullectomy and lung reduction surgery in severe COPD: Mechanisms of dyspnea relief. *Clin Invest Med* 1995; 18(4):B134.
35. O'Donnell DE. Qualitative aspects of exertional breathlessness in CAL: Role of neuro-mechanical dissociation. Presented at AGM of Network for Centres of Excellence in Respiratory Research, September 22nd, 1995, published in Proceedings.

36. Bertley J, VanVugt DA, Webb KA, O'Donnell DE. Exertional Breathlessness in Severe Chronic Airflow Limitation (CAL): Perceptual Responses to Endogenous Opioid Blockade. *Am J Resp Crit Care Med* 1995; 151:A409.
36. McGuire M, Samis L, O'Donnell DE, Webb KA. Exercise training in severe chronic airflow limitation (CAL): Mechanisms of relief of breathlessness. (In Proceedings of The Canadian Physiotherapy Cardio-Respiratory Society Annual National Meeting, June 1995).
38. O'Donnell DE, Bertley J, Webb KA. Qualitative Descriptors of Exertional Breathlessness in Normals and in Patients with Chronic Airflow Limitation. *Am J Resp Crit Care Med* 1995; 151:A574.
39. Chau LKL, Bertley JC, Webb KA, O'Donnell DE. Qualitative aspects of exertional breathlessness in patients with interstitial lung disease (ILD) and chronic airflow limitation (CAL). *Am J Resp Crit Care Med* 1996; 153(4):A116.
40. Webb KA, Flannery JF, Muir CM, Lougheed MD, O'Donnell DE. Respiratory symptoms during acute bronchoconstriction in low cervical cord quadriplegia. *Am J Resp Crit Care Med* 1996; 153(4):A117.
41. Chau LKL, Webb KA, Bertley JC, Conlan AA, O'Donnell DE. Relief of exertional breathlessness after unilateral bullectomy/pneumectomy in severe chronic obstructive pulmonary disease (COPD). *Am J Resp Crit Care Med* 1996; 153(4):A655.
42. Chau LKL, Webb KA, O'Donnell DE. Relief of exertional breathlessness with nebulized morphine sulfate in patients with chronic lung disease. *Am J Resp Crit Care Med* 1996; 153(4):A656.
43. O'Donnell DE, Forkert L, Fisher T, Webb KA. Relief of exercise induced bronchospasm with a new heat and moisture exchanger and nedocromil sodium. *Am Rev Resp Crit Care Med* 1997;155:A165.
44. Shinder N, Webb KA, O'Donnell DE. Relief of exertional dyspnea during different modes of non-invasive mechanical ventilation in severe COPD. *Am Rev Resp Crit Care Med* 1997;155:A912.
45. O'Donnell DE, McGuire MA, Samis L, Webb KA. Effects of general exercise training on ventilatory and peripheral muscle strength and endurance in severe COPD. *Am Rev Resp Crit Care Med* 1997;155:A918.
45. O'Donnell DE, Shinder N, Webb KA. Non-invasive ventilation as an adjunct to exercise training in COPD. Published in Proceedings of National Centers of Excellence Annual General Meeting, 1997.
46. D'Arsigny C, Raj S, Abdollah H, Webb KA, O'Donnell DE. Ventilatory assistance improves leg discomfort and exercise endurance in stable congestive heart failure (CHF). ALA/ATS International Conf. April, 1998. *Am J Resp Crit Care Med* 1998;157:A451.
48. O'Donnell DE, Lam M, Webb KA. Measurement of dyspnea intensity, inspiratory capacity and endurance during exercise testing in COPD: Repeatability and responsiveness. ALA/ATS International Conf. April, 1998. *Am J Resp Crit Care Med* 1998;157:A90.
49. Aitken AS, Webb KA, Wood G, O'Donnell DE. Respiratory comfort using different modes of mechanical ventilation during weaning. ALA/ATS International Conf. April, 1998. *Am J Resp Crit Care Med* 1998;157:A108.
50. D'Arsigny C, Webb KA, Raj S, Abdollah H, O'Donnell DE. Ventilatory constraints contribute to exercise limitation and dyspnea in stable congestive heart failure (CHF). ALA/ATS International Conference, April 23-28, 1999, San Diego, California. *Am J Crit Care Med* 1999;159:A148.
51. O'Donnell DE, Lam M, Webb KA. Spirometric predictors of improvement in exercise endurance and dyspnea after acute anticholinergic therapy in COPD. ALA/ATS International Conference, April 23-28, 1999, San Diego, California. *Am J Resp Crit Care Med* 1999;159:A689.
52. Hong HH, Webb KA, O'Donnell DE. Effects of chest wall restriction and dead space loading on exercise tolerance and dyspnea in healthy normals. ALA/ATS International Conference, April 23-28, 1999, San Diego, California. *Am J Resp Crit Care Med* 1999;159:A787.

53. Lougheed MD, Flannery JF, Webb KA, O'Donnell DE. Dyspnea during hyperinflation in asthma, quadriplegia and normals. ALA/ATS International Conference, April 23-28, 1999, San Diego, California. *Am J Respir Crit Care Med* 1999;159:A787.
54. Lam M, Webb KA, O'Donnell DE. Correlation between two variables in repeated measures. Joint Statistical Meeting (JSM) 1999, Baltimore.
55. O'Donnell DE, D'Arsigny C, Hollingworth EN, Webb KA. Oxygen reduces dynamic hyperinflation and improves exercise performance in hypoxic patients with COPD. 2000 ATS/ALA International Conference, May 5-10, Toronto.
56. Webb KA, O'Donnell DE. Ventilatory factors contributing to exercise limitation and dyspnea in cardiopulmonary disorders. 2000 ALA/ATS International Conference, May 5-10, Toronto,
57. Chau LKL, McGuire M, Webb KA, O'Donnell DE. Predictors of outcome of pulmonary rehabilitation in COPD patients. 2000 ALA/ATS International Conference, May 5-10, Toronto.
58. O'Donnell DE. Clinical work of breathing measurements in COPD. Supplement to *European Respiratory Journal* 2000.
59. O'Donnell DE. Exercise tolerance as a clinical outcome measure in COPD. Supplement to *European Respiratory Journal* 2000.
60. Newton M, O'Donnell DE, Forkert L. Response of lung volumes to inhaled Albuterol in a large population of patients with severe hyperinflation. *Am J Respir Crit Care Med* 2000;161:A209.
61. Dudgeon D, Webb KA, McAuley S, O'Donnell DE. Mechanism of dyspnea in cancer patients. 2000.
62. O'Donnell DE. How COPD limits exercise. . Eds. Jones. *Cdn J Physiology* 2000.
63. O'Donnell DE. How the respiratory system limits exercise in COPD. *Muscles in action*. Annual Scientific Conference of Canadian Society for Exercise Physiology (CSEP), Oct. 25-28, 2000. P 44-45, Conference Proceedings Booklet.
64. Lougheed MD, McAuley S, O'Donnell DE. Evolution of respiratory symptoms during bronchoconstriction in asthma. *Am J Respir Crit Care Med* 2001;163(5):A813.
65. O'Donnell DE, D'Arsigny C, Webb KA. Mechanisms of exercise induced hypercapnia in advanced COPD. *Am J Respir Crit Care Med* 2001;163(5):A21.
66. O'Donnell DE, Revill S, Webb KA. Dynamic hyperinflation (DH) during exercise in COPD: Physiological correlates. *Am J Respir Crit Care Med* 2001;163(5):A269.
67. Webb KA, D'Arsigny C, O'Donnell DE. Exercise responses to added oxygen in patients with COPD and variable gas exchange abnormalities. *Am Rev Respir Crit Care Med* 2001;163:A169.
68. Simpson JA, Labugger R, Ha A, Collier C, D'Arsigny C, O'Donnell DE, Iscoe S, Van Eyk J. Serum levels of troponin I: A marker of respiratory muscle dysfunction? *Am J Respir Crit Care Med* 2001;163(5):A512.
69. O'Donnell DE. The effect of ventilatory assist on exercise performance in cardiopulmonary disease. *Clin Invest Med* 2001;24(3):S17.
70. Webb KA, O'Donnell DE. Exercise intolerance and mechanical restriction in chronic obstructive pulmonary disease. *Clin Invest Med* 2001;24:S61.
71. O'Donnell DE: Evaluation of bronchodilator responses in patients with advanced COPD. *ERJ* 2001;18:1018. p. 148S.
72. Forkert L, O'Donnell DE: Prediction of inspiratory capacity in the normal population. *ERJ* 2001;18:181. p. 12S.
73. Dudgeon JD, Webb KA, O'Donnell DE. Unexplained dyspnea and exercise tolerance in patients with cancer: Physiological correlates. *Proceedings of ASCO* 2001;20:303b.
74. Lougheed MD, Palumbo G, Lawson B, McBride I, Webb KA, O'Donnell DE: Blunted sensory responses to hyperinflation (HI) in patients with life threatening asthma (LTA). *Am J Respir Crit Care Med* 2002;165:A266.

75. O'Donnell DE, Webb KA: Mechanisms of improved exercise performance in response to salmeterol therapy in COPD. *Am J Respir Crit Care Med* 2002;165:A506
76. Palumbo G, Webb KA, O'Donnell DE: Mechanisms of dyspnea during lung hyperinflation in COPD. *Am J Respir Crit Care Med* 2002;165:A503.
77. Loughheed MD, Lawson B, McBride I, Webb KA, O'Donnell DE: Partitioning the effects of hyperinflation and bronchoconstriction on dyspnea in asthma. *Am J Respir Crit Care Med* 2002;165:A266.
78. O'Donnell DE, Magnussen H, Aguilaniu B, Make B, Fluege T, Hamilton A. Spiriva (Tiotropium) reduces exertional dyspnea in COPD. *Am J Respir Crit Care Med* 2002;165:A227.
79. Magnussen H, O'Donnell DE, Casaburi R, Kesten S, Gerken F, Fluege T. Spiriva (Tiotropium) reduces lung hyperinflation in COPD. *Am J Respir Crit Care Med* 2002;165:A227.
80. O'Donnell DE, Magnussen H, Aguilaniu B, Gerken F, Hamilton A, Fluege T. Spiriva (Tiotropium) improves exercise tolerance in COPD. *Am J Respir Crit Care Med* 2002;165:A227.
81. Loughheed MD, Hawes R, Webb K, O'Donnell DE. The plateau response in asthma: hyperinflation and dyspnea do not plateau. *Am J Respir Crit Care Med* 2002;165:A777.
82. O'Donnell DE, Magnussen H, Gerken F, Kesten S, Fluege T. Mechanisms of improved exercise tolerance in COPD in response to tiotropium. European Respiratory Society, Sept.14-18, 2002.
83. Dudgeon JD, O'Donnell DE, Day A, Webb K, McBride I, Dillon K. Mechanisms of exertional dyspnea on patients with cancer – a case-matched study. Research Forum Paper presented at 14th international Congress on Care of the Terminally Ill. Montreal, Quebec, Oct. 5-10, 2002. *J Palliative Care* 2002;18(3)207.
84. Dudgeon JD, O'Donnell DE, McBride I, Dillon K, Webb K. Muscle weakness in unexplained dyspnea and exercise limitation of cancer patients: a case-matched control study. *Proceedings of ASCO* 2002;21:257b.
85. O'Donnell DE, Webb KA. Pharmacological volume reduction delays the threshold for intolerable dyspnea during acute hyperinflation in COPD. *Am J Respir Crit Care Med* 2003;167(7):A293.
86. Loughheed MD, Ross SE, O'Donnell DE. Clinical significance of the methacholine response plateau in asthma. *Am J Respir Crit Care Med* 2003;167(7):2003:A635.
87. Loughheed MD, Ross SE, Verton L, O'Donnell DE. Mechanisms of dyspnea on the methacholine response plateau in asthma. *Am J Respir Crit Care Med* 2003;167(7):A794.
88. Fitzpatrick M, McLean H, Urton AM, Driver HS, O'Donnell DE, Tan A. Effect of breathing route on upper airway resistance during sleep. *Am J Respir Crit Care Med* 2003;167(7):A600.
89. O'Donnell DE, Magnussen H, Gerken F, Kesten S, Fluege T. Cardiovascular evaluation of tiotropium during constant-work exercise in COPD. *Eur Respir J* 2003.
90. Forkert L, O'Donnell DE. The effects of bronchodilators on iso-volume flows in COPD. *Eur Respir J* 2003.
91. O'Donnell DE, Marciniuk D, Hernandez P, Richter K, Kesten S, Hamilton A. Spiriva (Tiotropium) reduces lung hyperinflation at rest and during exercise in COPD patients. *Am J Respir Crit Care Med* 2004;169(7):A772.
92. O'Donnell DE, Maltais F, Scjurma F, Kesten S, Hamilton A. Spiriva (Tiotropium) improves symptom-limited exercise tolerance in COPD patients. *Am J Respir Crit Care Med* 2004;169(7):A771.
93. O'Donnell DE, Muir JF, Jenkins C, Plit P, Brockhaus F, Witte S, Bredenbroeker D. Roflumilast, A novel, selective phosphodiesterase 4 inhibitor, improves quality of life and lowers exacerbation rate in patients with COPD. *Am J Respir Crit Care Med* 2004;169(7):A602.
94. Voduc N, Parker C, Verton L, McBride ID, O'Donnell DE. Pathophysiology of dyspnea during acute exacerbations of COPD (AECOPD). *Am J Respir Crit Care Med* 2004;169(7):A767.
95. Amjadi K, McBride ID, Dillon K, Dudgeon DJ, O'Donnell DE. Dyspnea and exercise intolerance in clinically stable outpatients with cancer. *Am J Respir Crit Care Med* 2004;169(7):A761

96. O'Donnell DE, Webb KA, Verton LE. Effects of hypercapnia on dyspnea during acute lung hyperinflation in COPD. *Am J Respir Crit Care Med* 2004;169(7):A760.
97. Amjadi K, Webb KA, O'Donnell DE. Bronchodilator-induced changes in isovolume maximal expiratory flows in flow-limited patients with COPD. *Am J Respir Crit Care Med* 2004;169(7):A610.
98. Loughed MD, Ross SE, Fisher T, O'Donnell DE. Comparison of methacholine dose-response characteristics and symptoms in asthmatics with fixed and reversible airway obstruction. *Am J Respir Crit Care Med* 2004;169(7):A761.
99. O'Donnell DE, et al. Tiotropium reduces lung hyperinflation at rest and during exercise in COPD patients. COPD4, Birmingham, UK, June 9-11, 2004. Published in Proceedings.
100. O'Donnell DE, et al. tiotropium improves symptom-limited exercise tolerance in COPD patients. COPD4, Birmingham, UK, June 9-11, 2004. Published in Proceedings.
101. O'Donnell DE, Johnson B, Richter K, Kesten S, Hamilton A. Inspiratory capacity (IC) and dyspnea during recovery from symptom-limited exercise in COPD patients treated with tiotropium. *Eur Respir J* 2004;24(48):P1358.
102. O'Donnell DE, Zhi He BM, Lam M, Webb K, Fluge T, Hamilton A. Reproducibility of measurements in inspiratory capacity, dyspnea intensity and exercise endurance in multicentre trials in COPD. *Eur Resp J* 2004;24(48):P2053.
103. O'Donnell DE, Rabe KF, Jenkins C, Muir JF, Witte S, Bredenbroeker D. FEV₆: a useful outcome measure of lung function in COPD as assessed in a large clinical study with roflumilast. *Eur Resp J* 2004;24(48):P2151.
104. Rabe KF, O'Donnell DE, Muir JF, Jenkins C, Wit S, Bredenbroeker D, Bethke TD. Roflumilast, an oral, once-daily PDE4 inhibitor, improves lung function and reduces exacerbation rates in patients with COPD. *Eur Resp J* 2004;24(48):P267.
105. Maltais F, O'Donnell DE, Annemie W, Hernandez P, Tellier J-M, Lussier B, Allas, Theriault, Vachon L. Effects of TH9507, a growth hormone releasing factor (GRF) on functional performance in patients with COPD. *Eur Resp J* 2004;24(48):P1603.
106. D'Arsigny C, Harris GA, Hopman W, O'Donnell DE. Weaning the "difficult-to-wean" patient. *Chest* 2004;126(4):755S.
107. Rabe KF, O'Donnell DE, Bateman ED, Andrae K, Witte S, Bredenbroeker D. Roflumilast improves lung function and quality of life in chronic obstructive pulmonary disease. *Chest* 2004;126(4):709S.
108. O'Donnell DE, Maltais F, Frith P, Southcott A, Kesten S, Hart L, Hamilton A. Perceived locus of symptom limitation during constant work rate cycle ergometry in COPD patients treated with tiotropium. *Chest* 2004;126(4):838S.
109. Peters MM, Webb KA, O'Donnell DE. The effects of supplemental oxygen and bronchodilators on exertional dyspnea and exercise performance in patients with COPD. *Am J Respir Crit Care Med* 2005;171:A495.
110. Ofir D, McBride I, Peters MM, Webb KA, Dudgeon DJ, O'Donnell DE. Age-related evolution of ventilatory constraints and dyspnea during exercise in health. *Am J Respir Crit Care Med* 2005;171:A494.
111. He Z, Lam M, Webb K, O'Donnell DE. Ventilatory constraints during exercise in patients with mild COPD. *Am J Respir Crit Care Med* 2005;171:A304.
112. O'Donnell DE, Webb KA. The effect of tiotropium on ventilatory mechanics during exercise in COPD. *Am J Respir Crit Care Med* 2005;171:A494.
113. Webb KA, O'Donnell DE. Comparative effects of a long-acting anticholinergic and a long-acting beta₂-agonist on lung hyperinflation during exercise in COPD. *Am J Respir Crit Care Med* 2005;2:A496.

114. Lougheed MD, Fisher T, O'Donnell DE. Symptom perception in asthma: Identification of poor perceivers of dynamic hyperinflation. *Am J Respir Crit Care Med* 2005;171:A626.
115. Maltais F, O'Donnell DE, Schols AMWJ, Hernandez P, Lussier B, Allas S, Deslauriers N, Aribat T, Vachon L. Effects of TH9507, a growth hormone releasing factor (GRF) analogue, on health-related quality of life and pulmonary muscle function in patients with COPD-associated wasting. *Am J Respir Crit Care Med* 2005;171:A127.
116. O'Donnell DE, Sciurba F, Celli B, Mahler DA, Webb K, Kalberg C, Crater G, Knobil K. Effect of fluticasone propionate/salmeterol 250/50 on lung hyperinflation and exercise endurance in patients with COPD. *Chest* 2005;128(4):178S.
117. Jensen D, Slatkovska L, Webb KA, O'Donnell DE, Davies GAL, Wolfe LA. Effects of pregnancy on the central chemoreflex response to carbon dioxide. *Med Sci Sports Exer* 2005;37:S333.
118. Jensen D, Webb KA, Davies GAL, Wolfe LA, O'Donnell DE. Effects of human pregnancy on chemoreflex and non-chemoreflex drives to breathe. *Med Sci Sports Exer*, 2006.
119. Lougheed MD, Fisher T, O'Donnell DE. Poor perception of hyperinflation and bronchoconstriction in asthma: Pathophysiologic mechanisms. *Proc Am Thorac Soc* 2006;3:A15.
120. Jensen D, Webb KA, Davies GAL, Wolfe LA, O'Donnell DE. Mechanical adaptations of the respiratory system that prevent increased respiratory discomfort during exercise in late gestation. *Proc Am Thorac Soc* 2006;3:A719.
121. Amjadi K, Harris-McAllister V, Webb KA, O'Donnell DE. Mechanisms of exertional dyspnea relief following nebulized furosemide in patients with COPD. *Proc Am Thorac Soc* 2006;3:A225.
122. Ofir D, McBride I, Webb KA, Dudgeon DJ, O'Donnell DE. Gender differences in exertional dyspnea with advancing age. *Proc Am Thorac Soc* 2006;3:224.
123. Ofir D, Webb KA, Harris-McAllister VL, O'Donnell DE. Effects of obesity on exertional dyspnea and ventilatory mechanics in the elderly. *Proc Am Thorac Soc* 2006;3:A211.
124. Green HJ, Bombardier E, D'Arsigny C, O'Donnell D, Ouyang J. Organization of metabolic pathways in skeletal muscle of patients with chronic obstructive lung disease. *Proc Am Thorac Soc* 2006;3:A460.
125. Aaron SD, Vandemheen K, Fergusson D, Fitzgerald M, Maltais F, Bourbeau J, Goldstein R, McIvor A, Balter M, O'Donnell DE. The Canadian Optimal Therapy of COPD Clinical Trial. *Proc Am Thorac Soc* 2006;3:A848.
126. O'Donnell DE. Effects of tiotropium on lung volumes during exercise in GOLD stage II to IV COPD patients. European Respiratory Society. Munich, Germany, Sept. 2006.
127. O'Donnell DE, Webb KA. Stability of the dyspnea/inspiratory reserve volume inflection point during exercise, mechanical and chemical loading in COPD. *Am J Respir Crit Care Med* 2007;175:A767.
128. Ofir D, Laveneziana P, Webb KA, O'Donnell DE. Abnormal ventilatory responses to incremental cycle exercise in mild COPD. *Am J Respir Crit Care Med* 2007;175:A768.
129. Laveneziana P, Ofir D, Palange P, O'Donnell DE. Bronchodilator effect on gas exchange kinetics during high-intensity exercise in COPD. *Am J Respir Crit Care Med* 2007;175:A766.
130. O'Donnell DE, Webb K, Hamilton A, Leimer I, Kesten S. Improvements in hyperinflation and exercise tolerance with tiotropium in COPD patients treated with and without inhaled steroids. *Am J Respir Crit Care Med* 2007;175:A811.
131. Travers J, Laveneziana P, Webb KA, O'Donnell DE. Effect of tiotropium bromide on the cardiovascular response to exercise in COPD. *Am J Respir Crit Care Med* 2007;175:A767.
132. Laveneziana P, O'Donnell DE, Agostoni P, Padeletti L, Galarducci A, Duranti R, Scano G. Effect of biventricular pacing on cardioventilatory responses, exertional dyspnea and exercise capacity in patients with stable chronic heart failure. *Eur Resp J* 2007;30(51):19s.
133. Wadell K, Ofir D, Laveneziana P, Webb KA, O'Donnell DE. Gender differences in exertional breathlessness in healthy older subjects. *Eur Resp J* 2007;30(51):599s.

134. Wadell K, Ofir D, Laveneziana P, Webb KA, O'Donnell DE. Gender differences in exertional breathlessness in patients with mild COPD. *Eur Resp J* 2007;30(51):730s.
135. O'Donnell DE. Heart rate responses to exercise with tiotropium in patients with COPD. *Eur Resp J* 2007;30(51).
136. Laveneziana P, O'Donnell DE, Agostoni P, Padeletti L, Galarducci A, Duranti R, Scano G. Effect of biventricular pacing on cardioventilatory responses, exertional dyspnea and exercise capacity in patients with stable chronic heart failure. *Eur Resp J* 2007;30(51):19s.
137. Jensen D, Webb KA, Davies GAL, O'Donnell DE. Ventilatory and perceptual responses to cycle exercise in human pregnancy. *Am J Respir Crit Care Med* 2008;A177:A999
138. Webb KA, Marciniuk D, Hernandez P, Hamilton A, Weisman I, Clemens R, Baran J, Preston M, O'Donnell DE. Refining the constant-load cycle exercise endurance test in COPD. *ATS* 2008.
139. Laveneziana P, Webb KA, Wadell K, O'Donnell DE. Expiratory muscle recruitment patterns during constant-work-rate and incremental cycle exercise in moderate to severe COPD patients. *Am J Respir Crit Care Med* 2008;177:A1000.
140. Ofir D, Laveneziana P, Webb KA, O'Donnell DE. Evaluation of bronchodilator efficacy in symptomatic patients with GOLD Stage I COPD. *Am J Respir Crit Care Med* 2008;177:A649.
141. Jensen D, O'Donnell DE, Webb K, Duffin J. Maternal hyperventilation: Physiologic mechanisms. *Am J Respir Crit Care Med* 2008;177:A744.
142. Laveneziana P, Ora J, Webb KA, O'Donnell DE. Expiratory muscle recruitment did not attenuate dynamic hyperinflation during cycle exercise in patients with advanced COPD. *ERS* 2008.
143. Ora J, Laveneziana P, Ofir D, Webb KA, O'Donnell DE. The effects of combined COPD and obesity on ventilatory mechanics, dyspnea and exercise tolerance. *ERS* 2008.
144. Ora J, Laveneziana P, Webb KA, O'Donnell DE. Similarities in ventilatory limitations to exercise across different cardiopulmonary diseases. *ERS* 2008.
145. Dudgeon D, Amjadi K, Laveneziana P, Ofir D, O'Donnell DE. Mechanisms of exertional dyspnea in patients with cancer. *International Palliative Care Mtg, Montreal, Sept 23-26, 2008.*
146. Jensen D, Webb KA, O'Donnell DE. The increased ventilatory response to exercise in pregnancy reflects alterations in the respiratory control system's resting PCO₂ equilibrium point. *Appl Physiol Nutrition and Metabolism* 2008;33:S49.
147. Jensen D, Webb KA, O'Donnell DE. Effects of human pregnancy on the intensity of perceived breathlessness during hypercapnia-induced hyperventilation. *Am J Respir Crit Care Med* 2009;179:A3693.
148. Deesomchok, A, Jensen D, Forkert L, Froese S, Webb KA, Moran-Mendoza O, O'Donnell DE. Static lung volumes and acute bronchodilator reversibility patterns in a COPD population: A comparison across GOLD stages. *Am J Resp Crit Care Med* 2009;179:A4079.
149. Deesomchok A, Ora J, Webb KA, Froese S, Moran-Mendoza O, Forkert L, O'Donnell DE. The impact of obesity on pulmonary function measurements in patients with COPD across GOLD stages. *Am J Respir Crit Care Med* 2009;179:A1460.
150. Deesomchok, A, Fisher T, Webb KA, Loughheed MD, O'Donnell DE. Impact of obesity and gender on perception of dyspnea during induced bronchoconstriction and dynamic lung hyperinflation in asthma. *Am J Respir Crit Care Med* 2009;179:A2430.
151. Webb KA, Ofir D, Waddell K, Laveneziana P, O'Donnell DE. Respiratory muscle recruitment patterns with disease progression in COPD. *Am J Respir Crit Care Med* 2009;179:A2050.
152. Laviolette L, Sava F, Hamilton AL, Kesten S, O'Donnell DE, Webb KA, Maltais F. Obesity and exercise tolerance in COPD. *Am J Respir Crit Care Med* 2009;179:A1549.
153. Wadell K, Deesomchok A, Preston M, O'Donnell DE. Effect of pulmonary rehabilitation on self-efficacy in patients with COPD. *ERS* 2009.

154. Ora J, Laveneziana P, Wadell K, Preston M, Deesomchok A, Webb KA, O'Donnell DE. The effects of combined COPD and obesity on lung volumes and respiratory mechanics during exercise. *ERS* 2009.
155. O'Donnell DE, Casaburi R, Swales J, Emery C, Kramer B. Effect of Indacaterol on exercise endurance in patients with moderate-to-severe COPD. *Am J Respir Crit Care Med* 2010;181:A4431.
156. Laveneziana P, Webb KA, Ora J, Wadell K, O'Donnell DE. The impact of critical volume constraints during exercise on the evolution of the intensity and quality of exertional dyspnea in advanced COPD. *Am J Respir Crit Care Med* 2010;181:A5332.
157. Webb KA, Ora J, Ofir D, O'Donnell DE. Respiratory mechanical constraints during exercise in patients with GOLD stage I COPD. *Am J Respir Crit Care Med* 2010;181:A5133.
158. Ora J, Amornputtisathaporn N, Preston M, Wadell K, Laveneziana P, Webb KA, O'Donnell DE. The effects of combined COPD and obesity on respiratory muscle function during exercise. *Am J Respir Crit Care Med* 2010;181:A5324.
159. Jensen D, Ora J, Webb KA, O'Donnell DE. Effects of dead space loading on the ventilatory and perceptual response to incremental cycle exercise in healthy elderly (60-80 yr) men and women. *Am J Respir Crit Care Med* 2010;181:A5318.
160. Jensen D, Ora J, Webb KA, O'Donnell DE. Effects of dead space loading on the intensity, quality and unpleasantness of perceived respiratory discomfort during incremental cycle exercise in the healthy elderly. *Am J Respir Crit Care Med* 2010;181:A6487.
161. Chapman KR, Bhutani M, Bourbeau J, Chan CK, Field SK, Fitzgerald JM, Flood DA, Grossman RF, Hernandez P, Levy RD, Marciniuk DD, O'Donnell DE, Stickland MK, Rea RM. The Hospital Burden of COPD in Canada. *Am J Respir Crit Care Med* 2010;181:A1500
162. Boulet L-P, Devlin H, O'Donnell DE. The Physicians Practice Assessment Questionnaire: A new tool for the assessment of implementation of asthma and COPD guidelines. *Am J Respir Crit Care Med* 2010;181:A1456.
163. Guenette A, Ofir D, Webb KA, Raghavan N, Jensen D, O'Donnell DE. Sex differences in exertional dyspnea in patients with mid COPD. *Chest* 2010;138:692A. (Oral presentation).
164. Jensen D, Powell G, Walker M, O'Donnell DE. Effects of metabolic acidosis on the ventilatory and perceptual response to incremental cycle exercise in healthy humans. *Chest* 2010;138:918A. (Oral presentation).
165. Jensen D, Walker M, Powell G, O'Donnell DE. The role of acid-base balance in the chemoreflex control of breathing: implications for respiratory sensation. *Chest* 2010;138:568A.
166. Jensen D, Li R, O'Donnell DE, Luo YM. Effects of increased chemostimulation on the relationship between increasing breathlessness intensity and increasing neural respiratory motor drive (diaphragm EMG) during exercise in healthy older humans. *Chest* 2010;138:567A.
167. O'Donnell DE, Webb KA. Impact of inhaled fluticasone/salmeterol combination on respiratory physiology in patients with milder COPD. *Am J Respir Crit Care Med* 2011;183:A1594.
168. O'Donnell DE, Preston M, Webb KA. Improvement in exertional dyspnea and cycle exercise endurance with short term administration of inhaled corticosteroid monotherapy in patients with COPD. *Am J Respir Crit Care Med* 2011;183:A3097.
169. Vozoris NT, O'Donnell DE. Prevalence, risk factors, and health outcomes of obese and underweight population cohorts with chronic obstructive pulmonary disease (COPD). *Am J Respir Crit Care Med* 2011;183:A1014.
170. Jensen D, Webb KA, O'Donnell E. Multi-dimensional evaluation of perceived respiratory discomfort during incremental cycle exercise in health and COPD. *Am J Respir Crit Care Med* 2011;183:A5813.

171. Jensen D, Alshail A, Viola R, Dudgeon D, O'Donnell DE. Inhaled Fentanyl citrate improves dynamic airway function, exertional dyspnea and exercise endurance in COPD. *Am J Respir Crit Care Med* 2011;183:A5627.
172. Guenette JA, Jensen D, Raghavan N, Webb KA, O'Donnell DE. Effects of healthy ageing and mild COPD on exertional dyspnea in women. *Cdn Resp J* 2011;18:21A.
173. Guenette JA, Raghavan N, O'Meara P, Amornputtisathaporn N, deMetz CE, Nolan RL, O'Donnell DE. Radiation induced lung volume reduction and dyspnea relief in a patient with severe COPD. *Chest*. ACCP Meeting October 2011. (Accepted).
174. Guenette JA, Webb KA, Maltais FM, O'Donnell DE. The Continuum of COPD severity: Implications for dyspnea, respiratory mechanics and exercise capacity. *Chest*. ACCP Meeting October 2011. (Accepted).
175. Guenette JA, Loughheed D, Webb KA, O'Donnell DE. Superior athletic performance in an 86 year old woman with advanced obstructive lung disease. Presented at the ATS International Conference 2012. *Am J Respir Crit Care Med* 2012;185:A2972.
176. O'Donnell DE, Webb KA, Amornputtisathaporn N, Li P, Benedetti A, Bourbeau J. Longitudinal changes in lung volume measurements in patients with varying COPD severity. Presented at the ATS International Conference 2012. *Am J Respir Crit Care Med* 2012;185:A6630.
177. Wadell K, Webb KA, Preston M, Amornputtisathaporn N, O'Donnell DE. A new comprehensive approach to measuring dyspnea in response to pulmonary rehabilitation in COPD. Presented at the ATS International Conference 2012. *Am J Respir Crit Care Med* 2012;185:A2380.
178. Guenette JA, Webb KA, O'Donnell DE. Dyspnea and exercise intolerance in COPD: are dynamic hyperinflators different from non-hyperinflators? Presented at the ATS International Conference 2012. *Am J Respir Crit Care Med* 2012;185:A1535.
179. Chin R, Guenette JA, Cheng J, Raghavan N, Amornputtisathaporn N, Cortés-Telles A, Webb KA, O'Donnell DE. A comparison of the mechanical and sensory consequences of dead space loading during exercise in mild COPD and in health. Presented at the ATS International Conference 2012. *Am J Respir Crit Care Med* 2012;185:A1547.
180. O'Donnell DE, Maltais F, Porszasz J, Albers F, Deng Q, Hernandez G, Iqbal A, Paden H, Casaburi R. Lung function and exercise impairment in patients with GOLD stage I and II COPD. Presented at the ATS International Conference 2012. *Am J Respir Crit Care Med* 2012;185:A6400.
181. Tan WC, Chuang J, Bourbeau J, Fitzgerald MJ, Cowie R, Hernandez P, Chapman K, Aaron SD, O'Donnell DE, Marciniuk D, Maltais F, Goldstein R, Sin D. Characteristics of COPD in non-smokers – results from the Canadian Obstructive Lung Disease (COLD) study. Presented at the ATS International Conference 2012. *Am J Respir Crit Care Med* 2012;185:A6033.
182. Tan WC, Chuang J, Bourbeau J, Fitzgerald MJ, Hernandez P, Cowie R, Chapman K, Aaron SD, Goldstein R, O'Donnell DE, Marciniuk D, Maltais F, Sin D. The lower limits of normal (LLN) of FEV₁/FEV₆ is not a substitute for FEV₁/FVC in screening for airway obstruction – results from the Canadian Obstructive Lung Disease (COLD) study. Presented at the ATS International Conference 2012. *Am J Respir Crit Care Med* 2012;185:A5875.
183. Raghavan N, Lam YM, Webb KA, Guenette JA, Amornputtisathaporn N, Raghavan R, Tan WC, Bourbeau J, O'Donnell DE. Components of the COPD Assessment Test (CAT) associated with a diagnosis of COPD in a random population sample. Presented at the ATS International Conference 2012. *Am J Respir Crit Care Med* 2012;185:A1506.
184. Labonte L, Tan WC, Cowie R, Hernandez P, Chapman KR, Li PZ, Aaron SD, Benedetti A, Fitzgerald M, Maltais F, Marciniuk D, O'Donnell DE, Sin D, Bourbeau J. Health status in mild to moderate chronic obstructive pulmonary disease (COPD) subject sampled from a general population. Presented at ATS International Conference, 2012. *Am R Respir Crit Care Med* 2012;185:A1511.

185. Casaburi R, O'Donnell DE: The effect of tiotropium on lung dynamic hyperinflation and treadmill exercise capacity in mild to moderate COPD. Presented at European Respiratory Society Annual Mtg, Vienna, Austria, Sept 3, 2012.
186. O'Donnell DE, Chin RC, Guenette JA, Cheng S, Raghavan N, Amornputtisathaporn N, Cortes-Telles A, Webb KA. Does the respiratory system limit exercise in mild COPD? ATS 2013 International Conference – Accepted (Poster). *Am J Respir Crit Care Med* 2013;187:A4866.
187. Ciavaglia CE, Guenette JA, Ora J, Webb KA, O'Donnell DE. Are sensory and physiological responses to linearized incremental treadmill and cycle exercise tests different in obese COPD? ATS 2013 International Conference – Accepted (Poster). *Am J Respir Crit Care Med* 2013;187:A1367.
188. Jensen D, Webb KA, O'Donnell DE. The respiratory system is not 'underbuilt' for exercise in healthy women aged 60-80 years. ATS 2013 International Conference – Accepted (Poster). *Am J Respir Crit Care Med* 2013;187:A4869.
189. Vozoris NT, O'Donnell DE. The impact of smoking history on activity level and exercise test outcomes in a young American population-level sample without overt cardio-pulmonary disease. ATS 2013 International Conference – Accepted (Poster). *Am J Respir Crit Care Med* 2013;187:A3649.
190. Gagnon P, Saey D, Provencher S, Milto J, Bourbeau J, Casaburi R, O'Donnell DE, Porszasz J, Maltais F. Cluster analysis in patients with GOLD I COPD. ATS 2013 International Conference – Accepted (Poster). *Am J Respir Crit Care Med* 2013;187:A3928.
191. Maltais F, O'Donnell DE, Porszasz J, Clerisme-Beaty E, Guo Z, Paden H, Casaburi R. The impact of GOLD 1 and 2 COPD on self-reported functional limitations, activity and correlations with symptom-limited exercise compared with age- and gender-matched control subjects. ATS 2013 International Conference – Accepted (Poster). *Am J Respir Crit Care Med* 2013;187:A1376.
192. To T, Tan W, Bourbeau J, O'Donnell D, Aaron S, Stanbrook M, Chapman K, Victor C, Jiandong S, Hwee J. The impact of pulmonary function testing on health outcomes of people with chronic obstructive pulmonary disease (COPD). ATS 2013 International Conference – Accepted (Poster). *Am J Respir Crit Care Med* 2013;187:A5018.
193. Tan WC, Bourbeau J, Fitzgerald JM, Cowie R, Chapman KR, Hernandez P, O'Donnell DE, Aaron SD, Maltais F, Marciniuk D, Sin D. Quality assurance of spirometry in a population-based study-prior experience in spirometry is not a pre-requisite for good outcome. ATS 2013 International Conference – Accepted (Poster). *Am J Respir Crit Care Med* 2013;187:A2834
194. Tan WC, Bourbeau J, Fitzgerald JM, Hernandez P, Chapman KR, Cowie R, Aaron SD, O'Donnell DE, Marciniuk D, Maltais F, Sin D. What is the optimal fixed cut-off for FEV1/FEV6 as alternative to FEV1/FVC for detection of airflow obstruction? Results from the Canadian Obstructive Lung Disease (COLD) Study. ATS 2013 International Conference – Accepted (Poster). *Am J Respir Crit Care Med* 2013;187:A2833.
195. Tan WC, Bourbeau J, Aaron SD, Maltais F, Marciniuk D, Fitzgerald M, Cowie R, Chapman KR, Hernandez P, O'Donnell DE, Sin D. The Canadian Obstructive Lung Disease (COLD) Study – comparison of responses from telephone surveys and face-to-face interviews. *Am J Respir Crit Care Med* 2013;187:A5501.
196. Labonte L, Baglolle CJ, Rico De Souza A, Tan W-C, Cowie R, Hernandez P, Chapman KR, Li PZ, Aaron SD, Benedetti A, Fitzgerald M, Maltais F, Marciniuk D, O'Donnell DE, Sin D, Bourbeau J. Mild to moderate chronic obstructive pulmonary disease (COPD) and the COPD Assessment Test (CAT): Evaluation of inflammatory markers in the Canadian Cohort of Obstructive Lung Disease (CanCOLD) Study. *Am J Respir Crit Care Med* 2013;187:A2945.
197. Gershon AS, Hwee J, Su J, Victor JC, Chapman KR, Stanbrook M, Aaron SD, O'Donnell DE, Bourbeau J, Tan W-C, To T. Quantifying the burden of undiagnosed and overdiagnosed chronic obstructive pulmonary disease (COPD). *Am J Respir Crit Care Med* 2013;187:A3640.

198. Guenette JA, Chin RC, Cheng S, Dominelli PB, Molavi B, Raghavan N, Webb KA, O'Donnell DE. Neuromechanical uncoupling of the respiratory system during exercise in patients with mild COPD. (Best Posters in Exercise Testing and Physical Inactivity). Presented at European Respiratory Society Annual Mtg, September 9, 2013. Barcelona, Spain, September 7-11, 2013.
199. Porszasz J, Ma S, Cao R, Gore A, Phillips W, Cooper R, Maltais F, Ferguson GT, O'Donnell DE, Paden H, Casaburi R. Effect of Tiotropium on spontaneous expiratory flow-volume curves during exercise in GOLD 1 & 2 COPD. Poster presentation at European Respiratory Society Annual Mtg, September 8, 2013. Barcelona, Spain, September 7-11, 2013.
200. Guenette JA, Casaburi R, Maltais F, Porszasz J, Clerisme-Beaty E, Guo Z, Paden H, O'Donnell DE. Sex differences in physical activity levels and dyspnea in mild-to-moderate COPD. American College of Chest Physicians (CHEST) Annual Mtg. Chicago, Illinois, October 26-31, 2013.
201. Langer D, Ciavaglia C, Webb K, Preston M, O'Donnell DE. Inspiratory muscle training reduces central neural drive to the diaphragm in patients with COPD. Poster presented May 20 at American Thoracic Society International Meeting May 16-21, San Diego, California. *Am J Respir Crit Care Med* 2014;189:A4159.
202. Morogan A, Pinto L, Tan WC, Aaron S, Chapman KR, Cowie R, Fitzgerald JM, Hernandez P, Marciniuk DD, Maltais F, O'Donnell DE, Sin DD, Bourbeau J for the CanCOLD Collaborative Research Group. Asthma COPD overlap syndrome (ACOS): What can we learn from the CanCOLD population? Poster presented May 21 at American Thoracic Society International Meeting, May 16-21, San Diego, California. *Am J Respir Crit Care Med* 2014;189:A5937.
203. Bourbeau J, Pinto L, Tan WC, Li PZ, Aaron S, Chapman KR, Cowie R, Fitzgerald JM, Hernandez P, Marciniuk D, Maltais F, O'Donnell DE, Sin DD for the CanCOLD Collaborative Research Group. Derivation of clinical phenotypes of COPD subjects in the Can COLD cohort at baseline. Poster presentation May 21 at American Thoracic Society International Meeting, May 16-21, San Diego, California. *Am J Respir Crit Care Med* 2014;189:A5912.
204. Tan WC, Leipsic J, Hague C, Bourbeau J, Sin D, Coxson H, O'Donnell D, Aaron S, Maltais F, Hernandez P, Cowie R, Chapman K, Marciniuk D, Raju R, Fitzgerald JM, Hogg JC for the CanCOLD Collaborative Research Group. Comparison of emphysema and bronchiolitis scores obtained by computerized tomography in current and former smokers in the general population. Poster presented May 21 at American Thoracic Society International Meeting, May 16-21, San Diego, California. *Am J Respir Crit Care Med* 2014;189:A5910.
205. Elbehairy AF, Raghavan N, Cheng S, Yang L, Webb KA, Neder JA, O'Donnell DE. Physiological characterization of the chronic bronchitis phenotype in patients with GOLD Grade 1-B COPD. Poster presented May 21 at American Thoracic Society International Meeting, May 16-21, San Diego, California. *Am J Respir Crit Care Med* 2014;189:A5928.
206. Laveneziana P, Webb KA, Wadell K, Neder JA, O'Donnell DE. Expiratory muscle activity, dynamic hyperinflation, diaphragmatic function and dyspnea during exercise in COPD. Poster presented May 21 at American Thoracic Society International Meeting, May 16-21, San Diego, California. *Am J Respir Crit Care Med* 2014;189:A5866.
207. Faisal A, Chin RC, Ciavaglia CE, Preston ME, Webb KA, Neder JA, O'Donnell DE. Respiratory system limitations to exercise performance in older men with high cardio-respiratory fitness. Poster presented May 20 at American Thoracic Society International Meeting, May 16-21, San Diego, California. *Am J Respir Crit Care Med* 2014;189:A5031.
208. Moran-Mendoza O, Cortes-Telles A, Forkert L, O'Donnell DE. Idiopathic pulmonary fibrosis: New insights on functional characteristics at diagnosis. Poster presented May 21 at American Thoracic Society International Meeting, May 16-21, San Diego, California. *Am J Respir Crit Care Med* 2014;189:A6403.
209. Ciavaglia CE, Guenette JA, Langer D, Webb KA, Neder JA, O'Donnell DE. The effect of obesity on respiratory neural drive during exercise in COPD. Poster presented May 11 at American

- Thoracic Society International Meeting, May 16-21, San Diego, California. *Am J Respir Crit Care Med* 2014;189:A5811.
210. Preston ME, Cheng S, Yang L, Webb KA, Neder JA, Jensen D, O'Donnell DE. Comparison of ventilatory control characteristics in mild COPD and in health. Poster presented May 19 at American Thoracic Society International Meeting, May 16-21, San Diego, California. *Am J Respir Crit Care Med* 2014;189:A3891.
 211. Guenette JA, Ryerson CJ, Wilkie SS, O'Donnell DE. How well do measures of resting pulmonary function predict exertional dyspnea in patients with COPD? Poster presented May 21 at American Thoracic Society International Meeting, May 16-21, San Diego, California. *Am J Respir Crit Care Med* 2014;189:A5860.
 212. O'Donnell CDJ, Cory JM, Yang L, Webb KA, O'Donnell DE, Neder JA. Impaired lung diffusing capacity, ventilatory inefficiency and exercise intolerance across chronic obstructive pulmonary disease stages. Poster presented May 21 at American Thoracic Society International Meeting, May 16-21, San Diego, California. *Am J Respir Crit Care Med* 2014;189:A5864.
 213. Neder JA, O'Donnell CDJ, Cory J, Webb KA, O'Donnell DE. Increased non-communicating lung volume predicts respiratory and exercise impairment in mild-to-advanced COPD. Poster presented May 21 at American Thoracic Society International Meeting, May 16-21, San Diego, California. *Am J Respir Crit Care Med* 2014;189:A5867.
 214. Neder JA, Arbex FF, Alencar MCN, O'Donnell CDJ, Cory J, Webb KA, O'Donnell DE. Effect of disease progression on exercise ventilation-carbon dioxide output coupling in patients with COPD. Poster presented May 21 at American Thoracic Society International Meeting, May 16-21, San Diego, California. *Am J Respir Crit Care Med* 2014;189:A6269.
 215. Alghamdi B, Faisal A, Ciavaglia C, Ora J, Webb KA, O'Donnell DE. Intensity and quality of exertional dyspnea are similar in patients with restrictive and obstructive lung diseases when resting inspiratory capacity is matched. Poster presented May 21 at American Thoracic Society International Meeting, May 16-21, San Diego, California. *Am J Respir Crit Care Med* 2014;189:A6273.
 216. Tan WC, Bourbeau J, Chapman KR, Hernandez P, Cowie R, Fitzgerald JM, Marciniuk D, Maltais F, Buist AS, O'Donnell DE, Aaron SD, Sin D. Acute respiratory exacerbations among individuals without chronic obstructive pulmonary disease: results from a population based study. Poster presented May 19 at American Thoracic Society International Meeting, May 16-21, San Diego, California. *Am J Respir Crit Care Med* 2014;189:A2878.
 217. DeSousa Sensa R, Tan WC, Li PZ, Aaron SD, Chapman KR, Cowie R, FitzGerald MJ, Hernandez P, Marciniuk D, Maltais F, O'Donnell DE, Sin D, Bourbeau J. Work impairment in individuals with mild to moderate COPD: lesson learned from the CanCOLD study. Poster presented May 19 at American Thoracic Society International Meeting, May 16-21, San Diego, California. *Am J Respir Crit Care Med* 2014;189:A2981.
 218. Tan WC, Bourbeau J, Chapman KR, Fitzgerald JM, Maltais F, Cowie R, Marciniuk D, Hernandez P, Buist AS, O'Donnell DE, Aaron SD, Sin D. The clinical phenotypes of non-COPD individuals with spirometric abnormalities in the general population – results from the Canadian Obstructive Lung Disease (COLD) Study. Poster presented May 21 at American Thoracic Society International Meeting, May 16-21, San Diego, California. *Am J Respir Crit Care Med* 2014;189:A5909.
 219. Tan WC, Leipsic J, Hague C, Bourbeau J, Sin DD, Coxson HO, O'Donnell DE, Aaron SD, Maltais F, Hernandez P, Cowie R, Chapman KR, Raju R, Marciniuk D, Fitzgerald JM, Hogg JC. Pathological phenotypes of COPD in the general population as defined by MDCT scans – results from the Can COLD Study. Poster presented May 21 at American Thoracic Society International Meeting, May 16-21, San Diego, California. *Am J Respir Crit Care Med* 2014; 19:A5963.

220. Langer D, Ciavaglia C, Webb K, Neder JA, O'Donnell D. Inspiratory muscle weakness in mildly-to-moderately-hyperinflated patients with COPD. European Respiratory Society Annual Congress, Munich, Germany, September 6-10, 2014. (Accepted)
221. Elbehairy A, Faisal A, Ciavaglia C, Langer D, Preston M, Webb K, Neder JA, O'Donnell D. Is ventilatory efficiency impaired during progressive exercise in COPD? European Respiratory Society Annual Congress, Munich, Germany, September 6-10, 2014. (Accepted)
222. Neder JA, Arbex F, Alencar MC, O'Donnell C, Cory J, Webb K, O'Donnell D. The effects of COPD progression on exercise ventilatory inefficiency. European Respiratory Society Annual Congress, Munich, Germany, September 6-10, 2014. (Accepted)
223. Oliveira M, Alencar MC, Mazzuco A, Sperandio P, Souza A, Siqueira G, Borghi-Silva A, O'Donnell D, Neder JA. Effects of systolic heart failure on cerebral oxygen delivery-to-utilization matching in COPD. European Respiratory Society Annual Congress, Munich, Germany, September 6-10, 2014. (Accepted)
224. Alencar MC, Arbex F, Santos R, Figliolino G, Mancuso F, Medeiros W, Almeida D, Nery LE, O'Donnell D, Neder JA. How does CHF influence the physiological and sensory responses to incremental exercise in patients with COPD? European Respiratory Society Annual Congress, Munich, Germany, September 6-10, 2014. (Accepted)
225. Ciavaglia C, Guenette JA, Langer D, Webb KA, Neder JA, O'Donnell DE. Neuromuscular dissociation of the diaphragm is more pronounced during treadmill exercise compared with cycle exercise in obese COPD patients. European respiratory Society Annual Congress, Munich, Germany, September 6-10, 2014. (Accepted)
226. Webb KA, Preston ME, Hamilton A, O'Donnell DE. Refining the constant work rate cycle exercise test in patients with COPD. American Thoracic Society International Meeting, Denver, Colorado, May 15-20, 2015. *Am J Crit Care Med* 2015;191:A5296.
227. Vozoris NT, Wang X, Fischer H, Austin PC, Bell CM, Gill SS, O'Donnell DE, Gershon AS, Stephenson AI, Rochon PA. Opioid drug use among older adults with chronic obstructive pulmonary disease: a population-based cohort study. American Thoracic Society International Meeting, Denver, Colorado, May 15-20, 2015. *Am J Respir Crit Care Med* 2015;191:A5805.
228. O'Donnell DE, Casaburi R, DeSousa D, Xue W, Frith P, Hamilton A, Kirsten A, Maltais F. Effects of 6 weeks' treatment with once-daily tiotropium and olodaterol fixed-dose combination on inspiratory capacity and exercise endurance in patients with COPD: the MORACTO™ studies. American Thoracic Society International Meeting, Denver, Colorado, May 15-20, 2015. *Am J Respir Crit Care Med* 2015;191:A3972.
229. Elbehairy AF, Ciavaglia CE, Guenette J, Jensen D, Webb KA, Neder JA, O'Donnell DE on behalf of the Canadian Respiratory Research Network (CRRN). Increased ventilatory inefficiency in mild COPD: Mechanisms and clinical implications. American Thoracic Society International Meeting, Denver, Colorado, May 15-20, 2015. *Am J Respir Crit Care Med* 2015;191:A1215.
230. Elbehairy AF, Faisal A, Ciavaglia CE, Preston M, Guenette J, Jensen D, Webb KA, Neder JA, O'Donnell DE on behalf of the Canadian Respiratory Research Network (CRRN). Respiratory neural drive and dyspnea are increased during exercise in smokers at risk for COPD. American Thoracic Society International Meeting, Denver, Colorado, May 15-20, 2015. *Am J Respir Crit Care Med* 2015;191:A4105.
231. Tan WC, Bourbeau J, Sin DD, Hernandez P, Chapman KR, Fitzgerald JM, Cowie R, Marciniuk DD, Maltais F, Buist AS, Hogg JC, O'Donnell DE, Aaron S for the CanCOLD Collaborative Research Group. Risk factors for non-reversible airway obstruction in never smokers: Results from the CanCOLD study: impact of gender and severity of airway obstruction. American Thoracic Society International Meeting, Denver, Colorado, May 15-20, 2015. *Am J Respir Crit Care Med* 2015;191:A2298.

232. Tan WC, Bourbeau J, Fitzgerald JM, Sin D, Hogg J, Cowie R, Chapman K, O'Donnell D, Hernandez P, Marciniuk D, Maltais F, Buist AS, Aaron S on behalf of the CanCOLD Collaborative Research Group. The effect of smoking on the threshold of bronchodilator response (BDR) in health and in COPD – Results from the Canadian Obstructive Lung Disease (COLD) study. American Thoracic Society International Meeting, Denver, Colorado, May 15-20, 2015. *Am J Respir Crit Care Med* 2015;191:A4474.
233. Elbehairy AF, Cheng S, Ciavaglia CE, Preston M, Guenette J, Jensen D, Webb KA, Neder JA, O'Donnell DE on behalf of CRRN. Predictors of exercise limitation in smokers with preserved spirometry. American Thoracic Society International Meeting, Denver, Colorado, May 15-20, 2015. *Am J Respir Crit Care Med* 2015;191:A2671.
234. Webb KA, Ciavaglia CE, Preston ME, O'Donnell DE. Effects of dual umeclidinium/vilanterol compared to umeclidinium on exertional dyspnea, respiratory mechanics and neural drive in patients with moderate COPD. American Thoracic Society International Meeting, Denver, Colorado, May 15-20, 2015. *Am J Respir Crit Care Med* 2015;191:A5735.
235. Davis C, Pike D, Svenningsen S, McCormack DG, O'Donnell D, Neder JA, Parraga G. Ventilation heterogeneity in older never-smokers and GOLD stage I-IV COPD: Poorly communicating fraction and MRI Ventilation defects in the TINCan Cohort. American Thoracic Society International Meeting, Denver, Colorado, May 15-20, 2015. *Am J Respir Crit Care Med* 2015;191:A2274.
236. Tan WC, Bourbeau J, Sin DD, Chapman KR, Hernandez P, Fitzgerald MD, Cowie R, Marciniuk D, Malais F, Road J, Leipsic J, Hague C, Coxson HO, Hogg JC, O'Donnell DE, Aaron SD on behalf of the CanCOLD Collaborative Research Group. Characterization of “potentially over diagnosed” chronic obstructive pulmonary disease showed early disease: Results from the CanCOLD Study. American Thoracic Society International Meeting, Denver, Colorado, May 15-20, 2015. *Am J Respir Crit Care Med* 2015;191:A4475.
237. Langer D, Webb KA, Elbehairy AF, Neder JA, Dudgeon DJ, O'Donnell DE. Dyspnea and exercise intolerance in breast cancer survivors: the role of inspiratory muscle weakness. ERS International Congress, September 2015. *ERS Sept 2015;46(Suppl 59)*. DOI: 10.1183/13993003.congress-2015.PA4816.
238. Alharbi B, Hirai D, Berton D, Abu-Ghazuleh N, Webb K, Neder JA, O'Donnell DE. Exercise ventilatory inefficiency is an independent predictor of mortality in COPD. To be presented at the ERS International Congress, September 2015. *ERS Sept 2015;46(Suppl 59)*. DOI: 10.1183/13993003.congress-2015.OA1982.
239. Alencar MC, Arbex F, Mancuso F, Oliveira M, Medina L, Mazzuco A, Borghi-Silva A, Hirai DM, O'Donnell DE, Neder JA. Predicting poor outcomes in COPD-heart failure overlap: the role of resting echocardiography and cardiopulmonary exercise testing. To be presented at the ERS International Congress, September 2015. *ERS Sept 2015;46(Suppl 59)*. DOI: 10.1183/13993003.congress-2015.PA1537.
240. Arbex F, Alencar MC, Oliveira M, Medeiros W, Souza A, Sperandio P, Hirai DM, O'Donnell D, Neder JA. Is cardiopulmonary exercise test useful to indicate heart failure in patients with COPD? To be presented at the ERS International Congress, September 2015. *ERS Sept 2015;46(Suppl 59)*. DOI: 10.1183/13993003.congress-2015.OA1986.
241. Hanania NA, Tashkin D, Kerwin E, Donohue J, Denenberg M, O'Donnell DE, Quinn D, Siddiqui S, Orevillo C, Maes A, Reisner C. Safety and efficacy of a novel LAMA/LABA co-suspension technology glycopyrrolate/formoterol fixed-dose combination delivered by MDI: Results of a one-year extension study in patients with COPD (PINNACLE-3). *Am J Respir Crit Care Med* 2016;193:A6791.

242. Vozoris N, Wang X, Fischer H, Bell C, O'Donnell DE, Austin P, Stephenson AL, Gill SS, Rochon PA. Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. *Am J Respir Crit Care Med* 2016;193:A3541.
243. Tan WC, Zheng L, Bourbeau J, Sin DD, O'Donnell DE, Maltais F, Hernandez P, Chapman KR, Marciniuk D, Road J, Leipsic J, Hague C, Coxson H, Kirby M, FitzGerald JM, Hogg JC, Aaron SD. How consistent and reproducible are prevalence estimates of COPD in the general population? *Am J Respir Crit Care Med* 2016; 193: A2000.
244. Tan WC, Zheng L, Aaron SD, Sin DD, Road J, O'Donnell DE, Maltais F, Hernandez P, Chapman KR, FitzGerald JM, Marciniuk D, Leipsic J, Hague C, Coxson H, Kirby M, Jogg JC, Bourbeau J. The relative contribution of a low baseline FEV1 versus rapid decline in lung function over time on incident COPD. *Am J Respir Crit Care Med* 2016; 193: A4279.
245. Nantel-Smith R, Olivenstein R, Martin JG, FitzGerald JM, Tan WC, Aaron SD, Road J, O'Donnell DE, Maltais F, Hernandez P, Cowie R, Chapman KR, Marciniuk D, Bourbeau J. A population based assessment of asthma and the asthma chronic obstructive pulmonary disease overlap syndrome (ACOS): a Canadian perspective. *Am J Respir Crit Care Med* 2016; 193: A4444.
246. Kirby M, Tan WC, Hague C, Leipsic J, Sin DD, Bourbeau J, Road J, O'Donnell DE, Maltais F, Hernandez P, Chapman KR, Marciniuk D, FitzGerald JM, Aaron SD, Hogg JC, Coxson H. Radiological phenotypes of smoking and non-smoking COPD. *Am J Respir Crit Care Med* 2016; 193: A5203.
247. Shorofsky M, Bourbeau J, Kimoff RJ, Ayas N, Tan WC, Aaron SD, Sin DD, Road J, O'Donnell DE, Maltais F, Chapman KR, FitzGerald JM, Marciniuk D, Coxson H, Kaminska M. A population based study of sleep disorders in chronic obstructive pulmonary disease: sleep quality and acute exacerbations of COPD. *Am J Respir Crit Care Med* 2016; 193: A5995.
248. O'Donnell CD, Webb KA, Neder JA, O'Donnell DE. Associations between lung diffusion impairment, ventilatory inefficiency and exercise intolerance in mild to very severe COPD. Presented at the ERS International Congress, September 2016. *Eur Respir J* 2016;48 (supplement 60).
249. Webb KA, Neder JA, O'Donnell DE. Descriptors of exertional dyspnea across the COPD severity spectrum. Presented at the ERS International Congress, September 2016. *Eur Respir J* 2016:48 (supplement 60).
250. Elbehairy AF, Guenette J, Jensen D, Webb KA, Neder JA, O'Donnell DE: on behalf of the Canadian Respiratory Research Network (CRRN). Resting physiological markers of exercise intolerance in smokers with mild airway obstruction. Presented at the ERS International Congress, September 2016. *Eur respire J* 2016:48 (supplement 60).
251. Jones J, Zelt J, Rafferty I, Castanhas L, Hirai D, O'Donnell D, Neder JA. Structural determinants of exercise ventilatory inefficiency in mild-to-moderate COPD. Presented at the ERS International Congress, September 2016. *Eur Resp J* 2016;48: (supplemental 60).
252. Bravo D, Gimenes AC, Alencar MC, Amorim B, Hirai D, O'Donnell D, Neder JA, Nery LE. Physiological determinants of reduced tolerance to interval exercise in moderate-to-severe COPD. Presented at the ERS International Congress, September 2016. *Eur Resp J* 2016:48 (supplement 60).
253. Sainte-Pierre M, Ladha J, Berton D, Zapotichny A, Faubert D, Crozier-Wells L, Tang J, Muir C, Forkert L, O'Donnell D, Neder-Serafini JA. Usefulness of FEV₁/SVC to uncover airflow obstruction in subjects with preserved FEV₁/FVC. Presented at the ERS International Congress, September 2016. *Eur Respir J* 2016:48 (supplement 60).
254. Rodrigues A Silva M, Berton D, Faubert D, Tang J, Zapotichny A, Crozier-Wells L, Muir C, Forkert L, O'Donnell D, Neder JA. Maximal inspiratory pressure: does the choice of reference values matter? To be presented at the ERS International Congress, September 2016.
255. Neder JA, Souza A, Sperandio P, Mazzuco A, Alencar MC, Arbex F, O'Donnell D. Influence of

- heart failure on resting inspiratory volumes in patients with COPD. Presented at the ERS International Congress, September 2016. *Eur Respir J* 2016;48 (supplement 60).
256. Hirai D, Zelt J, Jones J, Bentley R, Earle W, Staples P, Tschakovsky M, McCans J, O'Donnell D, Neder JA. Dietary nitrate supplementation and exercise tolerance in chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. Presented at the ERS International Congress, September 2016. *Eur Respir J* 2016;48 (supplement 60).
257. Tan WC, Zheng L, Bourbeau J, Sin D, Hogg J, O'Donnell D, Maltais F, Cowie R, Chapman K, Hernandez P, Marciniuk D, FitzGerald M, Aaron S. Marijuana smoking: health and socioeconomic impact in middle-aged and elderly adults. Presented at the ERS International Congress, September 2016. *Eur Resp J* 2016;48 (supplement 60).
258. Arbex FF, Alencar MC, Souza A, Mazzuco A, Sperandio P, Rocha A, Berton DC, Borghi-Silva A, O'Donnell DE, Neder JA. Influence of systolic heart failure on exercise PETCO₂ in COPD. Presented at the ERS International Congress, September 2016. *Eur Respir J* 2016;48 (supplement 60).
259. Zelt J, King T, Hirai D, Jones J, Rafferty I, Castanhas L, Pyke K, O'Donnell D, Neder JA. Do COPD patients with only mild-to-moderate airflow obstruction present with endothelial dysfunction? Presented at the ERS International Congress, September 2016. *Eur Respir J* 2016;48 (supplement 60).
260. Neder JA, Souza A, Sperandio P, Mazzuco A, Alencar MC, Arbex F, O'Donnell DE. Influence of heart failure on resting inspiratory volumes in patients with COPD. Presented at the ERS International Congress. *Eur Respir J* 2016;48 (supplement 60).
261. Dacha S, Langer D, Ciavaglia C, Webb K, Preston M, O'Donnell DE. Effect of inspiratory muscle training on respiratory muscle function and diaphragm activation in patients with COPD. *Am J Resp Crit Care Med* 2017;195:A2860
262. Maltais F, O'Donnell D, Hamilton A, Zhao Y, Casaburi R. Comparative measurement properties of constant work-rate cycling and endurance shuttle walking in patients with COPD: Data from the TORRACTO Study. *Am J Resp Crit Care Med* 2017;195:A5675
263. Vozoris N, Wang X, Austin P, Lee D, Stephenson A, O'Donnell DE, Gill S, Rochon P. Adverse cardiac outcomes associated with incident opioid drug use among older adults with COPD. *Am J Resp Crit Care Med* 2017;195:A4712.
264. Ladha J, Berton D, O'Donnell D, Neder A. Low DLCO but preserved KCO in chronic airflow limitation: effects of disease severity. *Am J Resp Crit Care Med* 2017;195:A5688.
265. Tan WC, Bourbeau J, Maltais F, Hernandez P, Marciniuk D, O'Donnell DE, Walker BL, Chapman KR, Fitzgerald JM, Road JD, Hogg JC, Aaron S, Sin DD. Marijuana smoking in the middle aged and elderly population is associated with exacerbation-like respiratory events. *Am J Resp Crit Care Med* 2017;195:A3073.
266. Tan WC, Bourbeau J, Leipsic JA, Hague CJ, Aaron SD, Marciniuk D, Maltais F, Hernandez P, O'Donnell DE, Road JD, Coxson HO, Kirby M, Hogg JC, Walker BL, Chapman KR, Fitzgerald JM, Sin DD. Occupational and biomass risk factors for emphysema in middle-aged and elderly never-smokers without chronic airflow limitation. *Am J Resp Crit Care Med* 2017;195:A1762.
267. Wald J, Tan WC, Pei Z Li, Aaron S, Benedetti A, Chapman KR, Walker BL, Hernandez P, Maltais F, Marciniuk D, O'Donnell DE, Sin DD, Bourbeau J. Undiagnosed chronic obstructive pulmonary disease leads to a significant symptom burden, with important differences between men and women. *Am J Resp Crit Care Med* 2017;195:A3665.
268. Degani-Costa L, Cunha Aranda L, Berton DC, Webb K, O'Donnell DE, Neder J, Nery L. A pragmatic approach to establish an acceptable work rate to assess the effect of interventions on exercise endurance in COPD. Submitted to European Respiratory Society International Congress-24, 2017.
269. Neder J, Rocha A, Arbex F, Biazzim L, Soars A, Hochhegger B, Alencar M, Mancuso F, Sperandio

- P, Berton D, Nery L, O'Donnell D. Determinants and consequences of exercise ventilatory inefficiency in patients with COPD-heart failure overlap. Submitted to European Respiratory Society International Congress, September 2017.
270. Sperandio P, Souza A, Noman M, Arbes F, Siquiera G, Medeiros W, Mazzuco A, Oliveira M, O'Donnell D, Nery L, Neder J. Bi-level positive pressure ventilation increases exertional inspiratory capacity and improves breathlessness in heart failure patients with co-morbid COPD. Submitted to European Respiratory Society International Congress, September 2017.
 271. Rodrigues Jr J, Selman J, Jose A, Farias M, Moreira F, Leitao L, Berton D, O'Donnell D, Lanza F, Neder J, Sal Corso S. Is high exercise ventilation actually critical to elicit bronchoconstriction in asthmatic children? Submitted to European Respiratory Society International Congress, September 2017.
 272. Diniz Marques R, Berton D, Domnik N, Driver H, Elbehairy A, Fagondes S, Fitzpatrick M, O'Donnell D, Neder J. Lung hyperinflation is related to poor sleep quality in patients with COPD. Submitted to European Respiratory Society International Congress, September 2017.
 273. Elbehairy A, Webb K, Neder J, O'Donnell D. Bronchodilators do not change ventilatory efficiency during exercise in COPD. Presented Sept. 9 at European Respiratory Society Annual Congress, Milan, Italy, Sept. 9-13, 2017.
 274. Webb K, Elbehairy A, Faisal A, Neder J, O'Donnell D. Effects of umeclidinium/vilanterol versus umeclidinium on exertional dyspnea and respiratory mechanics in moderate COPD. Presented Sept 9 at European Respiratory Society Annual Congress, Milan, Italy, Sept. 9-13, 2017.
 275. Dacha S, Langer D, Ciavaglia C, Webb K, Preston M, O'Donnell E. Effect of inspiratory muscle training (IMT) on static and dynamic respiratory muscle function in patients with COPD. Submitted to European Respiratory Society International Congress, September 2017.
 276. Domnik N, Preston M, Jensen D, Guenette J, Stickland M, Webb K, Neder JA, O'Donnell D. Ventilatory control characteristics in mild COPD. *Cdn J Respir Crit Care & Sleep Med* 2017;1(2):CRC2017-0122, p. 94-95.
 277. Domnik NK, James ME, Ciavaglia C, Garvey J, Driver HS, Webb K, O'Donnell DE. Nocturnal variations in supine lung volumes and spirometry in moderate to severe chronic obstructive pulmonary disease. American Thoracic Society International meeting 2018.
 278. Maltais F, O'Donnell DE, Kallsen K, Schaefer I. The effect of tiotropium/olodaterol versus tiotropium on breathlessness during the 3-minute constant speed shuttle walking test in patients with chronic obstructive pulmonary disease. American Thoracic Society International Meeting 2018, San Francisco, California.
 279. Domnik NJ, Preston M, Webb K, O'Donnell D. Ventilatory control characteristics and dyspnea in mild COPD. *Dyspnea* 2018. Montreal, June 2018.
 280. Berton DC, Marques RD, Palmer B, Webb K, O'Donnell DE, Neder JA. Effects of acute dual bronchodilator treatment (tiotropium + olodaterol) on cardiopulmonary interactions in hyperinflated patients with COPD. European Respiratory Society International Meeting. Paris, France, September 2018.
 281. Souza A, Mazzuco A, Alencar MC, Arbex F, Faria M, Muzzeti W, O'Donnell DE, Nery LE, Neder JA, Sperandio PA. Ventilatory assistance decreases mechanical inspiratory constraints and improves exercise tolerance in overlapping COPD-heart failure. European Respiratory Society International Meeting, Paris, France, September 2018.
 282. Berton DC, Marques Rd, Palmer B, D'Arsigny C, O'Donnell DE, Neder JA. Non-invasive assessment of pulmonary microcirculation at rest and exercise in patients with previous pulmonary thromboembolism. European Respiratory Society International Meeting, Paris, France, September 2018.
 283. Domnik N, Matthew J, Ciavaglia C, Driver H, Webb K, O'Donnell DE. "Breathe" Lung Association, January 25, 2019. Submitted November 2018.

284. Elbehairy AF, O'Donnell CD, Elhameed AA, Vincent SG, Milne KM, Neder JA, O'Donnell DE. The link between low resting diffusion capacity and exercise intolerance in COPD. ERS International Congress, Madrid, Spain. Sept 28 – Oct 2, 2019. Submitted February 2019.
285. Elbehairy AF, Faisal A, McIsaac H, Ciavaglia CE, Neder JA, O'Donnell DE. Mechanisms of orthopnea in patients with advanced COPD. ERS International Congress, Madrid, Spain. Sept 28-Oct 2, 2019. Submitted February 2019.
286. Neder JA, Costa C, Verrastro C, Ramos R, Ferreira EM, Paul-Ribero M, Nery LE, O'Donnell DE, Pereira CA, Ota-Arakaki J. Mechanisms and consequences of exertional dyspnoea in combined pulmonary fibrosis and emphysema (CPFE). ERS International Congress, Madrid, Spain. September 28-Oct 2, 2019. Submitted February 2019.
287. Domnik N, James M, Ciavaglia C, Driver H, Crinion S, Neder JA, O'Donnell D. Overnight deterioration of supine respiratory mechanics in COPD: impact of nocturnal aclidinium bromide-formoterol fumarate. ERS International Congress, Madrid, Spain. Sept 28-Oct 2, 2019. Submitted February 2019.
288. Milne K, Ibrahim-Masthan M, Elbehairy A, Neder JA, O'Donnell D. Impact of nebulized fentanyl on exertional dyspnea in interstitial lung disease. ERS International Congress, Madrid, Spain. Sept 28-Oct 2, 2019. Poster presented Sept 29, 2019
289. Neder JA, Berton DC, Marillier M, Bernard AC, O'Donnell DE. Critical inspiratory constraints and excess ventilation are superior to breathing reserve in predicting exertional dyspnoea in COPD. ERS International Congress, Madrid, Spain. Sept 28-Oct 2, 2019. Submitted February 2019.
290. Neder JA, Berton DC, Marillier M, Bernard AC, O'Donnell DE. Cardiopulmonary exercise testing in the investigation of unexplained dyspnoea: the role of inspiratory constraints and ventilatory inefficiency. ERS International Congress, Madrid, Spain. Sept 28-Oct 2, 2019. Submitted February 2019.
291. Marillier M, Bernard AC, Berton DC, Reimao G, Castelli G, O'Donnell DE, Neder JA. Do the 2012 spirometric Global Lung Function Initiative equations accurately diagnose restriction in the extreme obese? ERS International Congress, Madrid, Spain. Sept 28-Oct 2, 2019. Submitted February 2019.
292. Berton DC, Marillier M, Bernard AC, O'Donnell DE, Neder JA. Resting VE/VCO2 is a strong predictor of exertional dyspnoea in COPD. ERS International Congress, Madrid, Spain. Sept 28-Oct 2, 2019. Submitted February 2019.
293. O'Donnell DE, et al Effect of glycopyrronium/Indacaterol versus tiotropium on exertional dyspnea during the 3-minute constant speed shuttle test in patients with COPD: The Red Trial. Chest, 2019 Annual Meeting.

Number of publications	Total	Past 5 years
Peer-reviewed articles, published or in press	369	138
Book chapters	46	11
Books and monographs	13	7

Abstracts, published	293	67
TOTAL published or in press	721	249